drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.69k
| drug2_id
int64 0
1.69k
| drug_pair
sequencelengths 2
2
| drug1_name
stringlengths 4
85
| drug2_name
stringlengths 4
85
| drug1_desc
stringlengths 27
1.09k
| drug2_desc
stringlengths 27
6.14k
| label
stringclasses 3
values | label_idx
int64 0
2
| all_paths
sequencelengths 1
10
| all_paths_str
sequencelengths 1
10
| path_str
stringlengths 0
3.57k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00067 | DB08865 | 317 | 1,593 | [
"DDInter1921",
"DDInter448"
] | Vasopressin | Crizotinib | Vasopressin (arginine-vasopressin or antidiuretic hormone) is a nonapeptide primarily produced in the hypothalamus that exhibits diverse physiological functions related to diuresis, hemodynamic modulation, and behaviour.[A110, A111, A112, A113, A228008] Vasopressin is very similar to oxytocin, differing in the third and eighth amino acids. Despite a wide variety of functions, exogenous vasopressin is primarily used to control blood pressure during systemic shock by increasing vasoconstriction and renal fluid reuptake by acting through V<sub>1</sub> and V<sub>2</sub> cellular receptors.[A228008, A228013, A228018, L31413] The vasopressive effect of posterior pituitary gland extracts was noted in 1895, while vasopressin itself was not purified until 1951. It has been used for | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements. | Major | 2 | [
[
[
317,
25,
1593
]
],
[
[
317,
24,
450
],
[
450,
24,
1593
]
],
[
[
317,
24,
1662
],
[
1662,
63,
1593
]
],
[
[
317,
23,
112
],
[
112,
24,
1593
]
],
[
[
317,
24,
1181
],
[
1181,
25,
1593
]
],
[
[
317,
24,
36
],
[
36,
64,
1593
]
],
[
[
317,
25,
11
],
[
11,
25,
1593
]
],
[
[
317,
25,
1618
],
[
1618,
64,
1593
]
],
[
[
317,
63,
521
],
[
521,
25,
1593
]
],
[
[
317,
24,
450
],
[
450,
6,
8374
],
[
8374,
45,
1593
]
]
] | [
[
[
"Vasopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Vasopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Vasopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Vasopressin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Vasopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Crizotinib"
]
]
] | Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Vasopressin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may lead to a major life threatening interaction when taken with Crizotinib
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may lead to a major life threatening interaction when taken with Crizotinib
Vasopressin may lead to a major life threatening interaction when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Crizotinib
Vasopressin may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may lead to a major life threatening interaction when taken with Crizotinib
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin may lead to a major life threatening interaction when taken with Crizotinib
Vasopressin may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound) |
DB00668 | DB06204 | 874 | 768 | [
"DDInter652",
"DDInter1746"
] | Epinephrine | Tapentadol | Epinephrine, also known as _adrenaline_, is a hormone and neurotransmitter and produced by the adrenal glands that can also be used as a drug due to its various important functions. Though it has long been used in the treatment of hypersensitivity reactions, epinephrine in the auto-injector form (EpiPen) has been available since 1987 in the USA. Many new products/biosimilars and dosage routes have been approved under various names over the last several decades,,. On August 16, 2018, Teva Pharmaceuticals USA gained approval to market its generic epinephrine auto-injector in 0.3 mg and 0.15 mg strengths. Dosage delivery routes for epinephrine include intravenous, inhalation, nebulization, intramuscular injection, and subcutaneous injection. In general, the most common uses of parenteral epinephrine are to relieve respiratory distress due to | Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011. Used in the management of pain, tapentadol is typically reserved for patients who have limited alternative treatment options. | Moderate | 1 | [
[
[
874,
24,
768
]
],
[
[
874,
6,
6017
],
[
6017,
45,
768
]
],
[
[
874,
21,
28692
],
[
28692,
60,
768
]
],
[
[
874,
24,
1148
],
[
1148,
24,
768
]
],
[
[
874,
63,
999
],
[
999,
24,
768
]
],
[
[
874,
24,
659
],
[
659,
63,
768
]
],
[
[
874,
24,
1053
],
[
1053,
25,
768
]
],
[
[
874,
24,
1629
],
[
1629,
64,
768
]
],
[
[
874,
63,
73
],
[
73,
25,
768
]
],
[
[
874,
25,
1264
],
[
1264,
25,
768
]
]
] | [
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tapentadol"
]
],
[
[
"Epinephrine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Tapentadol"
]
],
[
[
"Epinephrine",
"{u} (Compound) causes {v} (Side Effect)",
"Mental disorder"
],
[
"Mental disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tapentadol"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tapentadol"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tapentadol"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tapentadol"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tapentadol"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tapentadol"
]
],
[
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tapentadol"
]
],
[
[
"Epinephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tapentadol"
]
]
] | Epinephrine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Tapentadol (Compound)
Epinephrine (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Tapentadol (Compound)
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Tapentadol
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Tapentadol
Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Tapentadol
Epinephrine may lead to a major life threatening interaction when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Tapentadol |
DB00619 | DB09498 | 1,419 | 810 | [
"DDInter909",
"DDInter1715"
] | Imatinib | Strontium chloride Sr-89 | Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy".. The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment can be tailored specifically to the unique cancer genetics of each patient. Imatinib was approved on February 1st,2001 by the FDA and November 7th, 2001 by the EMA; however, its European approval has been withdrawn in October 2023.[A263036,L49746,L49751] | Strontium chloride (Sr-89), initially FDA-approved in 1993, is used as a paliative therapeutic option to help relieve the pain from bone metastases. Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer. Bone metastases is a common and severe complication presented in advanced stages of the disease. It is usually presented mainly in patients with prostatic and breast cancer, as well as in cancer of lung, bladder and thyroid. There has been some cases of apparent tumor regression which has given it a potential tumoricidal effect. | Moderate | 1 | [
[
[
1419,
24,
810
]
],
[
[
1419,
63,
552
],
[
552,
24,
810
]
],
[
[
1419,
24,
60
],
[
60,
24,
810
]
],
[
[
1419,
24,
1060
],
[
1060,
63,
810
]
],
[
[
1419,
25,
503
],
[
503,
63,
810
]
],
[
[
1419,
25,
1362
],
[
1362,
24,
810
]
],
[
[
1419,
35,
1468
],
[
1468,
24,
810
]
],
[
[
1419,
62,
1101
],
[
1101,
24,
810
]
],
[
[
1419,
64,
695
],
[
695,
25,
810
]
],
[
[
1419,
63,
552
],
[
552,
24,
1555
],
[
1555,
24,
810
]
]
] | [
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capecitabine"
],
[
"Capecitabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
],
[
"Enfortumab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
],
[
"Zanubrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Imatinib",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Imatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Strontium chloride Sr-89"
]
],
[
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
]
]
] | Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Capecitabine and Capecitabine may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Imatinib may lead to a major life threatening interaction when taken with Zanubrutinib and Zanubrutinib may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Imatinib may lead to a major life threatening interaction when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Imatinib (Compound) resembles Ponatinib (Compound) and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Imatinib may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89
Imatinib may lead to a major life threatening interaction when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Strontium chloride Sr-89
Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 |
DB01075 | DB09118 | 1,376 | 1,580 | [
"DDInter569",
"DDInter1711"
] | Diphenhydramine | Stiripentol | Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes [L5263, L5266, L5269, F3379]. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties [L5269, F3352]. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system [L5263, L5266, L5269, F3379, A174541]. While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed | Stiripentol is an antiepileptic agent that is an aromatic allylic alcohol drug, which makes it structurally unique from other antiepileptic drugs.[A19740, A250825] The clinical development and marketing of stiripentol were first delayed due to the drug's potent inhibitory effects on hepatic cytochrome P450 (CYP) enzymes. However, its clinical efficacy as adjunctive therapy for epilepsies stems from its inhibitory action on CYP enzymes, as stiripentol reduces the degradation of CYP-sensitive antiepileptic drugs, hence boosting their therapeutic efficacy. Stiripentol may also exhibit direct anticonvulsant properties, although the exact mechanism of action is fully understood. Approved in the US, Canada, and Europe, stiripentol is used to treat seizures associated with Dravet syndrome.[L880,L42500,L42510] It is marketed under the brand name Diacomit. | Moderate | 1 | [
[
[
1376,
24,
1580
]
],
[
[
1376,
24,
283
],
[
283,
63,
1580
]
],
[
[
1376,
24,
1532
],
[
1532,
24,
1580
]
],
[
[
1376,
63,
1219
],
[
1219,
24,
1580
]
],
[
[
1376,
35,
820
],
[
820,
24,
1580
]
],
[
[
1376,
74,
662
],
[
662,
24,
1580
]
],
[
[
1376,
40,
11
],
[
11,
24,
1580
]
],
[
[
1376,
25,
1670
],
[
1670,
25,
1580
]
],
[
[
1376,
64,
888
],
[
888,
25,
1580
]
],
[
[
1376,
24,
283
],
[
283,
23,
466
],
[
466,
62,
1580
]
]
] | [
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
],
[
"Azatadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Diphenhydramine",
"{u} (Compound) resembles {v} (Compound)",
"Toremifene"
],
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stiripentol"
]
],
[
[
"Diphenhydramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Stiripentol"
]
],
[
[
"Diphenhydramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Stiripentol"
]
],
[
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Stiripentol"
]
]
] | Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Diphenhydramine (Compound) resembles Alimemazine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Diphenhydramine (Compound) resembles Carbinoxamine (Compound) and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Diphenhydramine (Compound) resembles Toremifene (Compound) and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Stiripentol
Diphenhydramine may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may lead to a major life threatening interaction when taken with Stiripentol
Diphenhydramine may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may lead to a major life threatening interaction when taken with Stiripentol
Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Stiripentol |
DB11837 | DB12141 | 1,297 | 971 | [
"DDInter1351",
"DDInter817"
] | Osilodrostat | Gilteritinib | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiologically elevated. Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice. As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery has not been curative. Osilodrostat is manufactured by Novartis under the brand name Isturisa. It has undergone phase II clinical trials for the treatment of solid tumours, hypertension, and | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status. | Moderate | 1 | [
[
[
1297,
24,
971
]
],
[
[
1297,
62,
1135
],
[
1135,
23,
971
]
],
[
[
1297,
23,
466
],
[
466,
62,
971
]
],
[
[
1297,
63,
485
],
[
485,
24,
971
]
],
[
[
1297,
24,
730
],
[
730,
63,
971
]
],
[
[
1297,
64,
697
],
[
697,
24,
971
]
],
[
[
1297,
24,
1017
],
[
1017,
24,
971
]
],
[
[
1297,
64,
540
],
[
540,
25,
971
]
],
[
[
1297,
25,
68
],
[
68,
64,
971
]
],
[
[
1297,
63,
1101
],
[
1101,
25,
971
]
]
] | [
[
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Osilodrostat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gilteritinib"
]
],
[
[
"Osilodrostat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gilteritinib"
]
],
[
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deutetrabenazine"
],
[
"Deutetrabenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Osilodrostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Osilodrostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Osilodrostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Troleandomycin"
],
[
"Troleandomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Osilodrostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
]
] | Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Osilodrostat may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Deutetrabenazine and Deutetrabenazine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Osilodrostat may lead to a major life threatening interaction when taken with Phenobarbital and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Osilodrostat may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone may lead to a major life threatening interaction when taken with Gilteritinib
Osilodrostat may lead to a major life threatening interaction when taken with Troleandomycin and Troleandomycin may lead to a major life threatening interaction when taken with Gilteritinib
Osilodrostat may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Gilteritinib |
DB01067 | DB06718 | 959 | 1,687 | [
"DDInter826",
"DDInter1709"
] | Glipizide | Stanozolol | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonyl | Stanozolol is a synthetic anabolic steroid with therapeutic uses in treating hereditary angioedema. Stanozolol is derived from testosterone, and has been abused by several high profile professional athletes. | Moderate | 1 | [
[
[
959,
24,
1687
]
],
[
[
959,
63,
1197
],
[
1197,
1,
1687
]
],
[
[
959,
24,
1546
],
[
1546,
1,
1687
]
],
[
[
959,
63,
1561
],
[
1561,
40,
1687
]
],
[
[
959,
24,
984
],
[
984,
40,
1687
]
],
[
[
959,
63,
1573
],
[
1573,
24,
1687
]
],
[
[
959,
24,
1220
],
[
1220,
24,
1687
]
],
[
[
959,
24,
1296
],
[
1296,
63,
1687
]
],
[
[
959,
1,
245
],
[
245,
24,
1687
]
],
[
[
959,
40,
1411
],
[
1411,
24,
1687
]
]
] | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stanozolol"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norethisterone"
],
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Stanozolol"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
],
[
"Methyltestosterone",
"{u} (Compound) resembles {v} (Compound)",
"Stanozolol"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
],
[
"Testosterone",
"{u} (Compound) resembles {v} (Compound)",
"Stanozolol"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danazol"
],
[
"Danazol",
"{u} (Compound) resembles {v} (Compound)",
"Stanozolol"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stanozolol"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stanozolol"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stanozolol"
]
],
[
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stanozolol"
]
],
[
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Stanozolol"
]
]
] | Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) resembles Stanozolol (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Stanozolol (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles Stanozolol (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Danazol and Danazol (Compound) resembles Stanozolol (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Stanozolol
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Stanozolol
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Stanozolol
Glipizide (Compound) resembles Glimepiride (Compound) and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Stanozolol
Glipizide (Compound) resembles Tolbutamide (Compound) and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Stanozolol |
DB01045 | DB08901 | 463 | 1,468 | [
"DDInter1590",
"DDInter1492"
] | Rifampicin | Ponatinib | A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160) | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
463,
24,
1468
]
],
[
[
463,
25,
478
],
[
478,
24,
1468
]
],
[
[
463,
6,
10083
],
[
10083,
45,
1468
]
],
[
[
463,
63,
1215
],
[
1215,
23,
1468
]
],
[
[
463,
24,
379
],
[
379,
23,
1468
]
],
[
[
463,
24,
460
],
[
460,
62,
1468
]
],
[
[
463,
25,
1135
],
[
1135,
62,
1468
]
],
[
[
463,
63,
458
],
[
458,
24,
1468
]
],
[
[
463,
25,
384
],
[
384,
63,
1468
]
],
[
[
463,
24,
1487
],
[
1487,
24,
1468
]
]
] | [
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Rifampicin",
"{u} (Compound) binds {v} (Gene)",
"ABCB11"
],
[
"ABCB11",
"{u} (Gene) is bound by {v} (Compound)",
"Ponatinib"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ponatinib"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ponatinib"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium carbonate"
],
[
"Magnesium carbonate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ponatinib"
]
],
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ponatinib"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tinidazole"
],
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Rifampicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Rifampicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
]
] | Rifampicin may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Rifampicin (Compound) binds ABCB11 (Gene) and ABCB11 (Gene) is bound by Ponatinib (Compound)
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Lansoprazole and Lansoprazole may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Rabeprazole and Rabeprazole may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium carbonate and Magnesium carbonate may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Rifampicin may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ponatinib
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Tinidazole and Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Rifampicin may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Rifampicin may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib |
DB01166 | DB11057 | 477 | 720 | [
"DDInter379",
"DDInter1223"
] | Cilostazol | Mineral oil | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. | Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that are then further refined. During the modern refining process, aromatics are reduced by solvent extraction, catalytic hydrotreating, or hydrocracking. Unrefined or mildly treated mineral oils are classified as Group 3 carcinogens by the World Health Organizations, as chronic exposure to these aromatics including alkylated polycyclic aromatic compounds (PAC) can lead to skin cancer. Mineral oil is a common ingredient in baby lotions, cold creams, ointments and cosmetics to treat and prevent dry, rough, scaly, itchy skin and minor skin irritations. It is also used as a mild laxative for human or veterinary uses. | Moderate | 1 | [
[
[
477,
24,
720
]
],
[
[
477,
24,
927
],
[
927,
63,
720
]
],
[
[
477,
24,
1151
],
[
1151,
24,
720
]
],
[
[
477,
25,
1069
],
[
1069,
24,
720
]
],
[
[
477,
63,
758
],
[
758,
24,
720
]
],
[
[
477,
64,
684
],
[
684,
24,
720
]
],
[
[
477,
25,
982
],
[
982,
63,
720
]
],
[
[
477,
24,
927
],
[
927,
63,
1151
],
[
1151,
24,
720
]
],
[
[
477,
24,
1151
],
[
1151,
24,
927
],
[
927,
63,
720
]
],
[
[
477,
25,
1069
],
[
1069,
25,
927
],
[
927,
63,
720
]
]
] | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mineral oil"
]
]
] | Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Cilostazol may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Cilostazol may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Cilostazol may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil
Cilostazol may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Mineral oil |
DB00518 | DB01254 | 510 | 1,213 | [
"DDInter35",
"DDInter484"
] | Albendazole | Dasatinib | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL kinase domain.[A2226,A11377] Also, mutations in the kinase domain of BCR-ABL may lead to relapse during imatinib treatment. Since dasatinib does not interact with some of the residues involved in those mutations, the use of this drug represents a therapeutic alternative for patients with cancers that have developed imatinib-resistance. The use of dasatinib was first approved by the FDA in 2006.[L45171,L45186] | Moderate | 1 | [
[
[
510,
24,
1213
]
],
[
[
510,
6,
4973
],
[
4973,
45,
1213
]
],
[
[
510,
7,
4786
],
[
4786,
45,
1213
]
],
[
[
510,
7,
4519
],
[
4519,
46,
1213
]
],
[
[
510,
18,
10488
],
[
10488,
46,
1213
]
],
[
[
510,
7,
4729
],
[
4729,
57,
1213
]
],
[
[
510,
18,
2701
],
[
2701,
57,
1213
]
],
[
[
510,
6,
5816
],
[
5816,
57,
1213
]
],
[
[
510,
21,
28882
],
[
28882,
60,
1213
]
],
[
[
510,
24,
563
],
[
563,
24,
1213
]
]
] | [
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
],
[
[
"Albendazole",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Albendazole",
"{u} (Compound) upregulates {v} (Gene)",
"EPHB2"
],
[
"EPHB2",
"{u} (Gene) is bound by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Albendazole",
"{u} (Compound) upregulates {v} (Gene)",
"HDAC6"
],
[
"HDAC6",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Albendazole",
"{u} (Compound) downregulates {v} (Gene)",
"B4GAT1"
],
[
"B4GAT1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Albendazole",
"{u} (Compound) upregulates {v} (Gene)",
"EBNA1BP2"
],
[
"EBNA1BP2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Albendazole",
"{u} (Compound) downregulates {v} (Gene)",
"CCNE2"
],
[
"CCNE2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Albendazole",
"{u} (Compound) binds {v} (Gene)",
"TUBB4B"
],
[
"TUBB4B",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Albendazole",
"{u} (Compound) causes {v} (Side Effect)",
"Body temperature increased"
],
[
"Body temperature increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
],
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
]
]
] | Albendazole (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dasatinib (Compound)
Albendazole (Compound) upregulates EPHB2 (Gene) and EPHB2 (Gene) is bound by Dasatinib (Compound)
Albendazole (Compound) upregulates HDAC6 (Gene) and HDAC6 (Gene) is upregulated by Dasatinib (Compound)
Albendazole (Compound) downregulates B4GAT1 (Gene) and B4GAT1 (Gene) is upregulated by Dasatinib (Compound)
Albendazole (Compound) upregulates EBNA1BP2 (Gene) and EBNA1BP2 (Gene) is downregulated by Dasatinib (Compound)
Albendazole (Compound) downregulates CCNE2 (Gene) and CCNE2 (Gene) is downregulated by Dasatinib (Compound)
Albendazole (Compound) binds TUBB4B (Gene) and TUBB4B (Gene) is downregulated by Dasatinib (Compound)
Albendazole (Compound) causes Body temperature increased (Side Effect) and Body temperature increased (Side Effect) is caused by Dasatinib (Compound)
Albendazole may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib |
DB01174 | DB09241 | 697 | 1,629 | [
"DDInter1442",
"DDInter1186"
] | Phenobarbital | Methylene blue | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. Its use as an urinary tract antiseptic has also been investigated. Methylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early clinical trials to be an inhibitor of Tau protein aggregation. The drug is of potential interest for the treatment of patients with Alzheimer's disease. | Moderate | 1 | [
[
[
697,
24,
1629
]
],
[
[
697,
40,
1023
],
[
1023,
24,
1629
]
],
[
[
697,
1,
536
],
[
536,
24,
1629
]
],
[
[
697,
24,
1311
],
[
1311,
24,
1629
]
],
[
[
697,
63,
593
],
[
593,
25,
1629
]
],
[
[
697,
24,
407
],
[
407,
64,
1629
]
],
[
[
697,
64,
475
],
[
475,
25,
1629
]
],
[
[
697,
62,
1133
],
[
1133,
25,
1629
]
],
[
[
697,
40,
1023
],
[
1023,
1,
1269
],
[
1269,
24,
1629
]
],
[
[
697,
1,
536
],
[
536,
40,
1023
],
[
1023,
24,
1629
]
]
] | [
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
],
[
[
"Phenobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
],
[
[
"Phenobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Secobarbital"
],
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
],
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
],
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Phenobarbital",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Phenobarbital",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Phenobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Methohexital"
],
[
"Methohexital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
],
[
[
"Phenobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Secobarbital"
],
[
"Secobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
]
] | Phenobarbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Phenobarbital (Compound) resembles Secobarbital (Compound) and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Methylene blue
Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may lead to a major life threatening interaction when taken with Methylene blue
Phenobarbital may lead to a major life threatening interaction when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Methylene blue
Phenobarbital may cause a minor interaction that can limit clinical effects when taken with Granisetron and Granisetron may lead to a major life threatening interaction when taken with Methylene blue
Phenobarbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital (Compound) resembles Methohexital (Compound) and Methohexital may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Phenobarbital (Compound) resembles Secobarbital (Compound) and Secobarbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue |
DB01114 | DB01619 | 272 | 830 | [
"DDInter362",
"DDInter1441"
] | Chlorpheniramine | Phenindamine | A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than promethazine. | Phenindamine is an antihistamine. Phenindamine blocks the effects of the naturally occurring chemical histamine in your body. Antihistamines such as phenindamine appear to compete with histamine for histamine H1- receptor sites on effector cells. The antihistamines antagonize those pharmacological effects of histamine which are mediated through activation of H1- receptor sites and thereby reduce the intensity of allergic reactions and tissue injury response involving histamine release. It is used to treat sneezing, runny nose, itching, watery eyes, hives, rashes, itching, and other symptoms of allergies and the common cold. Symptoms of a phenindamine overdose include extreme sleepiness, confusion, weakness, ringing in the ears, blurred vision, large pupils, dry mouth, flushing, fever, shaking, insomnia, hallucinations, and possibly seizures. | Moderate | 1 | [
[
[
272,
24,
830
]
],
[
[
272,
63,
1251
],
[
1251,
1,
830
]
],
[
[
272,
24,
537
],
[
537,
40,
830
]
],
[
[
272,
63,
1219
],
[
1219,
40,
830
]
],
[
[
272,
63,
357
],
[
357,
24,
830
]
],
[
[
272,
40,
465
],
[
465,
1,
830
]
],
[
[
272,
6,
10104
],
[
10104,
45,
830
]
],
[
[
272,
23,
771
],
[
771,
62,
830
]
],
[
[
272,
24,
580
],
[
580,
63,
830
]
],
[
[
272,
74,
662
],
[
662,
24,
830
]
]
] | [
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} (Compound) resembles {v} (Compound)",
"Phenindamine"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} (Compound) resembles {v} (Compound)",
"Phenindamine"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azatadine"
],
[
"Azatadine",
"{u} (Compound) resembles {v} (Compound)",
"Phenindamine"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Benzatropine"
],
[
"Benzatropine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Chlorpheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Chlorcyclizine"
],
[
"Chlorcyclizine",
"{u} (Compound) resembles {v} (Compound)",
"Phenindamine"
]
],
[
[
"Chlorpheniramine",
"{u} (Compound) binds {v} (Gene)",
"HRH1"
],
[
"HRH1",
"{u} (Gene) is bound by {v} (Compound)",
"Phenindamine"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hyaluronidase"
],
[
"Hyaluronidase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenindamine"
]
],
[
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opicapone"
],
[
"Opicapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
],
[
[
"Chlorpheniramine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenindamine"
]
]
] | Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Mirtazapine and Mirtazapine (Compound) resembles Phenindamine (Compound)
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Phenindamine (Compound)
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Azatadine and Azatadine (Compound) resembles Phenindamine (Compound)
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Benzatropine and Benzatropine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine
Chlorpheniramine (Compound) resembles Chlorcyclizine (Compound) and Chlorcyclizine (Compound) resembles Phenindamine (Compound)
Chlorpheniramine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Phenindamine (Compound)
Chlorpheniramine may cause a minor interaction that can limit clinical effects when taken with Hyaluronidase and Hyaluronidase may cause a minor interaction that can limit clinical effects when taken with Phenindamine
Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Opicapone and Opicapone may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine
Chlorpheniramine (Compound) resembles Carbinoxamine (Compound) and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Phenindamine |
DB09083 | DB12245 | 880 | 823 | [
"DDInter996",
"DDInter1863"
] | Ivabradine | Triclabendazole | Ivabradine is a novel heart rate lowering medicine for the symptomatic management of stable angina pectoralis and symptomatic chronic heart failure. Ivabradine, brand name Corlanor, was approved by the FDA in April 2015 for the treatment of chronic heart failure in patients with an ejection fraction of ≤35%, in sinus rhythm with resting heart rate ≥70 beats per minute, who are not on beta-blockers due to contraindications or already receiving maximum beta-blocker dose. Recently a new indication was added to treat symptomatic heart failure from dilated cardiomyopathy for patients 6 months or more in age[Label]. Ivabradine acts by selectively inhibiting the "funny" channel pacemaker current (If) in the sinoatrial node in a dose-dependent fashion, resulting in a lower heart rate and thus more blood to flow to the myocardium. Although non-dihydropyridine calcium channel blockers and beta | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common liver fluke” or “the sheep liver fluke” or by _Fasciola gigantica_, another helminth. These parasites can infect humans following ingestion of larvae in contaminated water or food. Triclabendazole was previously used in the treatment of fascioliasis in livestock, but is now approved for human use. This drug is currently the only FDA-approved drug for individuals with fascioliasis, which affects 2.4 million people worldwide.[A174988,L5452] | Major | 2 | [
[
[
880,
25,
823
]
],
[
[
880,
64,
1010
],
[
1010,
24,
823
]
],
[
[
880,
25,
971
],
[
971,
24,
823
]
],
[
[
880,
25,
1619
],
[
1619,
63,
823
]
],
[
[
880,
63,
144
],
[
144,
24,
823
]
],
[
[
880,
64,
868
],
[
868,
25,
823
]
],
[
[
880,
25,
985
],
[
985,
25,
823
]
],
[
[
880,
25,
982
],
[
982,
64,
823
]
],
[
[
880,
63,
1011
],
[
1011,
25,
823
]
],
[
[
880,
64,
1010
],
[
1010,
23,
1247
],
[
1247,
23,
823
]
]
] | [
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Ivabradine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Ivabradine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Triclabendazole"
]
],
[
[
"Ivabradine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triclabendazole"
]
]
] | Ivabradine may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Ivabradine may lead to a major life threatening interaction when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Ivabradine may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Ivabradine may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may lead to a major life threatening interaction when taken with Triclabendazole
Ivabradine may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Triclabendazole
Ivabradine may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Triclabendazole
Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Triclabendazole
Ivabradine may lead to a major life threatening interaction when taken with Mefloquine and Mefloquine may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Triclabendazole |
DB06282 | DB09061 | 516 | 1,627 | [
"DDInter1053",
"DDInter284"
] | Levocetirizine | Cannabidiol | Levocetirizine is a selective histamine H<sub>1</sub> antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine]. Levocetirizine has greater affinity for the histamine H<sub>1</sub> receptor than cetirizine. Levocetirizine was granted FDA approval in 1995. | Cannabidiol, or CBD, is one of at least 85 active cannabinoids identified within the Cannabis plant. It is a major phytocannabinoid, accounting for up to 40% of the Cannabis plant's extract, that binds to a wide variety of physiological targets of the endocannabinoid system within the body. Although the exact medical implications are currently being investigated, CBD has shown promise as a therapeutic and pharmaceutical drug target. In particular, CBD has shown promise as an analgesic, anticonvulsant, muscle relaxant, anxiolytic, antipsychotic and has shown neuroprotective, anti-inflammatory, and antioxidant activity, among other currently investigated uses [A32477, A32469]. CBD's exact place within medical practice is still currently hotly debated, however as the body of evidence grows and legislation changes to reflect its wide-spread use, public and medical opinion have changed significantly with regards to its usefulness in a number of medical conditions ranging from anxiety to epilepsy. From a pharmacological perspective, Cannabis' (and CBD's) diverse receptor profile explains its potential application for such a wide variety of medical conditions. Cannabis contains more than 400 different chemical compounds, of which 61 are considered cannabinoids, a class of compounds that act upon endogenous cannabinoid receptors of the body . Cannabinoid receptors are utilized endogenously by the body through the endocannabinoid system, which includes a group of lipid proteins, enzymes, and receptors that are involved in many physiological processes. Through its modulation of neurotransmitter release, the endocannabinoid system regulates cognition, pain sensation, appetite, memory, sleep, immune function, and mood among many other bodily systems. These effects are largely mediated through two members of the G-protein coupled receptor family, cannabinoid receptors 1 and 2 (CB1 and CB2)[A32585,A32824]. CB1 receptors are found in both the central and peripheral nervous systems, with the majority of receptors localized to the hippocampus and amygdala of the brain. Physiological effects of using cannabis make sense in the context of its receptor activity as the hippocampus and amygdala are primarily involved with regulation of memory, fear, and emotion. In contrast, CB2 receptors are mainly found peripherally in immune cells, lymphoid tissue, and peripheral nerve terminals . Tetrahydrocannabinol (THC) and cannabidiol (CBD) are two types of cannabinoids found naturally in the resin of the marijuana plant, both of which interact with the cannabinoid receptors that are found throughout the body. Although THC and CBD have been the most studied cannabinoids, there are many others identified to date including cannabinol (CBN), cannabigerol (CBG), (CBDV), and (THCV) that can be found within the medical cannabis . While both CBD and THC are used for medicinal purposes, they have different receptor activity, function, and physiological effects. If not provided in their activated form (such as through synthetic forms of THC like or ), THC and CBD are obtained through conversion from their precursors, tetrahydrocannabinolic acid-A (THCA-A) and cannabidiolic acid (CBDA), through decarboxylation reactions. This can be achieved through heating, smoking, vaporization, or baking of dried unfertilized female cannabis flowers. The primary psychoactive component of Cannabis, delta 9-tetrahydrocannabinol (Δ9-THC), demonstrates its effects through weak partial agonist activity at Cannabinoid-1 (CB1R) and Cannabinoid-2 (CB2R) receptors. This activity results in the well-known effects of smoking cannabis such as increased appetite, reduced pain, and changes in emotional and cognitive processes. In contrast to THC's weak agonist activity, CBD has been shown to act as a negative allosteric modulator of the cannabinoid CB1 receptor, the most abundant G-Protein Coupled Receptor (GPCR) in the body . Allosteric regulation is achieved through the modulation of receptor activity on a functionally distinct site from the agonist or antagonist binding site which is clinically significant as direct agonists (such as THC) are limited by their psychomimetic effects such as changes to mood, memory, and anxiety. In addition to the well-known activity on CB1 and CB2 receptors, there is further evidence that CBD also activates 5-HT1A/2A/3A serotonergic and TRPV1–2 vanilloid receptors, antagonizes alpha-1 adrenergic and µ-opioid receptors, inhibits synaptosomal uptake of noradrenaline, dopamine, serotonin and gamma-aminobutyric acid (GABA), and cellular uptake of anandamide, acts on mitochondria Ca2+ stores, blocks low-voltage-activated (T-type) Ca2+ channels, stimulates activity of the inhibitory glycine-receptor, and inhibits activity of fatty amide hydrolase (FAAH) [A31555, A31574]. CBD is currently available in Canada within a 1:1 formulation with tetrahydrocannbinol (THC) (as the formulation known as "nabiximols") as the brand name product Sativex. It is approved for use as adjunctive treatment for symptomatic relief of spasticity in adult patients with multiple sclerosis (MS). Sativex was also given a conditional Notice of Compliance (NOC/c) for use as adjunctive treatment for the symptomatic relief of neuropathic pain in adult patients with multiple sclerosis and as adjunctive analgesic treatment for moderate to severe pain in adult patients with advanced cancer . In April 2018, a Food and Drug Administration advisory panel unanimously recommended approval of Epidiolex (cannabidiol oral solution) for the treatment of two rare forms of epilepsy - Lennox-Gastaut syndrome and Dravet syndrome, which are among the two most difficult types of epilepsy to treat [L2721, L2719]. Epidiolex was granted Orphan Drug designation as well as Fast Track Approval from the FDA for further study in these hard to treat conditions. Notably, phase 3 clinical trials of Epidiolex have demonstrated clinically significant improvement in Lennox-Gastaut syndrome and Dravet syndrome . On June 25th, 2018, Epidiolex was approved by the FDA to be the first CBD-based product available on the US market. | Moderate | 1 | [
[
[
516,
24,
1627
]
],
[
[
516,
63,
1594
],
[
1594,
24,
1627
]
],
[
[
516,
24,
407
],
[
407,
63,
1627
]
],
[
[
516,
62,
1031
],
[
1031,
24,
1627
]
],
[
[
516,
24,
849
],
[
849,
24,
1627
]
],
[
[
516,
63,
1594
],
[
1594,
40,
888
],
[
888,
24,
1627
]
],
[
[
516,
63,
662
],
[
662,
63,
1594
],
[
1594,
24,
1627
]
],
[
[
516,
63,
1648
],
[
1648,
24,
384
],
[
384,
23,
1627
]
],
[
[
516,
63,
104
],
[
104,
63,
1419
],
[
1419,
23,
1627
]
],
[
[
516,
24,
407
],
[
407,
63,
1594
],
[
1594,
24,
1627
]
]
] | [
[
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Levocetirizine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Theophylline"
],
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound)",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carbinoxamine"
],
[
"Carbinoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
],
[
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
]
],
[
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cannabidiol"
]
],
[
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
]
]
] | Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Levocetirizine may cause a minor interaction that can limit clinical effects when taken with Theophylline and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine (Compound) resembles Tamoxifen (Compound) and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Carbinoxamine and Carbinoxamine may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol
Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a minor interaction that can limit clinical effects when taken with Cannabidiol
Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol |
DB09052 | DB14443 | 250 | 987 | [
"DDInter220",
"DDInter1931"
] | Blinatumomab | Vibrio cholerae CVD 103-HgR strain live antigen | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of malignant B-cells. Since blinatumomab has an affinity to both antigens, it redirects T-cells to tumor cells expressing CD19 and promotes tumor cell lysis and apoptosis.[A7659,A7660,A254831] Blinatumomab is manufactured by Amgen Inc. and marketed under the brand Blincyto. It was first approved by the FDA in December 2014 for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients. | _Vibrio cholerae_ CVD 103-HgR strain live antigen is a component of Vaxchora, an oral vaccine for immunization against _Vibrio cholerae_ serogroup O1. Cholera is an acute bacterial disease of the small intestine caused by _Vibrio cholerae_, which is gram-negative bacteria. Two serogroups of _V. cholerae_, O1 and O139, are causative agents of epidemic cholera. Serogroup O1 is responsible for the majority of cholera outbreaks. Cholera outbreaks remain a major global public health problem that mainly affects countries with limited access to clean water, poor hygiene, and proper sanitation; thus, effective vaccines to protect individuals against cholera disease are critical. The FDA approved the cholera vaccine containing _Vibrio cholerae_ CVD 103-HgR strain live antigen under the brand name Vaxchora in June 2016, making it the first vaccine indicated for cholera prevention to become available in the U.S. Vaxchora was later approved by the European Commission in April 2020. It is indicated for individuals aged two years and older. | Moderate | 1 | [
[
[
250,
24,
987
]
],
[
[
250,
63,
305
],
[
305,
24,
987
]
],
[
[
250,
24,
1362
],
[
1362,
24,
987
]
],
[
[
250,
64,
581
],
[
581,
24,
987
]
],
[
[
250,
25,
1259
],
[
1259,
24,
987
]
],
[
[
250,
25,
676
],
[
676,
63,
987
]
],
[
[
250,
63,
305
],
[
305,
24,
1468
],
[
1468,
24,
987
]
],
[
[
250,
24,
1362
],
[
1362,
24,
1480
],
[
1480,
24,
987
]
],
[
[
250,
64,
581
],
[
581,
25,
1480
],
[
1480,
24,
987
]
],
[
[
250,
24,
738
],
[
738,
63,
1480
],
[
1480,
24,
987
]
]
] | [
[
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Blinatumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Blinatumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Blinatumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Blinatumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
],
[
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
]
]
] | Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Blinatumomab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Blinatumomab may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Blinatumomab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Blinatumomab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen
Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen |
DB00855 | DB01050 | 213 | 848 | [
"DDInter72",
"DDInter900"
] | Aminolevulinic acid | Ibuprofen | A compound produced from succinyl-CoA and glycine as an intermediate in heme synthesis. It is used as a photochemotherapy for actinic keratosis. [PubChem] | Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID. On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than the R-enantiomer. | Major | 2 | [
[
[
213,
25,
848
]
],
[
[
213,
21,
29124
],
[
29124,
60,
848
]
],
[
[
213,
64,
1299
],
[
1299,
24,
848
]
],
[
[
213,
25,
178
],
[
178,
63,
848
]
],
[
[
213,
25,
1680
],
[
1680,
24,
848
]
],
[
[
213,
36,
842
],
[
842,
24,
848
]
],
[
[
213,
25,
1650
],
[
1650,
64,
848
]
],
[
[
213,
64,
663
],
[
663,
25,
848
]
],
[
[
213,
64,
1274
],
[
1274,
35,
848
]
],
[
[
213,
21,
29124
],
[
29124,
60,
362
],
[
362,
23,
848
]
]
] | [
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibuprofen"
]
],
[
[
"Aminolevulinic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Rash pustular"
],
[
"Rash pustular",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ibuprofen"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trovafloxacin"
],
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Polythiazide"
],
[
"Polythiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Aminolevulinic acid",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Methyl aminolevulinate"
],
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Avapritinib"
],
[
"Avapritinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibuprofen"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibuprofen"
]
],
[
[
"Aminolevulinic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
]
],
[
[
"Aminolevulinic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Rash pustular"
],
[
"Rash pustular",
"{u} (Side Effect) is caused by {v} (Compound)",
"Phenytoin"
],
[
"Phenytoin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ibuprofen"
]
]
] | Aminolevulinic acid (Compound) causes Rash pustular (Side Effect) and Rash pustular (Side Effect) is caused by Ibuprofen (Compound)
Aminolevulinic acid may lead to a major life threatening interaction when taken with Trovafloxacin and Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Aminolevulinic acid may lead to a major life threatening interaction when taken with Polythiazide and Polythiazide may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Aminolevulinic acid may lead to a major life threatening interaction when taken with Etacrynic acid and Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Aminolevulinic acid (Compound) resembles Methyl aminolevulinate (Compound) and Aminolevulinic acid may lead to a major life threatening interaction when taken with Methyl aminolevulinate and Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Aminolevulinic acid may lead to a major life threatening interaction when taken with Avapritinib and Avapritinib may lead to a major life threatening interaction when taken with Ibuprofen
Aminolevulinic acid may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may lead to a major life threatening interaction when taken with Ibuprofen
Aminolevulinic acid may lead to a major life threatening interaction when taken with Flurbiprofen and Flurbiprofen (Compound) resembles Ibuprofen (Compound) and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen
Aminolevulinic acid (Compound) causes Rash pustular (Side Effect) and Rash pustular (Side Effect) is caused by Phenytoin (Compound) and Phenytoin may cause a minor interaction that can limit clinical effects when taken with Ibuprofen |
DB08871 | DB11853 | 36 | 230 | [
"DDInter666",
"DDInter1577"
] | Eribulin | Relugolix | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors. | Relugolix is a gonadotropin-releasing hormone (GnRH) receptor antagonist used in the treatment of several hormone-responsive conditions. It was first approved in Japan in 2019, under the brand name Relumina, for the symptomatic treatment of uterine fibroids, and more recently by the United States' FDA in 2020, under the brand name Orgovyx, for the treatment of advanced prostate cancer.[L27991,L27996] This branded product was later approved by the European Commission on April 29, 2022. Relugolix has also been studied in the symptomatic treatment of endometriosis. Relugolix is the first (and currently only) orally-administered GnRH receptor antagonist approved for the treatment of prostate cancer - similar therapies such as [degarelix] require subcutaneous administration - and therefore provides a less burdensome therapeutic option for patients who might otherwise require clinic visits for administration by healthcare professionals. In addition to its relative ease-of-use, relugolix was shown to be superior in the depression of testosterone levels when compared to [leuprolide], another androgen deprivation therapy used in the treatment of prostate cancer. In May 2021, the FDA approved the combination product made up of relugolix, [estradiol], and [norethindrone] under the market name Myfembree for the first once-daily treatment for the management of heavy menstrual bleeding associated with uterine fibroids in premenopausal women. | Moderate | 1 | [
[
[
36,
24,
230
]
],
[
[
36,
24,
129
],
[
129,
23,
230
]
],
[
[
36,
63,
112
],
[
112,
23,
230
]
],
[
[
36,
63,
480
],
[
480,
24,
230
]
],
[
[
36,
24,
1662
],
[
1662,
24,
230
]
],
[
[
36,
24,
1619
],
[
1619,
63,
230
]
],
[
[
36,
64,
1487
],
[
1487,
24,
230
]
],
[
[
36,
24,
351
],
[
351,
25,
230
]
],
[
[
36,
63,
392
],
[
392,
25,
230
]
],
[
[
36,
64,
1011
],
[
1011,
25,
230
]
]
] | [
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Relugolix"
]
],
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Relugolix"
]
],
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Eribulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Relugolix"
]
],
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Relugolix"
]
],
[
[
"Eribulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Relugolix"
]
],
[
[
"Eribulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Relugolix"
]
]
] | Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Relugolix
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Relugolix
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Eribulin may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Relugolix
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Relugolix
Eribulin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may lead to a major life threatening interaction when taken with Relugolix
Eribulin may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Relugolix |
DB01319 | DB13928 | 34 | 1,385 | [
"DDInter777",
"DDInter1660"
] | Fosamprenavir | Semaglutide | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to manage type 2 diabetes along with lifestyle changes, such as dietary restrictions and increased physical activity.[A31421,L8681] Other members of this drug class include [Exenatide] and [Liraglutide]. Semaglutide was developed by Novo Nordisk and approved by the FDA for subcutaneous injection in December 2017. The tablet formulation was approved for oral administration in September 2019. Semaglutide works by binding to and activating the GLP-1 receptor, thereby stimulating insulin secretion and reducing blood glucose. The subcutaneous injection is administered once weekly and the tablet is administered once a day. Semaglutide offers a competitive advantage over other drugs used to manage diabetes, which may require several daily doses. Clinical trials have determined that this drug reduces glycosylated hemoglobin (HbA1c) levels and reduces body weight, proving to be effective for patients with type 2 diabetes. In June 2021, semaglutide was approved by the FDA for chronic weight management in adults with general obesity or overweight who have at least one weight-related condition, marking semaglutide as the first approved drug for such use since 2014. The use of semaglutide in weight management is also approved by Health Canada and the EMA. On May 31, 2023, the FDA issued a warning regarding the use of compounded semaglutide after receiving adverse event reports. The use of salt forms of semaglutide, including semaglutide sodium and semaglutide acetate, has not been proven to be safe or effective. | Moderate | 1 | [
[
[
34,
24,
1385
]
],
[
[
34,
63,
891
],
[
891,
24,
1385
]
],
[
[
34,
25,
1476
],
[
1476,
24,
1385
]
],
[
[
34,
1,
1091
],
[
1091,
24,
1385
]
],
[
[
34,
64,
1486
],
[
1486,
24,
1385
]
],
[
[
34,
24,
1296
],
[
1296,
24,
1385
]
],
[
[
34,
62,
609
],
[
609,
24,
1385
]
],
[
[
34,
63,
1101
],
[
1101,
25,
1385
]
],
[
[
34,
63,
891
],
[
891,
40,
1103
],
[
1103,
23,
1385
]
],
[
[
34,
25,
1476
],
[
1476,
24,
1399
],
[
1399,
63,
1385
]
]
] | [
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Fosamprenavir",
"{u} (Compound) resembles {v} (Compound)",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Fosamprenavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Semaglutide"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Semaglutide"
]
],
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
]
]
] | Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Fosamprenavir may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Fosamprenavir (Compound) resembles Amprenavir (Compound) and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Fosamprenavir may lead to a major life threatening interaction when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Fosamprenavir may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Semaglutide
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Semaglutide
Fosamprenavir may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide |
DB00444 | DB01165 | 63 | 1,539 | [
"DDInter1765",
"DDInter1325"
] | Teniposide | Ofloxacin | Teniposide is a semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Teniposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent cells from entering into the mitotic phase of the cell cycle, and lead to cell death. Teniposide acts primarily in the G2 and S phases of the cycle. | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Minor | 0 | [
[
[
63,
23,
1539
]
],
[
[
63,
23,
1467
],
[
1467,
1,
1539
]
],
[
[
63,
62,
1176
],
[
1176,
1,
1539
]
],
[
[
63,
23,
945
],
[
945,
40,
1539
]
],
[
[
63,
33,
3199
],
[
3199,
45,
1539
]
],
[
[
63,
7,
3696
],
[
3696,
57,
1539
]
],
[
[
63,
21,
29209
],
[
29209,
60,
1539
]
],
[
[
63,
24,
112
],
[
112,
23,
1539
]
],
[
[
63,
23,
147
],
[
147,
23,
1539
]
],
[
[
63,
35,
896
],
[
896,
23,
1539
]
]
] | [
[
[
"Teniposide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
]
],
[
[
"Teniposide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enoxacin"
],
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Ofloxacin"
]
],
[
[
"Teniposide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Ofloxacin"
]
],
[
[
"Teniposide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Ofloxacin"
]
],
[
[
"Teniposide",
"{u} (Compound) binds {v} (Gene) and {u} (Compound) downregulates {v} (Gene)",
"TOP2A"
],
[
"TOP2A",
"{u} (Gene) is bound by {v} (Compound)",
"Ofloxacin"
]
],
[
[
"Teniposide",
"{u} (Compound) upregulates {v} (Gene)",
"ALAS1"
],
[
"ALAS1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ofloxacin"
]
],
[
[
"Teniposide",
"{u} (Compound) causes {v} (Side Effect)",
"Anorexia"
],
[
"Anorexia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ofloxacin"
]
],
[
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
]
],
[
[
"Teniposide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
]
],
[
[
"Teniposide",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"Etoposide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ofloxacin"
]
]
] | Teniposide may cause a minor interaction that can limit clinical effects when taken with Enoxacin and Enoxacin (Compound) resembles Ofloxacin (Compound)
Teniposide may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Ofloxacin (Compound)
Teniposide may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin (Compound) resembles Ofloxacin (Compound)
Teniposide (Compound) binds TOP2A (Gene) and Teniposide (Compound) downregulates TOP2A (Gene) and TOP2A (Gene) is bound by Ofloxacin (Compound)
Teniposide (Compound) upregulates ALAS1 (Gene) and ALAS1 (Gene) is downregulated by Ofloxacin (Compound)
Teniposide (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Ofloxacin (Compound)
Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Ofloxacin
Teniposide may cause a minor interaction that can limit clinical effects when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Ofloxacin
Teniposide (Compound) resembles Etoposide (Compound) and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a minor interaction that can limit clinical effects when taken with Ofloxacin |
DB01035 | DB09082 | 1,401 | 659 | [
"DDInter1524",
"DDInter1934"
] | Procainamide | Vilanterol | A derivative of procaine with less CNS action. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol's pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.[A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and with both [fluticasone furoate] and [umeclidinium bromide] under the trade name TRELEGY ELLIPTA.[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.[L46876,L46881,L46886] Although all 3 products are approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), only TRELEGY ELLIPTA and BREO ELLIPTA are approved for maintenance treatments of asthma in patients aged 18 years and older and 5 years and older respectively.[L46481,L44461,L44456] | Moderate | 1 | [
[
[
1401,
24,
659
]
],
[
[
1401,
25,
927
],
[
927,
63,
659
]
],
[
[
1401,
25,
1069
],
[
1069,
24,
659
]
],
[
[
1401,
64,
485
],
[
485,
24,
659
]
],
[
[
1401,
36,
1151
],
[
1151,
24,
659
]
],
[
[
1401,
63,
455
],
[
455,
24,
659
]
],
[
[
1401,
24,
144
],
[
144,
24,
659
]
],
[
[
1401,
25,
877
],
[
877,
64,
659
]
],
[
[
1401,
25,
927
],
[
927,
64,
1220
],
[
1220,
23,
659
]
],
[
[
1401,
25,
1069
],
[
1069,
63,
1220
],
[
1220,
23,
659
]
]
] | [
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Procainamide",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Procainamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olodaterol"
],
[
"Olodaterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vilanterol"
]
],
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
]
],
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
]
]
] | Procainamide may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Procainamide may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Procainamide may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Procainamide (Compound) resembles Sunitinib (Compound) and Procainamide may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Olodaterol and Olodaterol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Procainamide may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may lead to a major life threatening interaction when taken with Vilanterol
Procainamide may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Procainamide may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol |
DB08865 | DB08875 | 1,593 | 1,618 | [
"DDInter448",
"DDInter262"
] | Crizotinib | Cabozantinib | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used | Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133] | Major | 2 | [
[
[
1593,
25,
1618
]
],
[
[
1593,
25,
1135
],
[
1135,
62,
1618
]
],
[
[
1593,
63,
112
],
[
112,
23,
1618
]
],
[
[
1593,
62,
1247
],
[
1247,
23,
1618
]
],
[
[
1593,
63,
723
],
[
723,
24,
1618
]
],
[
[
1593,
25,
384
],
[
384,
63,
1618
]
],
[
[
1593,
62,
307
],
[
307,
24,
1618
]
],
[
[
1593,
24,
1032
],
[
1032,
63,
1618
]
],
[
[
1593,
24,
850
],
[
850,
24,
1618
]
],
[
[
1593,
23,
283
],
[
283,
63,
1618
]
]
] | [
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cabozantinib"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cabozantinib"
]
],
[
[
"Crizotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cabozantinib"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Crizotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
],
[
"Levosalbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
],
[
[
"Crizotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabozantinib"
]
]
] | Crizotinib may lead to a major life threatening interaction when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Crizotinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Cabozantinib
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Crizotinib may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Crizotinib may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib
Crizotinib may cause a minor interaction that can limit clinical effects when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Cabozantinib |
DB11943 | DB12332 | 255 | 1,619 | [
"DDInter495",
"DDInter1626"
] | Delafloxacin | Rucaparib | Delafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, among others. It was approved in June 2017 under the trade name Baxdela for use in the treatment of acute bacterial skin and skin structure infections. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185] | Moderate | 1 | [
[
[
255,
24,
1619
]
],
[
[
255,
64,
1019
],
[
1019,
24,
1619
]
],
[
[
255,
24,
1501
],
[
1501,
63,
1619
]
],
[
[
255,
63,
848
],
[
848,
24,
1619
]
],
[
[
255,
62,
147
],
[
147,
24,
1619
]
],
[
[
255,
24,
1033
],
[
1033,
24,
1619
]
],
[
[
255,
63,
351
],
[
351,
25,
1619
]
],
[
[
255,
64,
1019
],
[
1019,
64,
307
],
[
307,
23,
1619
]
],
[
[
255,
64,
1486
],
[
1486,
62,
307
],
[
307,
23,
1619
]
],
[
[
255,
24,
1501
],
[
1501,
63,
154
],
[
154,
24,
1619
]
]
] | [
[
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Delafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enasidenib"
],
[
"Enasidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Delafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Delafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
]
],
[
[
"Delafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
]
],
[
[
"Delafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enasidenib"
],
[
"Enasidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
],
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
]
] | Delafloxacin may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib and Enasidenib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Delafloxacin may cause a minor interaction that can limit clinical effects when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Rucaparib
Delafloxacin may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may lead to a major life threatening interaction when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Delafloxacin may lead to a major life threatening interaction when taken with Methylprednisolone and Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Delafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib and Enasidenib may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib |
DB00731 | DB06663 | 1,144 | 1,154 | [
"DDInter1269",
"DDInter1398"
] | Nateglinide | Pasireotide | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Moderate | 1 | [
[
[
1144,
24,
1154
]
],
[
[
1144,
63,
966
],
[
966,
40,
1154
]
],
[
[
1144,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
1144,
24,
112
],
[
112,
23,
1154
]
],
[
[
1144,
24,
1385
],
[
1385,
63,
1154
]
],
[
[
1144,
63,
88
],
[
88,
24,
1154
]
],
[
[
1144,
24,
699
],
[
699,
24,
1154
]
],
[
[
1144,
1,
136
],
[
136,
24,
1154
]
],
[
[
1144,
64,
839
],
[
839,
25,
1154
]
],
[
[
1144,
63,
600
],
[
600,
25,
1154
]
]
] | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[
"Octreotide",
"{u} (Compound) resembles {v} (Compound)",
"Pasireotide"
]
],
[
[
"Nateglinide",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pasireotide"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pasireotide"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
],
[
"Semaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nadolol"
],
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Nateglinide",
"{u} (Compound) resembles {v} (Compound)",
"Lacosamide"
],
[
"Lacosamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Nateglinide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
]
] | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide (Compound) resembles Pasireotide (Compound)
Nateglinide (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pasireotide
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Nadolol and Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Nateglinide (Compound) resembles Lacosamide (Compound) and Lacosamide may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Nateglinide may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may lead to a major life threatening interaction when taken with Pasireotide
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may lead to a major life threatening interaction when taken with Pasireotide |
DB00675 | DB00816 | 888 | 1,674 | [
"DDInter1744",
"DDInter1346"
] | Tamoxifen | Orciprenaline | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977. | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Moderate | 1 | [
[
[
888,
24,
1674
]
],
[
[
888,
18,
8355
],
[
8355,
46,
1674
]
],
[
[
888,
7,
16549
],
[
16549,
57,
1674
]
],
[
[
888,
21,
28921
],
[
28921,
60,
1674
]
],
[
[
888,
24,
1220
],
[
1220,
62,
1674
]
],
[
[
888,
24,
1164
],
[
1164,
24,
1674
]
],
[
[
888,
63,
534
],
[
534,
24,
1674
]
],
[
[
888,
64,
758
],
[
758,
24,
1674
]
],
[
[
888,
24,
484
],
[
484,
63,
1674
]
],
[
[
888,
1,
939
],
[
939,
63,
1674
]
]
] | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
]
],
[
[
"Tamoxifen",
"{u} (Compound) downregulates {v} (Gene)",
"DPH2"
],
[
"DPH2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Orciprenaline"
]
],
[
[
"Tamoxifen",
"{u} (Compound) upregulates {v} (Gene)",
"SLC2A6"
],
[
"SLC2A6",
"{u} (Gene) is downregulated by {v} (Compound)",
"Orciprenaline"
]
],
[
[
"Tamoxifen",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Orciprenaline"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Orciprenaline"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
],
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
]
],
[
[
"Tamoxifen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
]
],
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
]
],
[
[
"Tamoxifen",
"{u} (Compound) resembles {v} (Compound)",
"Benzphetamine"
],
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
]
]
] | Tamoxifen (Compound) downregulates DPH2 (Gene) and DPH2 (Gene) is upregulated by Orciprenaline (Compound)
Tamoxifen (Compound) upregulates SLC2A6 (Gene) and SLC2A6 (Gene) is downregulated by Orciprenaline (Compound)
Tamoxifen (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Orciprenaline (Compound)
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Orciprenaline
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Tamoxifen may lead to a major life threatening interaction when taken with Fluoxetine and Fluoxetine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline
Tamoxifen (Compound) resembles Benzphetamine (Compound) and Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline |
DB11986 | DB14730 | 484 | 1,412 | [
"DDInter648",
"DDInter264"
] | Entrectinib | Calaspargase pegol | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets. | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparaginase treatment in ALL , , . Calaspargase pegol, also known as _asparlas_, is an asparagine specific enzyme which is indicated as a part of a multi-agent chemotherapy regimen for the treatment of ALL . The asparagine specific enzyme is derived from Escherichia coli, as a conjugate of L-asparaginase (L-asparagine amidohydrolase) and monomethoxypolyethylene glycol (mPEG) with a succinimidyl carbonate (SC) linker to create a stable molecule which increases the half-life and decreases the dosing frequency [FDA label], . Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) . | Moderate | 1 | [
[
[
484,
24,
1412
]
],
[
[
484,
63,
792
],
[
792,
24,
1412
]
],
[
[
484,
24,
159
],
[
159,
24,
1412
]
],
[
[
484,
64,
868
],
[
868,
24,
1412
]
],
[
[
484,
63,
770
],
[
770,
25,
1412
]
],
[
[
484,
64,
1377
],
[
1377,
25,
1412
]
],
[
[
484,
63,
792
],
[
792,
64,
1439
],
[
1439,
24,
1412
]
],
[
[
484,
24,
159
],
[
159,
63,
792
],
[
792,
24,
1412
]
],
[
[
484,
63,
883
],
[
883,
24,
159
],
[
159,
24,
1412
]
],
[
[
484,
64,
868
],
[
868,
63,
792
],
[
792,
24,
1412
]
]
] | [
[
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ipilimumab"
],
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
]
] | Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Entrectinib may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Calaspargase pegol
Entrectinib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Calaspargase pegol
Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may lead to a major life threatening interaction when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib and Gefitinib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Entrectinib may lead to a major life threatening interaction when taken with Vemurafenib and Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol |
DB00005 | DB01284 | 1,057 | 1,042 | [
"DDInter687",
"DDInter1782"
] | Etanercept | Tetracosactide | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA). | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. Tetracosactide exhibits the same activity as natural ACTH with regard to all its biological activities. The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration. | Major | 2 | [
[
[
1057,
25,
1042
]
],
[
[
1057,
25,
1683
],
[
1683,
63,
1042
]
],
[
[
1057,
25,
1184
],
[
1184,
24,
1042
]
],
[
[
1057,
24,
599
],
[
599,
24,
1042
]
],
[
[
1057,
24,
1270
],
[
1270,
63,
1042
]
],
[
[
1057,
25,
1011
],
[
1011,
64,
1042
]
],
[
[
1057,
25,
1064
],
[
1064,
25,
1042
]
],
[
[
1057,
25,
1683
],
[
1683,
25,
1137
],
[
1137,
63,
1042
]
],
[
[
1057,
25,
1137
],
[
1137,
64,
1683
],
[
1683,
63,
1042
]
],
[
[
1057,
25,
1184
],
[
1184,
24,
1683
],
[
1683,
63,
1042
]
]
] | [
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
],
[
"Tuberculin purified protein derivative",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
],
[
"Measles virus vaccine live attenuated",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Measles virus vaccine live attenuated"
],
[
"Measles virus vaccine live attenuated",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
]
] | Etanercept may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Etanercept may lead to a major life threatening interaction when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative and Tuberculin purified protein derivative may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Etanercept may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Tetracosactide
Etanercept may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Tetracosactide
Etanercept may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated and Measles virus vaccine live attenuated may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Etanercept may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated and Measles virus vaccine live attenuated may lead to a major life threatening interaction when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Etanercept may lead to a major life threatening interaction when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide |
DB01319 | DB12500 | 34 | 283 | [
"DDInter777",
"DDInter714"
] | Fosamprenavir | Fedratinib | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
34,
25,
283
]
],
[
[
34,
23,
466
],
[
466,
62,
283
]
],
[
[
34,
25,
351
],
[
351,
23,
283
]
],
[
[
34,
24,
761
],
[
761,
24,
283
]
],
[
[
34,
25,
436
],
[
436,
24,
283
]
],
[
[
34,
25,
676
],
[
676,
63,
283
]
],
[
[
34,
64,
147
],
[
147,
24,
283
]
],
[
[
34,
63,
891
],
[
891,
24,
283
]
],
[
[
34,
23,
1374
],
[
1374,
24,
283
]
],
[
[
34,
25,
1406
],
[
1406,
25,
283
]
]
] | [
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Fosamprenavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Artemether"
],
[
"Artemether",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Fosamprenavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
],
[
"Neratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
]
] | Fosamprenavir may cause a minor interaction that can limit clinical effects when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Fosamprenavir may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Fosamprenavir may lead to a major life threatening interaction when taken with Artemether and Artemether may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Fosamprenavir may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Fosamprenavir may lead to a major life threatening interaction when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Prednisolone and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Fosamprenavir may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Fosamprenavir may lead to a major life threatening interaction when taken with Neratinib and Neratinib may lead to a major life threatening interaction when taken with Fedratinib |
DB00019 | DB00488 | 1,257 | 196 | [
"DDInter1405",
"DDInter57"
] | Pegfilgrastim | Altretamine | Pegfilgrastim is a PEGylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue, [filgrastim]. The drug is approved for use to decrease the incidence of infection, as manifested by febrile neutropenia, in susceptible patients with with non-myeloid cancer receiving myelosuppressive anti-cancer treatment. Although the risk of developing febrile neutropenia is less than 20% in many readily used chemotherapy regimens, infections pose risks of hospitalization and mortalities. Due to the relatively short circulating half-life of filgrastim, a 20 kDa PEG moiety was covalently conjugated to the N-terminus of filgrastim (at the methionine residue) to develop longer-acting pegfilgrastim.[A29,A187607] Due to a longer half-life and slower elimination rate than filgrastim | An alkylating agent proposed as an antineoplastic. It also acts as a chemosterilant for male houseflies and other insects. | Moderate | 1 | [
[
[
1257,
24,
196
]
],
[
[
1257,
24,
4
],
[
4,
63,
196
]
],
[
[
1257,
24,
599
],
[
599,
24,
196
]
],
[
[
1257,
25,
1064
],
[
1064,
25,
196
]
],
[
[
1257,
24,
770
],
[
770,
64,
196
]
],
[
[
1257,
24,
4
],
[
4,
63,
139
],
[
139,
63,
196
]
],
[
[
1257,
24,
599
],
[
599,
24,
139
],
[
139,
63,
196
]
],
[
[
1257,
24,
1362
],
[
1362,
63,
839
],
[
839,
23,
196
]
],
[
[
1257,
24,
869
],
[
869,
5,
11583
],
[
11583,
44,
196
]
],
[
[
1257,
25,
1064
],
[
1064,
7,
18110
],
[
18110,
46,
196
]
]
] | [
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Altretamine"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Altretamine"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Altretamine"
]
],
[
[
"Pegfilgrastim",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Altretamine"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Altretamine"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Altretamine"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zidovudine"
],
[
"Zidovudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Altretamine"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Altretamine"
]
],
[
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} (Compound) treats {v} (Disease)",
"ovarian cancer"
],
[
"ovarian cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Altretamine"
]
],
[
[
"Pegfilgrastim",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} (Compound) upregulates {v} (Gene)",
"ST6GALNAC2"
],
[
"ST6GALNAC2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Altretamine"
]
]
] | Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Altretamine
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Altretamine
Pegfilgrastim may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Altretamine
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Altretamine
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Altretamine
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Zidovudine and Zidovudine may cause a moderate interaction that could exacerbate diseases when taken with Altretamine
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Grepafloxacin and Grepafloxacin may cause a minor interaction that can limit clinical effects when taken with Altretamine
Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan (Compound) treats ovarian cancer (Disease) and ovarian cancer (Disease) is treated by Altretamine (Compound)
Pegfilgrastim may lead to a major life threatening interaction when taken with Cladribine and Cladribine (Compound) upregulates ST6GALNAC2 (Gene) and ST6GALNAC2 (Gene) is upregulated by Altretamine (Compound) |
DB01229 | DB10276 | 973 | 1,624 | [
"DDInter1378",
"DDInter1623"
] | Paclitaxel (protein-bound) | Rotavirus vaccine | Paclitaxel can cause developmental toxicity, female reproductive toxicity and male reproductive toxicity according to state or federal government labeling requirements. | Rotavirus commonly infects children and infants causing severe diarrhea and vomiting leading to potentially fatal dehydration. Two rotavirus vaccines are available for the prevention of rotavirus gastroenteritis, Rotateq and Rotarix. Rotateq is a live vaccine consisting of 5 reassorted human-bovine viral strains. Rotarix is a live attenuated vaccine containing the 89-12 human strain.[Label] Rotavirus vaccines are 90% effective in protecting against severe rotavirus infection. | Major | 2 | [
[
[
973,
25,
1624
]
],
[
[
973,
64,
770
],
[
770,
25,
1624
]
],
[
[
973,
24,
1480
],
[
1480,
25,
1624
]
],
[
[
973,
25,
375
],
[
375,
25,
1624
]
],
[
[
973,
63,
1488
],
[
1488,
25,
1624
]
],
[
[
973,
24,
270
],
[
270,
64,
1624
]
],
[
[
973,
25,
1259
],
[
1259,
64,
1624
]
],
[
[
973,
64,
770
],
[
770,
64,
552
],
[
552,
25,
1624
]
],
[
[
973,
24,
1480
],
[
1480,
63,
770
],
[
770,
25,
1624
]
],
[
[
973,
25,
375
],
[
375,
64,
617
],
[
617,
24,
1624
]
]
] | [
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludarabine"
],
[
"Fludarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carmustine"
],
[
"Carmustine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rotavirus vaccine"
]
],
[
[
"Paclitaxel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Budesonide"
],
[
"Budesonide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rotavirus vaccine"
]
]
] | Paclitaxel may lead to a major life threatening interaction when taken with Rotavirus vaccine
Paclitaxel may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Rotavirus vaccine
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may lead to a major life threatening interaction when taken with Rotavirus vaccine
Paclitaxel may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Rotavirus vaccine
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Fludarabine and Fludarabine may lead to a major life threatening interaction when taken with Rotavirus vaccine
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may lead to a major life threatening interaction when taken with Rotavirus vaccine
Paclitaxel may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Rotavirus vaccine
Paclitaxel may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Carmustine and Carmustine may lead to a major life threatening interaction when taken with Rotavirus vaccine
Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Rotavirus vaccine
Paclitaxel may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Budesonide and Budesonide may cause a moderate interaction that could exacerbate diseases when taken with Rotavirus vaccine |
DB00734 | DB01259 | 1,664 | 392 | [
"DDInter1605",
"DDInter1024"
] | Risperidone | Lapatinib | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. 9-hydroxyrisperidone). Schizophrenia and various mood disorders are thought to be caused by an excess of dopaminergic D2 and serotonergic 5-HT2A activity, resulting in overactivity of central mesolimbic pathways and mesocortical pathways, respectively. Risperidone is thought to reduce this overactivity through inhibition of dopaminergic D2 receptors and serotonergic 5-HT2A receptors in the brain. Risperidone binds with a very high affinity to 5-HT2A receptors, approximately 10-20 fold greater than the drug's | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epidermal growth factor receptor type 2 (HER2/ERBB2) and epidermal growth factor receptor (HER1/EGFR/ERBB1) tyrosine kinases inhibitor. It binds to the intracellular phosphorylation domain to prevent receptor autophosphorylation upon ligand binding. | Moderate | 1 | [
[
[
1664,
24,
392
]
],
[
[
1664,
6,
4973
],
[
4973,
45,
392
]
],
[
[
1664,
21,
29429
],
[
29429,
60,
392
]
],
[
[
1664,
23,
112
],
[
112,
23,
392
]
],
[
[
1664,
24,
918
],
[
918,
24,
392
]
],
[
[
1664,
63,
1010
],
[
1010,
24,
392
]
],
[
[
1664,
24,
603
],
[
603,
63,
392
]
],
[
[
1664,
62,
752
],
[
752,
24,
392
]
],
[
[
1664,
23,
1194
],
[
1194,
24,
392
]
],
[
[
1664,
1,
519
],
[
519,
63,
392
]
]
] | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Risperidone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Lapatinib"
]
],
[
[
"Risperidone",
"{u} (Compound) causes {v} (Side Effect)",
"Infestation NOS"
],
[
"Infestation NOS",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lapatinib"
]
],
[
[
"Risperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lapatinib"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bicalutamide"
],
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Risperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Risperidone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ranitidine"
],
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Risperidone",
"{u} (Compound) resembles {v} (Compound)",
"Paliperidone"
],
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
]
] | Risperidone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Risperidone (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Lapatinib (Compound)
Risperidone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lapatinib
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Bicalutamide and Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Risperidone may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Risperidone may cause a minor interaction that can limit clinical effects when taken with Ranitidine and Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Risperidone (Compound) resembles Paliperidone (Compound) and Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib |
DB00681 | DB01234 | 1,287 | 1,220 | [
"DDInter85",
"DDInter513"
] | Amphotericin B | Dexamethasone | Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses. | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen. | Moderate | 1 | [
[
[
1287,
24,
1220
]
],
[
[
1287,
24,
870
],
[
870,
1,
1220
]
],
[
[
1287,
63,
175
],
[
175,
40,
1220
]
],
[
[
1287,
63,
1573
],
[
1573,
1,
1220
]
],
[
[
1287,
24,
1486
],
[
1486,
40,
1220
]
],
[
[
1287,
21,
28835
],
[
28835,
60,
1220
]
],
[
[
1287,
64,
228
],
[
228,
23,
1220
]
],
[
[
1287,
24,
1477
],
[
1477,
63,
1220
]
],
[
[
1287,
63,
894
],
[
894,
24,
1220
]
],
[
[
1287,
25,
540
],
[
540,
63,
1220
]
]
] | [
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Amphotericin B",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperglycaemia"
],
[
"Hyperglycaemia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dexamethasone"
]
],
[
[
"Amphotericin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dofetilide"
],
[
"Dofetilide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telbivudine"
],
[
"Telbivudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Capreomycin"
],
[
"Capreomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
],
[
[
"Amphotericin B",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
]
]
] | Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Dexamethasone (Compound)
Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Dexamethasone (Compound)
Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Dexamethasone (Compound)
Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone (Compound) resembles Dexamethasone (Compound)
Amphotericin B (Compound) causes Hyperglycaemia (Side Effect) and Hyperglycaemia (Side Effect) is caused by Dexamethasone (Compound)
Amphotericin B may lead to a major life threatening interaction when taken with Dofetilide and Dofetilide may cause a minor interaction that can limit clinical effects when taken with Dexamethasone
Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Telbivudine and Telbivudine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Capreomycin and Capreomycin may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone
Amphotericin B may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone |
DB00976 | DB09054 | 1,056 | 384 | [
"DDInter1758",
"DDInter905"
] | Telithromycin | Idelalisib | Telithromycin, a semi-synthetic erythromycin derivative, belongs to a new chemical class of antibiotics called ketolides. Ketolides have been recently added to the macrolide-lincosamide-streptogramin class of antibiotics. Similar to the macrolide antibiotics, telithromycin prevents bacterial growth by interfering with bacterial protein synthesis. Telithromycin binds to the 50S subunit of the 70S bacterial ribosome and blocks further peptide elongation. Binding occurs simultaneously at to two domains of 23S RNA of the 50S ribosomal subunit, domain II and V, where older macrolides bind only to one. It is used to treat mild to moderate respiratory infections. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability. | Moderate | 1 | [
[
[
1056,
24,
384
]
],
[
[
1056,
24,
222
],
[
222,
23,
384
]
],
[
[
1056,
25,
1618
],
[
1618,
24,
384
]
],
[
[
1056,
63,
305
],
[
305,
24,
384
]
],
[
[
1056,
1,
1570
],
[
1570,
24,
384
]
],
[
[
1056,
24,
1228
],
[
1228,
63,
384
]
],
[
[
1056,
24,
761
],
[
761,
24,
384
]
],
[
[
1056,
64,
1181
],
[
1181,
24,
384
]
],
[
[
1056,
35,
609
],
[
609,
24,
384
]
],
[
[
1056,
25,
405
],
[
405,
64,
384
]
]
] | [
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Telithromycin",
"{u} (Compound) resembles {v} (Compound)",
"Azithromycin"
],
[
"Azithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lenvatinib"
],
[
"Lenvatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Telithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Telithromycin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Telithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
]
] | Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Telithromycin may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Telithromycin (Compound) resembles Azithromycin (Compound) and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Lenvatinib and Lenvatinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Telithromycin may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Telithromycin (Compound) resembles Clarithromycin (Compound) and Telithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Telithromycin may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may lead to a major life threatening interaction when taken with Idelalisib |
DB00682 | DB12015 | 126 | 1,033 | [
"DDInter1951",
"DDInter53"
] | Warfarin | Alpelisib | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. | Alpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various biological processes, including proliferation, survival, differentiation, and metabolism. Alpelisib was designed to target this enzyme that appears to be mutated at a rate of nearly 30% in human cancers, leading to hyperactivation. There are several isoform-specific PI3K inhibitors that are under clinical development or currently approved, such as [idelalisib] used for chronic lymphocytic leukemia (CLL). Approved by the FDA in May 2019, alpelisib is the first approved PI3K inhibitor indicated for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer in combination with [fulvestrant] for postmenopausal women and male patients. To initiate alpelisib therapy, it is required that the presence of a PIK3CA mutation in the tissue and/or liquid biopsy sample collection should be confirmed via FDA-approved diagnostic tests. Alpelisib is marketed under the trade name Piqray and is available as oral tablets. Studies evaluating the therapeutic effectiveness of alpelisib in other cancers, such as ovarian cancer and colorectal cancer , are under ongoing investigations. Alpelisib was granted FDA approval on 24 May 2019. In April 2022, the FDA granted the use of alpelisib in the treatment of PIK3CA-Related Overgrowth Spectrum (PROS) in adults and children who require systemic therapy. | Moderate | 1 | [
[
[
126,
24,
1033
]
],
[
[
126,
24,
738
],
[
738,
24,
1033
]
],
[
[
126,
1,
1335
],
[
1335,
24,
1033
]
],
[
[
126,
63,
837
],
[
837,
24,
1033
]
],
[
[
126,
62,
467
],
[
467,
24,
1033
]
],
[
[
126,
64,
536
],
[
536,
24,
1033
]
],
[
[
126,
23,
700
],
[
700,
24,
1033
]
],
[
[
126,
24,
1375
],
[
1375,
63,
1033
]
],
[
[
126,
25,
1247
],
[
1247,
24,
1033
]
],
[
[
126,
25,
1421
],
[
1421,
63,
1033
]
]
] | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Warfarin",
"{u} (Compound) resembles {v} (Compound)",
"Oxcarbazepine"
],
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pantoprazole"
],
[
"Pantoprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Secobarbital"
],
[
"Secobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Atorvastatin"
],
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
],
[
"Lefamulin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
],
[
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
]
]
] | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Warfarin (Compound) resembles Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Pantoprazole and Pantoprazole may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Warfarin may cause a minor interaction that can limit clinical effects when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Warfarin may lead to a major life threatening interaction when taken with Secobarbital and Secobarbital may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Warfarin may cause a minor interaction that can limit clinical effects when taken with Atorvastatin and Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Warfarin may lead to a major life threatening interaction when taken with Sulfamethoxazole and Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib
Warfarin may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib |
DB08880 | DB12498 | 1,510 | 76 | [
"DDInter1771",
"DDInter1238"
] | Teriflunomide | Mogamulizumab | Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide. | Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect the skin, causing various types of skin lesions. On August 8 2018, the U.S. Food and Drug Administration (FDA) approved mogamulizumab injection (also known as _Poteligeo_) for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. It was approved for the same indications in Canada in June 2022. Mogamulizumab is derived from Kyowa Hakko Kirin's POTELLIGENT (®) technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma. | Major | 2 | [
[
[
1510,
25,
76
]
],
[
[
1510,
62,
1461
],
[
1461,
23,
76
]
],
[
[
1510,
23,
1193
],
[
1193,
23,
76
]
],
[
[
1510,
64,
1531
],
[
1531,
24,
76
]
],
[
[
1510,
24,
496
],
[
496,
24,
76
]
],
[
[
1510,
24,
987
],
[
987,
63,
76
]
],
[
[
1510,
25,
384
],
[
384,
24,
76
]
],
[
[
1510,
63,
248
],
[
248,
24,
76
]
],
[
[
1510,
25,
287
],
[
287,
63,
76
]
],
[
[
1510,
25,
676
],
[
676,
64,
76
]
]
] | [
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Teriflunomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Teriflunomide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
],
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
],
[
"Vibrio cholerae CVD 103-HgR strain live antigen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diroximel fumarate"
],
[
"Diroximel fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mogamulizumab"
]
]
] | Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Mogamulizumab
Teriflunomide may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Mogamulizumab
Teriflunomide may lead to a major life threatening interaction when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine and Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab
Teriflunomide may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab
Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab
Teriflunomide may lead to a major life threatening interaction when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab
Teriflunomide may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Mogamulizumab |
DB00005 | DB01098 | 1,057 | 14 | [
"DDInter687",
"DDInter1622"
] | Etanercept | Rosuvastatin | Dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) tumor necrosis factor receptor (TNFR) linked to the Fc portion of human IgG1.[L14862,A216522] The Fc component of etanercept contains the CH2 domain, the CH3 domain and hinge region, but not the CH1 domain of IgG1. Etanercept is produced by recombinant DNA technology in a Chinese hamster ovary (CHO) mammalian cell expression system. It consists of 934 amino acids. It is used to treat or manage a variety of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis (AS), and juvenile idiopathic poly-articular arthritis (JIA). | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those with Type 2 Diabetes. The clear evidence of the benefit of statin use coupled with very minimal side effects or long term effects has resulted in this class becoming one of the most widely prescribed medications in North America.[A181087, A181406] Rosuvastatin and other drugs from the statin class of medications including [atorvastatin], [pravastatin], [simvastatin], [fluvastatin], and [lovastatin] are considered first-line options for the treatment of dyslipidemia.[A181087, A181406] This is largely due to the fact that cardiovascular disease (CVD), which includes heart attack, atherosclerosis, angina, peripheral artery disease, and stroke, has become a leading cause of death in high-income countries and a major cause of morbidity around the world. Elevated cholesterol levels, and in particular, elevated low-density lipoprotein (LDL) levels, are an important risk factor for the development of CVD.[A181087,A181553] Use of statins to target and reduce LDL levels has been shown in a number of landmark studies to significantly reduce the risk of development of CVD and all-cause mortality.[A181090,A181093,A181096,A181427,A181475,A181538] Statins are considered a cost-effective treatment option for CVD due to their evidence of reducing all-cause mortality including fatal and non-fatal CVD as well as the need for surgical revascularization or angioplasty following a heart attack.[A181087, A181406] Evidence has shown that even for low-risk individuals (with <10% risk of a major vascular event occurring within 5 years) statins cause a 20%-22% relative reduction in major cardiovascular events (heart attack, stroke, coronary revascularization, and coronary death) for every 1 mmol/L reduction in LDL without any significant side effects or risks.[A181397, A181403] While all statin medications are considered equally effective from a clinical standpoint, rosuvastatin is considered the most potent; doses of 10 to 40mg rosuvastatin per day were found in clinical studies to result in a 45.8% to 54.6% decreases in LDL cholesterol levels, which is about three-fold more potent than [atorvastatin]'s effects on LDL cholesterol.[A181409,A1793] However, the results of the SATURN trial concluded that despite this difference in potency, there was no difference in their effect on the progression of coronary atherosclerosis. Rosuvastatin is also a unique member of the class of statins due to its high hydrophilicity which increases hepatic uptake at the site of action, low bioavailability, and minimal metabolism via the Cytochrome P450 system. This last point results in less risk of drug-drug interactions compared to [atorvastatin], [lovastatin], and [simvastatin], which are all extensively metabolized by Cytochrome P450 (CYP) 3A4, an enzyme involved in the metabolism of many commonly used drugs. Drugs such as [ciclosporin], [gemfibrozil], and some antiretrovirals are more likely to interact with this statin through antagonism of OATP1B1 organic anion transporter protein 1B1-mediated hepatic uptake of rosuvastatin.[F4649, F4652] | Moderate | 1 | [
[
[
1057,
24,
14
]
],
[
[
1057,
24,
671
],
[
671,
24,
14
]
],
[
[
1057,
24,
1336
],
[
1336,
23,
14
]
],
[
[
1057,
24,
517
],
[
517,
62,
14
]
],
[
[
1057,
25,
305
],
[
305,
24,
14
]
],
[
[
1057,
25,
1250
],
[
1250,
63,
14
]
],
[
[
1057,
24,
1487
],
[
1487,
63,
14
]
],
[
[
1057,
25,
1377
],
[
1377,
25,
14
]
],
[
[
1057,
25,
1510
],
[
1510,
64,
14
]
],
[
[
1057,
24,
1554
],
[
1554,
64,
14
]
]
] | [
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etonogestrel"
],
[
"Etonogestrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norgestrel"
],
[
"Norgestrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rosuvastatin"
]
],
[
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colchicine"
],
[
"Colchicine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rosuvastatin"
]
]
] | Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Fluvastatin and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Etonogestrel and Etonogestrel may cause a minor interaction that can limit clinical effects when taken with Rosuvastatin
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Norgestrel and Norgestrel may cause a minor interaction that can limit clinical effects when taken with Rosuvastatin
Etanercept may lead to a major life threatening interaction when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Etanercept may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Etanercept may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Rosuvastatin
Etanercept may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Rosuvastatin
Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Colchicine and Colchicine may lead to a major life threatening interaction when taken with Rosuvastatin |
DB10989 | DB11834 | 496 | 1,303 | [
"DDInter858",
"DDInter849"
] | Hepatitis A Vaccine | Guselkumab | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infection and safely confers strong protection against the disease caused by infection with this virus.[A199185,L12756] In the US, the approved vaccine is inactivated while live Hepatitis A vaccines are currently available in other countries. | Guselkumab is a human immunoglobulin G1 lambda (IgG1λ) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation . In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis. Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis. | Moderate | 1 | [
[
[
496,
24,
1303
]
],
[
[
496,
63,
713
],
[
713,
24,
1303
]
],
[
[
496,
24,
270
],
[
270,
63,
1303
]
],
[
[
496,
24,
1456
],
[
1456,
24,
1303
]
],
[
[
496,
63,
375
],
[
375,
25,
1303
]
],
[
[
496,
24,
1259
],
[
1259,
25,
1303
]
],
[
[
496,
24,
676
],
[
676,
64,
1303
]
],
[
[
496,
63,
713
],
[
713,
24,
949
],
[
949,
24,
1303
]
],
[
[
496,
63,
58
],
[
58,
23,
1193
],
[
1193,
23,
1303
]
],
[
[
496,
63,
147
],
[
147,
63,
1461
],
[
1461,
23,
1303
]
]
] | [
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Guselkumab"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Guselkumab"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Guselkumab"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clostridium tetani toxoid antigen (formaldehyde inactivated)"
],
[
"Clostridium tetani toxoid antigen (formaldehyde inactivated)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guselkumab"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Guselkumab"
]
],
[
[
"Hepatitis A Vaccine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Guselkumab"
]
]
] | Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Guselkumab
Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Guselkumab
Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Guselkumab
Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Clostridium tetani toxoid antigen (formaldehyde inactivated) and Clostridium tetani toxoid antigen (formaldehyde inactivated) may cause a moderate interaction that could exacerbate diseases when taken with Guselkumab
Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Guselkumab
Hepatitis A Vaccine may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Guselkumab |
DB00749 | DB01191 | 59 | 1,039 | [
"DDInter699",
"DDInter518"
] | Etodolac | Dexfenfluramine | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Dexfenfluramine, also marketed under the name Redux, is a serotoninergic anorectic drug. For a fairly limited time during the middle of the nineties, the US FDA had approved it for use in managing weight loss. However, following multiple concerns about the cardiovascular side-effects of the drug, such approval was withdrawn. | Moderate | 1 | [
[
[
59,
24,
1039
]
],
[
[
59,
6,
6017
],
[
6017,
45,
1039
]
],
[
[
59,
24,
1046
],
[
1046,
63,
1039
]
],
[
[
59,
25,
500
],
[
500,
63,
1039
]
],
[
[
59,
63,
702
],
[
702,
24,
1039
]
],
[
[
59,
24,
477
],
[
477,
24,
1039
]
],
[
[
59,
64,
834
],
[
834,
24,
1039
]
],
[
[
59,
24,
222
],
[
222,
25,
1039
]
],
[
[
59,
63,
121
],
[
121,
25,
1039
]
],
[
[
59,
25,
39
],
[
39,
64,
1039
]
]
] | [
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Etodolac",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Dexfenfluramine"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Caplacizumab"
],
[
"Caplacizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Etodolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enoxaparin"
],
[
"Enoxaparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Etodolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Drotrecogin alfa"
],
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
]
],
[
[
"Etodolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexfenfluramine"
]
]
] | Etodolac (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Dexfenfluramine (Compound)
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Caplacizumab and Caplacizumab may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Etodolac may lead to a major life threatening interaction when taken with Enoxaparin and Enoxaparin may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Anagrelide and Anagrelide may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Etodolac may lead to a major life threatening interaction when taken with Drotrecogin alfa and Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Dexfenfluramine
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may lead to a major life threatening interaction when taken with Dexfenfluramine
Etodolac may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Dexfenfluramine |
DB00549 | DB11560 | 522 | 1,678 | [
"DDInter1955",
"DDInter1038"
] | Zafirlukast | Lesinurad | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages. | Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter associated with diuretic-induced hyperuricemia. Marketed as the product Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone. In August 2017, a combination oral therapy consisting of lesinurad and was FDA-approved under the brand name Duzallo indicated for the treatment of gout-related hyperuricemia in patients with uncontrolled gout. | Moderate | 1 | [
[
[
522,
24,
1678
]
],
[
[
522,
63,
168
],
[
168,
23,
1678
]
],
[
[
522,
24,
263
],
[
263,
24,
1678
]
],
[
[
522,
24,
484
],
[
484,
63,
1678
]
],
[
[
522,
63,
11
],
[
11,
24,
1678
]
],
[
[
522,
25,
1377
],
[
1377,
24,
1678
]
],
[
[
522,
63,
168
],
[
168,
25,
913
],
[
913,
63,
1678
]
],
[
[
522,
24,
263
],
[
263,
25,
913
],
[
913,
63,
1678
]
],
[
[
522,
24,
1479
],
[
1479,
24,
877
],
[
877,
63,
1678
]
],
[
[
522,
24,
1491
],
[
1491,
63,
1374
],
[
1374,
24,
1678
]
]
] | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lesinurad"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lesinurad"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
],
[
"Axitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lesinurad"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lesinurad"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lesinurad"
]
],
[
[
"Zafirlukast",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lesinurad"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lesinurad"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Axitinib"
],
[
"Axitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lesinurad"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lesinurad"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lesinurad"
]
]
] | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Lesinurad
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Axitinib and Axitinib may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad
Zafirlukast may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Axitinib and Axitinib may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Lesinurad |
DB01254 | DB06372 | 1,213 | 259 | [
"DDInter484",
"DDInter1594"
] | Dasatinib | Rilonacept | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL | Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old. | Moderate | 1 | [
[
[
1213,
24,
259
]
],
[
[
1213,
24,
1619
],
[
1619,
63,
259
]
],
[
[
1213,
63,
1565
],
[
1565,
24,
259
]
],
[
[
1213,
25,
985
],
[
985,
63,
259
]
],
[
[
1213,
25,
478
],
[
478,
24,
259
]
],
[
[
1213,
24,
309
],
[
309,
24,
259
]
],
[
[
1213,
64,
704
],
[
704,
24,
259
]
],
[
[
1213,
25,
1011
],
[
1011,
64,
259
]
],
[
[
1213,
64,
1377
],
[
1377,
25,
259
]
],
[
[
1213,
24,
1619
],
[
1619,
63,
1565
],
[
1565,
24,
259
]
]
] | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonazepam"
],
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fentanyl"
],
[
"Fentanyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilonacept"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rilonacept"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clonazepam"
],
[
"Clonazepam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilonacept"
]
]
] | Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Clonazepam and Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Dasatinib may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Dasatinib may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Dasatinib may lead to a major life threatening interaction when taken with Fentanyl and Fentanyl may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Dasatinib may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Rilonacept
Dasatinib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Rilonacept
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Clonazepam and Clonazepam may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept |
DB00026 | DB06650 | 1,184 | 1,500 | [
"DDInter94",
"DDInter1324"
] | Anakinra | Ofatumumab | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta. Anakinra is indicated for the management of rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease-modifying antirheumatic drugs (DMARDs), as well as the treatment of neonatal-onset multisystem inflammatory disease (NOMID) and deficiency of interleukin-1 receptor antagonist (DIRA). Since IL-1 has an important role in inflammation and immunological responses, anakinra is also used for the off-label treatment of inflammatory diseases. Anakinra is produced using the _ | Ofatumumab is a novel anti-CD20 monoclonal antibody that targets B-cells. It is an IgG1κ human monoclonal antibody produced from a recombinant murine cell line (NS0) via transgenic mouse and hybridoma technology. Ofatumumab works by recognizing antigens that are expressed on the tumour cells in certain cancers; however, the antigen is not tumour-specific and can also be found in normal B-cells. Ofatumumab was first approved by the FDA in 2009. It is used in the treatment of recurrent, progressive, or recurrent chronic lymphocytic leukemia (CLL) or CLL in treatment-naive patients in whom fludarabine-based therapy is considered inappropriate. Ofatumumab is used as monotherapy or in combination with other medications, depending on the patient profile and previous treatment history. Although it has a similar molecular mechanism of action as [rituximab], another CD-20 monoclonal antibody used in the treatment of rheumatoid arthritis and B-cell non-Hodgkin's lymphoma, ofatumumab has a higher affinity towards CD20. Ofatumumab is available for intravenous administration and is marketed as Arzerra. In Phase III clinical trials consisting of subjects with relapsing forms of multiple sclerosis (RMS), subcutaneous administration of ofatumumab reduced the number of relapses and delayed disease progression. In February 2020, FDA and EMA approved Supplemental Biologics License Application (sBLA) and Marketing Authorization Application (MAA), respectively, for ofatumumab for the treatment of RMS in adults. The FDA subsequently approved ofatumumab for the treatment of RMS on August 20, 2020. The potential therapeutic use of ofatumumab in various lymphomas and rheumatoid arthritis has also been investigated. | Moderate | 1 | [
[
[
1184,
24,
1500
]
],
[
[
1184,
24,
270
],
[
270,
63,
1500
]
],
[
[
1184,
24,
869
],
[
869,
24,
1500
]
],
[
[
1184,
25,
1510
],
[
1510,
64,
1500
]
],
[
[
1184,
64,
1057
],
[
1057,
25,
1500
]
],
[
[
1184,
25,
1064
],
[
1064,
25,
1500
]
],
[
[
1184,
24,
270
],
[
270,
24,
1129
],
[
1129,
63,
1500
]
],
[
[
1184,
24,
1129
],
[
1129,
63,
270
],
[
270,
63,
1500
]
],
[
[
1184,
25,
1510
],
[
1510,
25,
270
],
[
270,
63,
1500
]
],
[
[
1184,
64,
1057
],
[
1057,
25,
270
],
[
270,
63,
1500
]
]
] | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofatumumab"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofatumumab"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofatumumab"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ofatumumab"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ofatumumab"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ofatumumab"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
],
[
"Human adenovirus e serotype 4 strain cl-68578 antigen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofatumumab"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
],
[
"Human adenovirus e serotype 4 strain cl-68578 antigen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofatumumab"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofatumumab"
]
],
[
[
"Anakinra",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ofatumumab"
]
]
] | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab
Anakinra may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Ofatumumab
Anakinra may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Ofatumumab
Anakinra may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Ofatumumab
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen and Human adenovirus e serotype 4 strain cl-68578 antigen may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab
Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen and Human adenovirus e serotype 4 strain cl-68578 antigen may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab
Anakinra may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab
Anakinra may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Ofatumumab |
DB00295 | DB00808 | 475 | 1,605 | [
"DDInter1244",
"DDInter916"
] | Morphine | Indapamide | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941. | The most significant modifiable risk factor for cardiovascular disease and the most prominent contributor to all-cause mortality is hypertension. Characterized by an office blood pressure of ≥140/90, hypertension is pervasive and impacts an estimated 25% of adults globally. Treatment for hypertension should include a number of lifestyle changes (ie. reduced sodium intake) along with pharmacotherapy - it should be noted that treatment with several antihypertensive agents may be required in order to achieve blood pressure targets. Thiazide-like diuretics such as indapamide are a valuable tool for the treatment of hypertension and continue to grow in popularity, falling behind only ACE inhibitors in terms of prescription frequency. When compared to [hydrochlorothiazide] (another commonly prescribed diuretic), indapamide has been shown to be superior at lowering systolic blood pressure, reducing left ventricular mass index, lowering oxidative stress, inhibiting platelet aggregation, and reducing microalbuminuria associated with diabetes. Interestingly, unlike thiazide diuretics, several sources suggest that indapamide is not associated with glucose or lipid disturbances.[A204134,A204161] Indapamide is characterized by both a methylindoline and a sulfamoyl chlorobenzamide functional group, with the former being largely responsible for the molecule’s lipid solubility. | Moderate | 1 | [
[
[
475,
24,
1605
]
],
[
[
475,
24,
811
],
[
811,
1,
1605
]
],
[
[
475,
24,
1335
],
[
1335,
40,
1605
]
],
[
[
475,
6,
8374
],
[
8374,
45,
1605
]
],
[
[
475,
21,
29135
],
[
29135,
60,
1605
]
],
[
[
475,
24,
1511
],
[
1511,
62,
1605
]
],
[
[
475,
24,
85
],
[
85,
23,
1605
]
],
[
[
475,
63,
352
],
[
352,
23,
1605
]
],
[
[
475,
24,
104
],
[
104,
63,
1605
]
],
[
[
475,
25,
593
],
[
593,
63,
1605
]
]
] | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
],
[
"Metolazone",
"{u} (Compound) resembles {v} (Compound)",
"Indapamide"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
],
[
"Oxcarbazepine",
"{u} (Compound) resembles {v} (Compound)",
"Indapamide"
]
],
[
[
"Morphine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Indapamide"
]
],
[
[
"Morphine",
"{u} (Compound) causes {v} (Side Effect)",
"Blister"
],
[
"Blister",
"{u} (Side Effect) is caused by {v} (Compound)",
"Indapamide"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Indapamide"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atropine"
],
[
"Atropine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Indapamide"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trospium"
],
[
"Trospium",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Indapamide"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indapamide"
]
]
] | Morphine may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone (Compound) resembles Indapamide (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine (Compound) resembles Indapamide (Compound)
Morphine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Indapamide (Compound)
Morphine (Compound) causes Blister (Side Effect) and Blister (Side Effect) is caused by Indapamide (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a minor interaction that can limit clinical effects when taken with Indapamide
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Atropine and Atropine may cause a minor interaction that can limit clinical effects when taken with Indapamide
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospium may cause a minor interaction that can limit clinical effects when taken with Indapamide
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Indapamide
Morphine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Indapamide |
DB01254 | DB04835 | 1,213 | 1,655 | [
"DDInter484",
"DDInter1125"
] | Dasatinib | Maraviroc | Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL | Maraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the interaction between HIV and CCR5. It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007. | Moderate | 1 | [
[
[
1213,
24,
1655
]
],
[
[
1213,
6,
8374
],
[
8374,
45,
1655
]
],
[
[
1213,
7,
6952
],
[
6952,
46,
1655
]
],
[
[
1213,
21,
29538
],
[
29538,
60,
1655
]
],
[
[
1213,
63,
1051
],
[
1051,
24,
1655
]
],
[
[
1213,
64,
1061
],
[
1061,
24,
1655
]
],
[
[
1213,
25,
1468
],
[
1468,
63,
1655
]
],
[
[
1213,
24,
1017
],
[
1017,
63,
1655
]
],
[
[
1213,
24,
392
],
[
392,
24,
1655
]
],
[
[
1213,
64,
1377
],
[
1377,
25,
1655
]
]
] | [
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maraviroc"
]
],
[
[
"Dasatinib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Maraviroc"
]
],
[
[
"Dasatinib",
"{u} (Compound) upregulates {v} (Gene)",
"MCOLN1"
],
[
"MCOLN1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Maraviroc"
]
],
[
[
"Dasatinib",
"{u} (Compound) causes {v} (Side Effect)",
"Herpes virus infection"
],
[
"Herpes virus infection",
"{u} (Side Effect) is caused by {v} (Compound)",
"Maraviroc"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maraviroc"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maraviroc"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maraviroc"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maraviroc"
]
],
[
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Maraviroc"
]
],
[
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Maraviroc"
]
]
] | Dasatinib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Maraviroc (Compound)
Dasatinib (Compound) upregulates MCOLN1 (Gene) and MCOLN1 (Gene) is upregulated by Maraviroc (Compound)
Dasatinib (Compound) causes Herpes virus infection (Side Effect) and Herpes virus infection (Side Effect) is caused by Maraviroc (Compound)
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Maraviroc
Dasatinib may lead to a major life threatening interaction when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Maraviroc
Dasatinib may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Maraviroc
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Maraviroc
Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Maraviroc
Dasatinib may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Maraviroc |
DB00033 | DB00352 | 342 | 482 | [
"DDInter949",
"DDInter1814"
] | Interferon gamma-1b | Tioguanine | Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography. The sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b. | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Moderate | 1 | [
[
[
342,
24,
482
]
],
[
[
342,
24,
869
],
[
869,
63,
482
]
],
[
[
342,
24,
912
],
[
912,
24,
482
]
],
[
[
342,
63,
1257
],
[
1257,
24,
482
]
],
[
[
342,
25,
593
],
[
593,
63,
482
]
],
[
[
342,
25,
1101
],
[
1101,
24,
482
]
],
[
[
342,
25,
1292
],
[
1292,
64,
482
]
],
[
[
342,
25,
1064
],
[
1064,
25,
482
]
],
[
[
342,
24,
869
],
[
869,
21,
28868
],
[
28868,
60,
482
]
],
[
[
342,
24,
322
],
[
322,
5,
11555
],
[
11555,
44,
482
]
]
] | [
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
]
],
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
]
],
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
]
],
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegfilgrastim"
],
[
"Pegfilgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
]
],
[
[
"Interferon gamma-1b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
]
],
[
[
"Interferon gamma-1b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
]
],
[
[
"Interferon gamma-1b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
],
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tioguanine"
]
],
[
[
"Interferon gamma-1b",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tioguanine"
]
],
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} (Compound) causes {v} (Side Effect)",
"Stomatitis"
],
[
"Stomatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tioguanine"
]
],
[
[
"Interferon gamma-1b",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Tioguanine"
]
]
] | Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine
Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine
Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Pegfilgrastim and Pegfilgrastim may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine
Interferon gamma-1b may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine
Interferon gamma-1b may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine
Interferon gamma-1b may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Tioguanine
Interferon gamma-1b may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Tioguanine
Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan (Compound) causes Stomatitis (Side Effect) and Stomatitis (Side Effect) is caused by Tioguanine (Compound)
Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Tioguanine (Compound) |
DB00081 | DB00446 | 273 | 597 | [
"DDInter1838",
"DDInter351"
] | Tositumomab | Chloramphenicol | Murine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a radioactive isotope of iodine). | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.[L43942,L44022] | Moderate | 1 | [
[
[
273,
24,
597
]
],
[
[
273,
24,
1230
],
[
1230,
23,
597
]
],
[
[
273,
24,
318
],
[
318,
62,
597
]
],
[
[
273,
24,
599
],
[
599,
24,
597
]
],
[
[
273,
24,
810
],
[
810,
63,
597
]
],
[
[
273,
25,
126
],
[
126,
63,
597
]
],
[
[
273,
64,
581
],
[
581,
24,
597
]
],
[
[
273,
25,
927
],
[
927,
64,
597
]
],
[
[
273,
25,
695
],
[
695,
25,
597
]
],
[
[
273,
24,
1230
],
[
1230,
6,
10215
],
[
10215,
45,
597
]
]
] | [
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
],
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Tositumomab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Chloramphenicol"
]
],
[
[
"Tositumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Chloramphenicol"
]
]
] | Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a minor interaction that can limit clinical effects when taken with Chloramphenicol
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram and Escitalopram may cause a minor interaction that can limit clinical effects when taken with Chloramphenicol
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 and Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol
Tositumomab may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol
Tositumomab may lead to a major life threatening interaction when taken with Infliximab and Infliximab may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol
Tositumomab may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may lead to a major life threatening interaction when taken with Chloramphenicol
Tositumomab may lead to a major life threatening interaction when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Chloramphenicol
Tositumomab may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Chloramphenicol (Compound) |
DB09039 | DB11963 | 1,670 | 1,045 | [
"DDInter629",
"DDInter465"
] | Eliglustat | Dacomitinib | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs. This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide. Eliglustat is mainly metabolized by CYP2D6. Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers ( | Dacomitinib, designed as (2E)-N-16-4-(piperidin-1-yl) but-2-enamide, is an oral highly selective quinazalone part of the second-generation tyrosine kinase inhibitors which are characterized by the irreversible binding at the ATP domain of the epidermal growth factor receptor family kinase domains. Dacomitinib was developed by Pfizer Inc and approved by the FDA on September 27, 2018. Some evidence in the literature suggests the therapeutic potential of dacomitinib in the epithelial ovarian cancer model, although further investigations are needed. | Major | 2 | [
[
[
1670,
25,
1045
]
],
[
[
1670,
62,
479
],
[
479,
23,
1045
]
],
[
[
1670,
63,
1039
],
[
1039,
24,
1045
]
],
[
[
1670,
64,
1376
],
[
1376,
24,
1045
]
],
[
[
1670,
25,
384
],
[
384,
24,
1045
]
],
[
[
1670,
24,
710
],
[
710,
63,
1045
]
],
[
[
1670,
63,
843
],
[
843,
25,
1045
]
],
[
[
1670,
24,
1427
],
[
1427,
25,
1045
]
],
[
[
1670,
64,
1568
],
[
1568,
25,
1045
]
],
[
[
1670,
25,
1241
],
[
1241,
25,
1045
]
]
] | [
[
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacomitinib"
]
],
[
[
"Eliglustat",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dacomitinib"
]
],
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacomitinib"
]
],
[
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacomitinib"
]
],
[
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacomitinib"
]
],
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Binimetinib"
],
[
"Binimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dacomitinib"
]
],
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetrabenazine"
],
[
"Tetrabenazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacomitinib"
]
],
[
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
],
[
"Vortioxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacomitinib"
]
],
[
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pimozide"
],
[
"Pimozide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacomitinib"
]
],
[
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brexpiprazole"
],
[
"Brexpiprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dacomitinib"
]
]
] | Eliglustat may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Dacomitinib
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Eliglustat may lead to a major life threatening interaction when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Eliglustat may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib and Binimetinib may cause a moderate interaction that could exacerbate diseases when taken with Dacomitinib
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Tetrabenazine and Tetrabenazine may lead to a major life threatening interaction when taken with Dacomitinib
Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine and Vortioxetine may lead to a major life threatening interaction when taken with Dacomitinib
Eliglustat may lead to a major life threatening interaction when taken with Pimozide and Pimozide may lead to a major life threatening interaction when taken with Dacomitinib
Eliglustat may lead to a major life threatening interaction when taken with Brexpiprazole and Brexpiprazole may lead to a major life threatening interaction when taken with Dacomitinib |
DB00099 | DB00544 | 440 | 970 | [
"DDInter735",
"DDInter757"
] | Filgrastim | Fluorouracil | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the sequence for expression in _E. Coli_. Human G-CSF is a glycoprotein that regulates the production and release of neutrophils from the bone marrow. Filgrastim mimics the biological actions of G-CSF to increase the levels of neutrophils in the blood. It has a number of therapeutic uses, including the management and prevention of infections and febrile neutropenia in patients receiving myelosuppressive chemotherapy or radiation therapy. It is also used to manage severe chronic neutropenia and mobilize hematopoietic progenitor cells to the | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Moderate | 1 | [
[
[
440,
24,
970
]
],
[
[
440,
24,
132
],
[
132,
1,
970
]
],
[
[
440,
24,
147
],
[
147,
62,
970
]
],
[
[
440,
24,
1686
],
[
1686,
63,
970
]
],
[
[
440,
24,
141
],
[
141,
24,
970
]
],
[
[
440,
63,
1648
],
[
1648,
24,
970
]
],
[
[
440,
25,
1064
],
[
1064,
25,
970
]
],
[
[
440,
24,
770
],
[
770,
64,
970
]
],
[
[
440,
24,
377
],
[
377,
25,
970
]
],
[
[
440,
24,
132
],
[
132,
23,
956
],
[
956,
62,
970
]
]
] | [
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Uracil mustard"
],
[
"Uracil mustard",
"{u} (Compound) resembles {v} (Compound)",
"Fluorouracil"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluorouracil"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Temozolomide"
],
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Floxuridine"
],
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
]
],
[
[
"Filgrastim",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluorouracil"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluorouracil"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mitomycin"
],
[
"Mitomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluorouracil"
]
],
[
[
"Filgrastim",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Uracil mustard"
],
[
"Uracil mustard",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluorouracil"
]
]
] | Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Uracil mustard and Uracil mustard (Compound) resembles Fluorouracil (Compound)
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Fluorouracil
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Temozolomide and Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil
Filgrastim may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Fluorouracil
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Fluorouracil
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Mitomycin and Mitomycin may lead to a major life threatening interaction when taken with Fluorouracil
Filgrastim may cause a moderate interaction that could exacerbate diseases when taken with Uracil mustard and Uracil mustard may cause a minor interaction that can limit clinical effects when taken with Norfloxacin and Norfloxacin may cause a minor interaction that can limit clinical effects when taken with Fluorouracil |
DB01176 | DB01320 | 537 | 651 | [
"DDInter453",
"DDInter783"
] | Cyclizine | Fosphenytoin | A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935) | Fosphenytoin is a water-soluble phenytoin prodrug used only in hospitals for the treatment of epileptic seizures. It works by slowing down impulses in the brain that cause seizures. Its main mechanism is to block frequency-dependent, use-dependent and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials. | Moderate | 1 | [
[
[
537,
24,
651
]
],
[
[
537,
40,
307
],
[
307,
1,
651
]
],
[
[
537,
40,
11234
],
[
11234,
40,
651
]
],
[
[
537,
63,
362
],
[
362,
1,
651
]
],
[
[
537,
6,
6017
],
[
6017,
45,
651
]
],
[
[
537,
21,
28691
],
[
28691,
60,
651
]
],
[
[
537,
63,
1264
],
[
1264,
24,
651
]
],
[
[
537,
24,
516
],
[
516,
63,
651
]
],
[
[
537,
24,
1311
],
[
1311,
24,
651
]
],
[
[
537,
40,
104
],
[
104,
24,
651
]
]
] | [
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Cyclizine",
"{u} (Compound) resembles {v} (Compound)",
"Modafinil"
],
[
"Modafinil",
"{u} (Compound) resembles {v} (Compound)",
"Fosphenytoin"
]
],
[
[
"Cyclizine",
"{u} (Compound) resembles {v} (Compound)",
"Benzyl Benzoate"
],
[
"Benzyl Benzoate",
"{u} (Compound) resembles {v} (Compound)",
"Fosphenytoin"
]
],
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Fosphenytoin"
]
],
[
[
"Cyclizine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Fosphenytoin"
]
],
[
[
"Cyclizine",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fosphenytoin"
]
],
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levocetirizine"
],
[
"Levocetirizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Cyclizine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
],
[
[
"Cyclizine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
],
[
"Methdilazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
]
]
] | Cyclizine (Compound) resembles Modafinil (Compound) and Modafinil (Compound) resembles Fosphenytoin (Compound)
Cyclizine (Compound) resembles Benzyl Benzoate (Compound) and Benzyl Benzoate (Compound) resembles Fosphenytoin (Compound)
Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin (Compound) resembles Fosphenytoin (Compound)
Cyclizine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Fosphenytoin (Compound)
Cyclizine (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Fosphenytoin (Compound)
Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Levocetirizine and Levocetirizine may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin
Cyclizine (Compound) resembles Methdilazine (Compound) and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin |
DB00637 | DB12130 | 1,557 | 1,017 | [
"DDInter128",
"DDInter1094"
] | Astemizole | Lorlatinib | Astemizole is a long-acting, non-sedating second generation antihistamine used in the treatment of allergy symptoms. It was withdrawn from market by the manufacturer in 1999 due to the potential to cause arrhythmias at high doses, especially when when taken with CYP inhibitors or grapefruit juice. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. | Moderate | 1 | [
[
[
1557,
24,
1017
]
],
[
[
1557,
24,
1612
],
[
1612,
23,
1017
]
],
[
[
1557,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
1557,
24,
786
],
[
786,
24,
1017
]
],
[
[
1557,
64,
11
],
[
11,
24,
1017
]
],
[
[
1557,
25,
1154
],
[
1154,
24,
1017
]
],
[
[
1557,
63,
21
],
[
21,
24,
1017
]
],
[
[
1557,
24,
971
],
[
971,
63,
1017
]
],
[
[
1557,
25,
877
],
[
877,
63,
1017
]
],
[
[
1557,
23,
1247
],
[
1247,
24,
1017
]
]
] | [
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
],
[
"Rilpivirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Astemizole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Astemizole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
]
] | Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Astemizole may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Astemizole may lead to a major life threatening interaction when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Astemizole may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Astemizole may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib |
DB00370 | DB09241 | 1,251 | 1,629 | [
"DDInter1230",
"DDInter1186"
] | Mirtazapine | Methylene blue | Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6157] The effects of this drug may be observed as early as 1 week after beginning therapy.[A178144,L6160] In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery. | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. Its use as an urinary tract antiseptic has also been investigated. Methylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early clinical trials to be an inhibitor of Tau protein aggregation. The drug is of potential interest for the treatment of patients with Alzheimer's disease. | Major | 2 | [
[
[
1251,
25,
1629
]
],
[
[
1251,
24,
1148
],
[
1148,
24,
1629
]
],
[
[
1251,
25,
593
],
[
593,
25,
1629
]
],
[
[
1251,
24,
407
],
[
407,
64,
1629
]
],
[
[
1251,
63,
475
],
[
475,
25,
1629
]
],
[
[
1251,
37,
247
],
[
247,
25,
1629
]
],
[
[
1251,
24,
1148
],
[
1148,
63,
1052
],
[
1052,
24,
1629
]
],
[
[
1251,
24,
1674
],
[
1674,
24,
1052
],
[
1052,
24,
1629
]
],
[
[
1251,
24,
480
],
[
480,
74,
1052
],
[
1052,
24,
1629
]
],
[
[
1251,
25,
593
],
[
593,
63,
1000
],
[
1000,
24,
1629
]
]
] | [
[
[
"Mirtazapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
],
[
[
"Mirtazapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
],
[
"Iobenguane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
],
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
],
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
],
[
[
"Mirtazapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
],
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
],
[
[
"Mirtazapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanadrel"
],
[
"Guanadrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
]
] | Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Mirtazapine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Methylene blue
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may lead to a major life threatening interaction when taken with Methylene blue
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Methylene blue
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Mirtazapine may lead to a major life threatening interaction when taken with Iobenguane and Iobenguane may lead to a major life threatening interaction when taken with Methylene blue
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Mirtazapine may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol (Compound) resembles Ritodrine (Compound) and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Mirtazapine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Guanadrel and Guanadrel may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue |
DB00431 | DB09052 | 1,503 | 250 | [
"DDInter1072",
"DDInter220"
] | Lindane | Blinatumomab | An organochlorine insecticide that has been used as a pediculicide and a scabicide. Lindane has been banned in California, United Kingdom, Australia, and many western countries due to concerns about neurotoxicity and adverse effects on the environment. In Canada, Lindane is not recommmended as a first-line therapy due to reports of resistance, neurotoxicity, and bone marrow suppression, but has been approved by the FDA as a second-line therapy for topical treatment of pediculosis capitis (head lice), pediculosis pubis (pubic lice), or scabies in patients greater than two years of age who cannot tolerate or have failed first-line treatment. Lindane is still allowed for pharmaceutical use until 2015. | Blinatumomab is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody formed by the recombinant fusion of an anti-CD3 single-chain variable fragment (scFV) and an anti-CD19 scFV through a short peptide linker.[A254836,L44311] CD3 is an antigen expressed on the surface of T-cells, while CD19 is mostly expressed on the surface of malignant B-cells. Since blinatumomab has an affinity to both antigens, it redirects T-cells to tumor cells expressing CD19 and promotes tumor cell lysis and apoptosis.[A7659,A7660,A254831] Blinatumomab is manufactured by Amgen Inc. and marketed under the brand Blincyto. It was first approved by the FDA in December 2014 for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients. In March 2018, it was approved under the FDA’s accelerated approval program for the treatment of CD19-positive B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) greater than or equal to 0.1% in adults and children. Full approval for this indication was granted in June 2023.[L46991,L46996] Blinatumomab has a short half-life, requiring patients to receive a continuous infusion over 4-week cycles using a portable mini-pump for optimum delivery. | Moderate | 1 | [
[
[
1503,
24,
250
]
],
[
[
1503,
24,
1662
],
[
1662,
63,
250
]
],
[
[
1503,
24,
828
],
[
828,
24,
250
]
],
[
[
1503,
63,
576
],
[
576,
24,
250
]
],
[
[
1503,
25,
497
],
[
497,
25,
250
]
],
[
[
1503,
64,
534
],
[
534,
25,
250
]
],
[
[
1503,
63,
695
],
[
695,
25,
250
]
],
[
[
1503,
24,
1662
],
[
1662,
63,
828
],
[
828,
24,
250
]
],
[
[
1503,
24,
828
],
[
828,
24,
1662
],
[
1662,
63,
250
]
],
[
[
1503,
24,
1267
],
[
1267,
63,
1662
],
[
1662,
63,
250
]
]
] | [
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Lindane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Blinatumomab"
]
],
[
[
"Lindane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Blinatumomab"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Blinatumomab"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxycodone"
],
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
],
[
[
"Lindane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifampridine"
],
[
"Amifampridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
]
]
] | Lindane may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Lindane may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Blinatumomab
Lindane may lead to a major life threatening interaction when taken with Tramadol and Tramadol may lead to a major life threatening interaction when taken with Blinatumomab
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Blinatumomab
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Oxycodone and Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab
Lindane may cause a moderate interaction that could exacerbate diseases when taken with Amifampridine and Amifampridine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab |
DB00013 | DB08918 | 1,255 | 41 | [
"DDInter1905",
"DDInter1059"
] | Urokinase | Levomilnacipran | Urokinase is an endogenous peptide that is cleaved in the presence of plasmin between lysine 158 and isoleucine 159 to yield active urokinase. Urokinase remains connected between these 2 chains by a sulfhydryl bond. Urokinase was granted FDA approval on 16 January 1978. | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults. While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use. | Moderate | 1 | [
[
[
1255,
24,
41
]
],
[
[
1255,
24,
901
],
[
901,
40,
41
]
],
[
[
1255,
25,
498
],
[
498,
63,
41
]
],
[
[
1255,
25,
330
],
[
330,
24,
41
]
],
[
[
1255,
24,
1061
],
[
1061,
24,
41
]
],
[
[
1255,
64,
1578
],
[
1578,
24,
41
]
],
[
[
1255,
24,
121
],
[
121,
25,
41
]
],
[
[
1255,
24,
901
],
[
901,
1,
1349
],
[
1349,
40,
41
]
],
[
[
1255,
25,
498
],
[
498,
63,
901
],
[
901,
40,
41
]
],
[
[
1255,
24,
1061
],
[
1061,
24,
901
],
[
901,
40,
41
]
]
] | [
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
[
"Milnacipran",
"{u} (Compound) resembles {v} (Compound)",
"Levomilnacipran"
]
],
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
],
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ramucirumab"
],
[
"Ramucirumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
[
"Milnacipran",
"{u} (Compound) resembles {v} (Compound)",
"Meperidine"
],
[
"Meperidine",
"{u} (Compound) resembles {v} (Compound)",
"Levomilnacipran"
]
],
[
[
"Urokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
],
[
"Edoxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
[
"Milnacipran",
"{u} (Compound) resembles {v} (Compound)",
"Levomilnacipran"
]
],
[
[
"Urokinase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
[
"Milnacipran",
"{u} (Compound) resembles {v} (Compound)",
"Levomilnacipran"
]
]
] | Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Urokinase may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Urokinase may lead to a major life threatening interaction when taken with Ramucirumab and Ramucirumab may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Urokinase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may lead to a major life threatening interaction when taken with Levomilnacipran
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Meperidine (Compound) and Meperidine (Compound) resembles Levomilnacipran (Compound)
Urokinase may lead to a major life threatening interaction when taken with Edoxaban and Edoxaban may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Urokinase may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound) |
DB00575 | DB09112 | 1,020 | 1,455 | [
"DDInter412",
"DDInter1306"
] | Clonidine | Nitrous acid | Clonidine is an imidazole derivate that acts as an agonist of alpha-2 adrenoceptors. This activity is useful for the treatment of hypertension, severe pain, and ADHD.[L7237,L7240,L7243,L7246] Clonidine was granted FDA approval on 3 September 1974. | Nitrous acid (as sodium nitrite) is used as part of an intravenous mixture with sodium thiosulfate to treat cyanide poisoning. It is on the World Health Organization's List of Essential Medicines, a list of the most important medications needed in a basic health system. There is also research to investigate its applicability towards treatments for heart attacks, brain aneurysms, pulmonary hypertension in infants, and Pseudomonas aeruginosa infections. | Moderate | 1 | [
[
[
1020,
24,
1455
]
],
[
[
1020,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
1020,
24,
433
],
[
433,
63,
1455
]
],
[
[
1020,
1,
1084
],
[
1084,
24,
1455
]
],
[
[
1020,
63,
1061
],
[
1061,
24,
1455
]
],
[
[
1020,
24,
1311
],
[
1311,
25,
1455
]
],
[
[
1020,
62,
608
],
[
608,
25,
1455
]
],
[
[
1020,
24,
1450
],
[
1450,
63,
312
],
[
312,
24,
1455
]
],
[
[
1020,
1,
1084
],
[
1084,
24,
1450
],
[
1450,
24,
1455
]
],
[
[
1020,
63,
1061
],
[
1061,
24,
312
],
[
312,
24,
1455
]
]
] | [
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
],
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Clonidine",
"{u} (Compound) resembles {v} (Compound)",
"Lofexidine"
],
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nitrous acid"
]
],
[
[
"Clonidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nitrous acid"
]
],
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eplerenone"
],
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Clonidine",
"{u} (Compound) resembles {v} (Compound)",
"Lofexidine"
],
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
],
[
[
"Clonidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eplerenone"
],
[
"Eplerenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitrous acid"
]
]
] | Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Clonidine (Compound) resembles Lofexidine (Compound) and Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may lead to a major life threatening interaction when taken with Nitrous acid
Clonidine may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may lead to a major life threatening interaction when taken with Nitrous acid
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Eplerenone and Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Clonidine (Compound) resembles Lofexidine (Compound) and Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid
Clonidine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Eplerenone and Eplerenone may cause a moderate interaction that could exacerbate diseases when taken with Nitrous acid |
DB01627 | DB09268 | 1,208 | 1,662 | [
"DDInter1071",
"DDInter1464"
] | Lincomycin | Picosulfuric acid | Lincomycin is a lincosamide antibiotic first isolated from the soil bacterium _Streptomyces lincolnensis_ in Lincoln, Nebraska. Clinical use of lincomycin has largely been superseded by its semisynthetic derivative [clindamycin] due to its higher efficacy and a wider range of susceptible organisms, though lincomycin remains in use.[A190657, A190621] Lincomycin was approved by the FDA on December 29, 1964. | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years. | Moderate | 1 | [
[
[
1208,
24,
1662
]
],
[
[
1208,
1,
568
],
[
568,
24,
1662
]
],
[
[
1208,
7,
4450
],
[
4450,
46,
1482
],
[
1482,
23,
1662
]
],
[
[
1208,
1,
568
],
[
568,
24,
68
],
[
68,
63,
1662
]
],
[
[
1208,
7,
7273
],
[
7273,
46,
314
],
[
314,
24,
1662
]
],
[
[
1208,
18,
4675
],
[
4675,
46,
1220
],
[
1220,
24,
1662
]
],
[
[
1208,
1,
568
],
[
568,
24,
129
],
[
129,
24,
1662
]
],
[
[
1208,
18,
10375
],
[
10375,
57,
1667
],
[
1667,
24,
1662
]
],
[
[
1208,
1,
568
],
[
568,
23,
339
],
[
339,
24,
1662
]
],
[
[
1208,
21,
28826
],
[
28826,
60,
519
],
[
519,
24,
1662
]
]
] | [
[
[
"Lincomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Lincomycin",
"{u} (Compound) resembles {v} (Compound)",
"Clindamycin"
],
[
"Clindamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Lincomycin",
"{u} (Compound) upregulates {v} (Gene)",
"RRP8"
],
[
"RRP8",
"{u} (Gene) is upregulated by {v} (Compound)",
"Digitoxin"
],
[
"Digitoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Lincomycin",
"{u} (Compound) resembles {v} (Compound)",
"Clindamycin"
],
[
"Clindamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
],
[
"Troleandomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Lincomycin",
"{u} (Compound) upregulates {v} (Gene)",
"GPATCH8"
],
[
"GPATCH8",
"{u} (Gene) is upregulated by {v} (Compound)",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Lincomycin",
"{u} (Compound) downregulates {v} (Gene)",
"PLOD3"
],
[
"PLOD3",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Lincomycin",
"{u} (Compound) resembles {v} (Compound)",
"Clindamycin"
],
[
"Clindamycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Lincomycin",
"{u} (Compound) downregulates {v} (Gene)",
"RPS4Y1"
],
[
"RPS4Y1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Phenoxymethylpenicillin"
],
[
"Phenoxymethylpenicillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Lincomycin",
"{u} (Compound) resembles {v} (Compound)",
"Clindamycin"
],
[
"Clindamycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bacampicillin"
],
[
"Bacampicillin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
],
[
[
"Lincomycin",
"{u} (Compound) causes {v} (Side Effect)",
"Jaundice"
],
[
"Jaundice",
"{u} (Side Effect) is caused by {v} (Compound)",
"Paliperidone"
],
[
"Paliperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
]
]
] | Lincomycin (Compound) resembles Clindamycin (Compound) and Clindamycin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Lincomycin (Compound) upregulates RRP8 (Gene) and RRP8 (Gene) is upregulated by Digitoxin (Compound) and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Picosulfuric acid
Lincomycin (Compound) resembles Clindamycin (Compound) and Clindamycin may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin and Troleandomycin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Lincomycin (Compound) upregulates GPATCH8 (Gene) and GPATCH8 (Gene) is upregulated by Nalbuphine (Compound) and Nalbuphine may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Lincomycin (Compound) downregulates PLOD3 (Gene) and PLOD3 (Gene) is upregulated by Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Lincomycin (Compound) resembles Clindamycin (Compound) and Clindamycin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Lincomycin (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Phenoxymethylpenicillin (Compound) and Phenoxymethylpenicillin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Lincomycin (Compound) resembles Clindamycin (Compound) and Clindamycin may cause a minor interaction that can limit clinical effects when taken with Bacampicillin and Bacampicillin may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid
Lincomycin (Compound) causes Jaundice (Side Effect) and Jaundice (Side Effect) is caused by Paliperidone (Compound) and Paliperidone may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid |
DB00388 | DB09082 | 1,636 | 659 | [
"DDInter1453",
"DDInter1934"
] | Phenylephrine | Vilanterol | Phenylephrine is an alpha-1 adrenergic receptor agonist used to treat hypotension,[L9416,L9410] dilate the pupil, and induce local vasoconstriction. The action of phenylephrine, or neo-synephrine, was first described in literature in the 1930s. Phenylephrine was granted FDA approval in 1939. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol's pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.[A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and with both [fluticasone furoate] and [umeclidinium bromide] under the trade name TRELEGY ELLIPTA.[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.[L46876,L46881,L46886] Although all 3 products are approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), only TRELEGY ELLIPTA and BREO ELLIPTA are approved for maintenance treatments of asthma in patients aged 18 years and older and 5 years and older respectively.[L46481,L44461,L44456] | Moderate | 1 | [
[
[
1636,
24,
659
]
],
[
[
1636,
24,
895
],
[
895,
24,
659
]
],
[
[
1636,
24,
1296
],
[
1296,
63,
659
]
],
[
[
1636,
63,
88
],
[
88,
24,
659
]
],
[
[
1636,
25,
1161
],
[
1161,
24,
659
]
],
[
[
1636,
64,
21
],
[
21,
24,
659
]
],
[
[
1636,
1,
874
],
[
874,
24,
659
]
],
[
[
1636,
35,
768
],
[
768,
24,
659
]
],
[
[
1636,
25,
1629
],
[
1629,
63,
659
]
],
[
[
1636,
23,
1399
],
[
1399,
63,
659
]
]
] | [
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylphenidate"
],
[
"Methylphenidate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Phenylephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Selegiline"
],
[
"Selegiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Phenylephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Phenylephrine",
"{u} (Compound) resembles {v} (Compound)",
"Epinephrine"
],
[
"Epinephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Phenylephrine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tapentadol"
],
[
"Tapentadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Phenylephrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Phenylephrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
]
] | Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Methylphenidate and Methylphenidate may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Phenylephrine may lead to a major life threatening interaction when taken with Selegiline and Selegiline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Phenylephrine may lead to a major life threatening interaction when taken with Amitriptyline and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Phenylephrine (Compound) resembles Epinephrine (Compound) and Epinephrine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Phenylephrine (Compound) resembles Tapentadol (Compound) and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol and Tapentadol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Phenylephrine may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Phenylephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol |
DB00295 | DB00418 | 475 | 536 | [
"DDInter1244",
"DDInter1650"
] | Morphine | Secobarbital | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [fentanyl], [methadone], [hydrocodone], [hydromorphone], [meperidine], and [oxycodone]. Morphine was granted FDA approval in 1941. | Secobarbital (marketed by Eli Lilly and Company under the brand names Seconal and Tuinal) is a barbiturate derivative drug with anaesthetic, anticonvulsant, sedative and hypnotic properties. It is commonly known as quinalbarbitone in the United Kingdom. | Major | 2 | [
[
[
475,
25,
536
]
],
[
[
475,
25,
1023
],
[
1023,
1,
536
]
],
[
[
475,
64,
288
],
[
288,
1,
536
]
],
[
[
475,
24,
682
],
[
682,
40,
536
]
],
[
[
475,
24,
1269
],
[
1269,
1,
536
]
],
[
[
475,
6,
3486
],
[
3486,
45,
536
]
],
[
[
475,
21,
28758
],
[
28758,
60,
536
]
],
[
[
475,
24,
752
],
[
752,
62,
536
]
],
[
[
475,
24,
1233
],
[
1233,
63,
536
]
],
[
[
475,
25,
593
],
[
593,
63,
536
]
]
] | [
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Secobarbital"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Secobarbital"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Butalbital"
],
[
"Butalbital",
"{u} (Compound) resembles {v} (Compound)",
"Secobarbital"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiopental"
],
[
"Thiopental",
"{u} (Compound) resembles {v} (Compound)",
"Secobarbital"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methohexital"
],
[
"Methohexital",
"{u} (Compound) resembles {v} (Compound)",
"Secobarbital"
]
],
[
[
"Morphine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Secobarbital"
]
],
[
[
"Morphine",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperkinesia"
],
[
"Hyperkinesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Secobarbital"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Secobarbital"
]
],
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triprolidine"
],
[
"Triprolidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
]
],
[
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Secobarbital"
]
]
] | Morphine may lead to a major life threatening interaction when taken with Pentobarbital and Pentobarbital (Compound) resembles Secobarbital (Compound)
Morphine may lead to a major life threatening interaction when taken with Butalbital and Butalbital (Compound) resembles Secobarbital (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Thiopental and Thiopental (Compound) resembles Secobarbital (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Methohexital and Methohexital (Compound) resembles Secobarbital (Compound)
Morphine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Secobarbital (Compound)
Morphine (Compound) causes Hyperkinesia (Side Effect) and Hyperkinesia (Side Effect) is caused by Secobarbital (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Secobarbital
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Triprolidine and Triprolidine may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital
Morphine may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Secobarbital |
DB01128 | DB09039 | 918 | 1,670 | [
"DDInter204",
"DDInter629"
] | Bicalutamide | Eliglustat | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease.[A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to the formation of Gaucher cells that infiltrate the liver, spleen, bone marrow and other organs. This leads to complications such as anemia and thrombocytopenia.[L41404,A246384] By inhibiting glucosylceramide synthase, eliglustat reduces the accumulation of glucosylceramide. Eliglustat is mainly metabolized by CYP2D6. Patients selected for eliglustat treatment undergo an FDA-cleared genotyping test to establish if they are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs). The results of this test dictate eliglustat dosing recommendations for each type of patient. There are no dosing recommendations for CYP2D6 ultra-rapid or indeterminate metabolizers.[L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease.[L41404,A7634] Enzyme replacement continues to be the standard of care for the treatment of type 1 Gaucher disease ([imiglucerase], [velaglucerase alfa], [taliglucerase alfa]); however, oral substrate reduction therapies with favourable safety profiles, such as eliglustat, represent a treatment alternative.[A246389,A7634] | Moderate | 1 | [
[
[
918,
24,
1670
]
],
[
[
918,
62,
479
],
[
479,
23,
1670
]
],
[
[
918,
63,
211
],
[
211,
23,
1670
]
],
[
[
918,
23,
1135
],
[
1135,
62,
1670
]
],
[
[
918,
63,
1164
],
[
1164,
24,
1670
]
],
[
[
918,
64,
839
],
[
839,
24,
1670
]
],
[
[
918,
24,
594
],
[
594,
24,
1670
]
],
[
[
918,
24,
861
],
[
861,
63,
1670
]
],
[
[
918,
25,
478
],
[
478,
24,
1670
]
],
[
[
918,
25,
982
],
[
982,
63,
1670
]
]
] | [
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Bicalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Eliglustat"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Eliglustat"
]
],
[
[
"Bicalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Eliglustat"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimipramine"
],
[
"Trimipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Bicalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ripretinib"
],
[
"Ripretinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Bicalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
],
[
[
"Bicalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
]
]
] | Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Eliglustat
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Trimipramine and Trimipramine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Bicalutamide may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib and Bosutinib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Ripretinib and Ripretinib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Bicalutamide may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat
Bicalutamide may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat |
DB06077 | DB09045 | 879 | 52 | [
"DDInter1102",
"DDInter607"
] | Lumateperone | Dulaglutide | Schizophrenia is a complex mental illness and impacts approximately 1% of the population. Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects. Lumateperone is a newly approved 2nd generation antipsychotic currently indicated for the treatment of schizophrenia. It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin and dopamine, which are all neurotransmitters that contribute to the pathophysiology of schizophrenia.[A189093,A189174] The data so far indicates that lumateperone can alleviate both positive and negative symptoms of schizophrenia. Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity. | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular events. It is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations. | Moderate | 1 | [
[
[
879,
24,
52
]
],
[
[
879,
63,
170
],
[
170,
23,
52
]
],
[
[
879,
64,
609
],
[
609,
24,
52
]
],
[
[
879,
63,
999
],
[
999,
24,
52
]
],
[
[
879,
24,
1296
],
[
1296,
63,
52
]
],
[
[
879,
25,
1476
],
[
1476,
63,
52
]
],
[
[
879,
64,
1101
],
[
1101,
25,
52
]
],
[
[
879,
63,
170
],
[
170,
62,
1103
],
[
1103,
23,
52
]
],
[
[
879,
64,
609
],
[
609,
24,
170
],
[
170,
23,
52
]
],
[
[
879,
64,
1573
],
[
1573,
40,
1103
],
[
1103,
23,
52
]
]
] | [
[
[
"Lumateperone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Lumateperone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dulaglutide"
]
],
[
[
"Lumateperone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Lumateperone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Lumateperone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Lumateperone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Lumateperone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dulaglutide"
]
],
[
[
"Lumateperone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dulaglutide"
]
],
[
[
"Lumateperone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dulaglutide"
]
],
[
[
"Lumateperone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dulaglutide"
]
]
] | Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Lumateperone may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Lumateperone may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Lumateperone may lead to a major life threatening interaction when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Dulaglutide
Lumateperone may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Lumateperone may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Lumateperone may lead to a major life threatening interaction when taken with Prednisone and Prednisone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Dulaglutide |
DB00647 | DB00662 | 675 | 717 | [
"DDInter528",
"DDInter1873"
] | Dextropropoxyphene | Trimethobenzamide | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States. The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. The levo-isomer appears to exhibit a very limited antitussive effect. | Trimethobenzamide is a novel antiemetic which prevents nausea and vomiting in humans. Its actions are unclear but most likely involves the chemoreceptor trigger zone (CTZ). In dogs pretreated with trimethobenzamide HCl, the emetic response to apomorphine is inhibited, while little or no protection is afforded against emesis induced by intragastric copper sulfate. | Major | 2 | [
[
[
675,
25,
717
]
],
[
[
675,
64,
1425
],
[
1425,
40,
717
]
],
[
[
675,
21,
28762
],
[
28762,
60,
717
]
],
[
[
675,
75,
1594
],
[
1594,
24,
717
]
],
[
[
675,
64,
13
],
[
13,
24,
717
]
],
[
[
675,
63,
506
],
[
506,
24,
717
]
],
[
[
675,
25,
1376
],
[
1376,
63,
717
]
],
[
[
675,
24,
1532
],
[
1532,
63,
717
]
],
[
[
675,
40,
358
],
[
358,
63,
717
]
],
[
[
675,
40,
576
],
[
576,
24,
717
]
]
] | [
[
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cisapride"
],
[
"Cisapride",
"{u} (Compound) resembles {v} (Compound)",
"Trimethobenzamide"
]
],
[
[
"Dextropropoxyphene",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Trimethobenzamide"
]
],
[
[
"Dextropropoxyphene",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Doxylamine"
],
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextromethorphan"
],
[
"Dextromethorphan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Dextropropoxyphene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diphenhydramine"
],
[
"Diphenhydramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Dextropropoxyphene",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
],
[
[
"Dextropropoxyphene",
"{u} (Compound) resembles {v} (Compound)",
"Methadone"
],
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethobenzamide"
]
]
] | Dextropropoxyphene may lead to a major life threatening interaction when taken with Cisapride and Cisapride (Compound) resembles Trimethobenzamide (Compound)
Dextropropoxyphene (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Trimethobenzamide (Compound)
Dextropropoxyphene (Compound) resembles Doxylamine (Compound) and Dextropropoxyphene may lead to a major life threatening interaction when taken with Doxylamine and Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Dextropropoxyphene may lead to a major life threatening interaction when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Dextromethorphan and Dextromethorphan may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Dextropropoxyphene may lead to a major life threatening interaction when taken with Diphenhydramine and Diphenhydramine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Dextropropoxyphene (Compound) resembles Orphenadrine (Compound) and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide
Dextropropoxyphene (Compound) resembles Methadone (Compound) and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Trimethobenzamide |
DB00011 | DB13007 | 1,451 | 1,060 | [
"DDInter944",
"DDInter642"
] | Interferon alfa-n1 | Enfortumab vedotin | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Enfortumab vedotin is an antibody-drug conjugate used in the treatment of patients with advanced, treatment-resistant urothelial cancers. It is comprised of a fully human monoclonal antibody targeted against Nectin-4 and a microtubule-disrupting chemotherapeutic agent, monomethyl auristatin E (MMAE), joined by a protease-cleavable link. It is similar to [brentuximab vedotin], another antibody conjugated with MMAE that targets CD-30 instead of Nectin-4. The clinical development of enfortumab vedotin was the result of a collaboration between Astellas Pharma and Seattle Genetics and it was first approved for use in the United States in December 2019 under the brand name Padcev<sup>TM</sup>. Enfortumab vedotin was later approved by the European Commission on April 13, 2022. | Moderate | 1 | [
[
[
1451,
24,
1060
]
],
[
[
1451,
24,
1593
],
[
1593,
24,
1060
]
],
[
[
1451,
63,
491
],
[
491,
24,
1060
]
],
[
[
1451,
25,
1011
],
[
1011,
25,
1060
]
],
[
[
1451,
24,
581
],
[
581,
25,
1060
]
],
[
[
1451,
63,
1057
],
[
1057,
25,
1060
]
],
[
[
1451,
25,
676
],
[
676,
64,
1060
]
],
[
[
1451,
24,
1593
],
[
1593,
25,
129
],
[
129,
23,
1060
]
],
[
[
1451,
24,
1439
],
[
1439,
24,
1593
],
[
1593,
24,
1060
]
],
[
[
1451,
24,
270
],
[
270,
63,
350
],
[
350,
24,
1060
]
]
] | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
],
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
]
]
] | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Interferon alfa-n1 may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Enfortumab vedotin
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Enfortumab vedotin
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Enfortumab vedotin
Interferon alfa-n1 may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Enfortumab vedotin
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may cause a minor interaction that can limit clinical effects when taken with Enfortumab vedotin
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin |
DB06203 | DB14731 | 1,002 | 1,518 | [
"DDInter51",
"DDInter1741"
] | Alogliptin | Tagraxofusp | Alogliptin is a selective, orally-bioavailable inhibitor of enzymatic activity of dipeptidyl peptidase-4 (DPP-4). Chemically, alogliptin is prepared as a benzoate salt and exists predominantly as the R-enantiomer (>99%). It undergoes little or no chiral conversion in vivo to the (S)-enantiomer. FDA approved January 25, 2013. | Tagraxofusp is a CD123-directed cytotoxin. It is a fusion protein composed of a human interleukin-3 (IL-3) that is genetically fused to the catalytic and translocation domains of truncated diphtheria toxin (DT) produced in _Escherichia coli_.[A253762, A253887, L43702] Tagraxofusp received its first global approval by the FDA on December 21, 2018 as the first FDA-approved treatment for blastic plasmacytoid dendritic cell neoplasm, which is a myeloid malignancy in the dendritic cell lineage. It was also approved by the European Commission on January 7, 2021. | Moderate | 1 | [
[
[
1002,
24,
1518
]
],
[
[
1002,
63,
176
],
[
176,
24,
1518
]
],
[
[
1002,
1,
1281
],
[
1281,
24,
1518
]
],
[
[
1002,
24,
850
],
[
850,
24,
1518
]
],
[
[
1002,
63,
695
],
[
695,
25,
1518
]
],
[
[
1002,
63,
176
],
[
176,
24,
123
],
[
123,
24,
1518
]
],
[
[
1002,
1,
1281
],
[
1281,
63,
1324
],
[
1324,
24,
1518
]
],
[
[
1002,
24,
850
],
[
850,
63,
123
],
[
123,
24,
1518
]
],
[
[
1002,
63,
1254
],
[
1254,
63,
123
],
[
123,
24,
1518
]
],
[
[
1002,
62,
1103
],
[
1103,
23,
123
],
[
123,
24,
1518
]
]
] | [
[
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Alogliptin",
"{u} (Compound) resembles {v} (Compound)",
"Linagliptin"
],
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Alogliptin",
"{u} (Compound) resembles {v} (Compound)",
"Linagliptin"
],
[
"Linagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
],
[
"Insulin glulisine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
],
[
[
"Alogliptin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Exenatide"
],
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tagraxofusp"
]
]
] | Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Alogliptin (Compound) resembles Linagliptin (Compound) and Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Clozapine and Clozapine may lead to a major life threatening interaction when taken with Tagraxofusp
Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Alogliptin (Compound) resembles Linagliptin (Compound) and Linagliptin may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine and Insulin glulisine may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp
Alogliptin may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Tagraxofusp |
DB00851 | DB10316 | 611 | 334 | [
"DDInter463",
"DDInter1248"
] | Dacarbazine | Mumps virus strain B level jeryl lynn live antigen | An antineoplastic agent. It has significant activity against melanomas. (from Martindale, The Extra Pharmacopoeia, 31st ed, p564). Dacarbazine with Oblimersen is in clinical trials for the treatment of malignant melanoma. | Mumps virus strain B level jeryl lynn live antigen is a live attenuated virus vaccine for subcutenous injection. It is an active immunization against mumps, which is a common childhood disease. | Major | 2 | [
[
[
611,
25,
334
]
],
[
[
611,
64,
1057
],
[
1057,
25,
334
]
],
[
[
611,
24,
328
],
[
328,
25,
334
]
],
[
[
611,
25,
908
],
[
908,
25,
334
]
],
[
[
611,
63,
589
],
[
589,
25,
334
]
],
[
[
611,
25,
1259
],
[
1259,
64,
334
]
],
[
[
611,
24,
270
],
[
270,
64,
334
]
],
[
[
611,
64,
1057
],
[
1057,
25,
1042
],
[
1042,
24,
334
]
],
[
[
611,
24,
328
],
[
328,
64,
1057
],
[
1057,
25,
334
]
],
[
[
611,
25,
908
],
[
908,
64,
1042
],
[
1042,
24,
334
]
]
] | [
[
[
"Dacarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Dacarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Dacarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Dacarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Dacarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Dacarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
],
[
[
"Dacarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetracosactide"
],
[
"Tetracosactide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
]
]
] | Dacarbazine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Dacarbazine may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Dacarbazine may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Dacarbazine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Mumps virus strain B level jeryl lynn live antigen
Dacarbazine may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Dacarbazine may lead to a major life threatening interaction when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Tetracosactide and Tetracosactide may cause a moderate interaction that could exacerbate diseases when taken with Mumps virus strain B level jeryl lynn live antigen |
DB00661 | DB06603 | 122 | 39 | [
"DDInter1928",
"DDInter1387"
] | Verapamil | Panobinostat | Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like [diltiazem] and [flunarizine], but is chemically unrelated to other cardioactive medications. Verapamil is administered as a racemic mixture containing equal amounts of the S- and R-enantiomer, each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater potency than the R-enantiomer, but is metabolized at a higher rate. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. | Moderate | 1 | [
[
[
122,
24,
39
]
],
[
[
122,
24,
578
],
[
578,
63,
39
]
],
[
[
122,
25,
1478
],
[
1478,
63,
39
]
],
[
[
122,
63,
1419
],
[
1419,
24,
39
]
],
[
[
122,
62,
1101
],
[
1101,
24,
39
]
],
[
[
122,
24,
86
],
[
86,
24,
39
]
],
[
[
122,
25,
543
],
[
543,
24,
39
]
],
[
[
122,
25,
594
],
[
594,
64,
39
]
],
[
[
122,
24,
976
],
[
976,
64,
39
]
],
[
[
122,
24,
714
],
[
714,
25,
39
]
]
] | [
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Verapamil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Verapamil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Verapamil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Verapamil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Verapamil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
]
] | Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Verapamil may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Verapamil may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Verapamil may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Verapamil may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Panobinostat
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Panobinostat
Verapamil may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may lead to a major life threatening interaction when taken with Panobinostat |
DB00432 | DB14711 | 1,083 | 779 | [
"DDInter1868",
"DDInter1680"
] | Trifluridine | Smallpox (Vaccinia) Vaccine, Live | Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine]. It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activity against Herpes simplex virus type 1 and 2. The combination product of trifluridine with tipiracil marketed as Lonsurf has been approved in Japan, the United States, and the European Union for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. In the anticancer therapy, trifluridine acts as a thymidine-based nucleoside metabolic inhibitor that gets | The New York City Board of Health strain of _Vaccinia_ is a viral strain used as a component of some smallpox vaccinations. ACAM2000, a percutaneously administered smallpox vaccine that was approved by the FDA in 2007, contains live antigens of this strain. | Major | 2 | [
[
[
1083,
25,
779
]
],
[
[
1083,
75,
1064
],
[
1064,
25,
779
]
],
[
[
1083,
25,
1377
],
[
1377,
25,
779
]
],
[
[
1083,
64,
581
],
[
581,
25,
779
]
],
[
[
1083,
24,
270
],
[
270,
25,
779
]
],
[
[
1083,
40,
1238
],
[
1238,
25,
779
]
],
[
[
1083,
25,
676
],
[
676,
64,
779
]
],
[
[
1083,
63,
66
],
[
66,
25,
779
]
],
[
[
1083,
75,
1064
],
[
1064,
25,
478
],
[
478,
25,
779
]
],
[
[
1083,
25,
1377
],
[
1377,
64,
1064
],
[
1064,
25,
779
]
]
] | [
[
[
"Trifluridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Trifluridine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Trifluridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Trifluridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Trifluridine",
"{u} (Compound) resembles {v} (Compound)",
"Pentostatin"
],
[
"Pentostatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Trifluridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Trifluridine",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
],
[
[
"Trifluridine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
]
]
] | Trifluridine (Compound) resembles Cladribine (Compound) and Trifluridine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Trifluridine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Trifluridine may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Trifluridine (Compound) resembles Pentostatin (Compound) and Pentostatin may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Trifluridine may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Trifluridine (Compound) resembles Cladribine (Compound) and Trifluridine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live
Trifluridine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live |
DB00446 | DB09074 | 597 | 1,362 | [
"DDInter351",
"DDInter1327"
] | Chloramphenicol | Olaparib | An antibiotic first isolated from cultures of _Streptomyces venezuelae_ in 1947 but now produced synthetically. It has a relatively simple structure and was the first broad-spectrum antibiotic to be discovered. It acts by interfering with bacterial protein synthesis and is mainly bacteriostatic. (From Martindale, The Extra Pharmacopoeia, 29th ed, p106) The FDA has withdrawn all oral drug products containing chloramphenicol, due to the high risk of fatal aplastic anemia associated with this specific route of administration.[L43942,L44022] | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016. | Moderate | 1 | [
[
[
597,
24,
1362
]
],
[
[
597,
24,
725
],
[
725,
63,
1362
]
],
[
[
597,
24,
896
],
[
896,
24,
1362
]
],
[
[
597,
63,
576
],
[
576,
24,
1362
]
],
[
[
597,
25,
1478
],
[
1478,
24,
1362
]
],
[
[
597,
23,
450
],
[
450,
24,
1362
]
],
[
[
597,
25,
975
],
[
975,
63,
1362
]
],
[
[
597,
62,
1101
],
[
1101,
24,
1362
]
],
[
[
597,
23,
307
],
[
307,
25,
1362
]
],
[
[
597,
63,
362
],
[
362,
25,
1362
]
]
] | [
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
],
[
"Satralizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
],
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Chloramphenicol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Chloramphenicol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Chloramphenicol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lurbinectedin"
],
[
"Lurbinectedin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Chloramphenicol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Chloramphenicol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
],
[
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
]
] | Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab and Satralizumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Methadone and Methadone may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Chloramphenicol may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Cyclophosphamide and Cyclophosphamide may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Chloramphenicol may lead to a major life threatening interaction when taken with Lurbinectedin and Lurbinectedin may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Chloramphenicol may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may lead to a major life threatening interaction when taken with Olaparib
Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Phenytoin and Phenytoin may lead to a major life threatening interaction when taken with Olaparib |
DB00414 | DB00627 | 590 | 265 | [
"DDInter16",
"DDInter1286"
] | Acetohexamide | Niacin | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Niacin is a B vitamin used to treat vitamin deficiencies as well as hyperlipidemia, dyslipidemia, hypertriglyceridemia, and to reduce the risk of myocardial infarctions.[L7550,L7553,L7556,L7559,L7562,L7565] | Moderate | 1 | [
[
[
590,
24,
265
]
],
[
[
590,
24,
1479
],
[
1479,
62,
265
]
],
[
[
590,
24,
1296
],
[
1296,
63,
265
]
],
[
[
590,
63,
1560
],
[
1560,
24,
265
]
],
[
[
590,
24,
127
],
[
127,
24,
265
]
],
[
[
590,
24,
1377
],
[
1377,
64,
265
]
],
[
[
590,
24,
1479
],
[
1479,
1,
11404
],
[
11404,
1,
265
]
],
[
[
590,
24,
1296
],
[
1296,
63,
1479
],
[
1479,
62,
265
]
],
[
[
590,
63,
1560
],
[
1560,
24,
1479
],
[
1479,
62,
265
]
],
[
[
590,
24,
433
],
[
433,
63,
245
],
[
245,
24,
265
]
]
] | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niacin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Niacin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niacin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niacin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miglitol"
],
[
"Miglitol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niacin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Niacin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} (Compound) resembles {v} (Compound)",
"Salicylic acid"
],
[
"Salicylic acid",
"{u} (Compound) resembles {v} (Compound)",
"Niacin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Niacin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Niacin"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
],
[
"Ertugliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niacin"
]
]
] | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Niacin
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Niacin
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Niacin
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Miglitol and Miglitol may cause a moderate interaction that could exacerbate diseases when taken with Niacin
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Niacin
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid (Compound) resembles Salicylic acid (Compound) and Salicylic acid (Compound) resembles Niacin (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Niacin
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a minor interaction that can limit clinical effects when taken with Niacin
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin and Ertugliflozin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Niacin |
DB00853 | DB06688 | 1,686 | 1,430 | [
"DDInter1762",
"DDInter1677"
] | Temozolomide | Sipuleucel-T | Refractory anaplastic astrocytoma (WHO grade III) and Glioblastoma multiforme (WHO grade IV) are primary malignant brain tumours with poor prognosis and limited treatment options. Despite considerable genetic heterogeneity, these tumours often have impaired DNA repair systems, rendering them initially sensitive to alkylating agents, although they invariably develop resistance to these agents over time.[A229848, A229858, L32033] Temozolomide is an imidazotetrazine prodrug that is stable at acidic pH but undergoes spontaneous nonenzymatic hydrolysis at neutral or slightly basic pH; these properties allow for both oral and intravenous administration.[A229853, A229888, A229923, L32033] Following initial hydrolysis, further reactions liberate a highly reactive methyl diazonium cation capable of methylating various residues on adenosine and guanine bases leading to DNA lesions and eventual | Sipuleucel-T is a personalized, autologous, cellular immunotherapy. Sipuleucel-T is a therapeutic cancer vaccine for prostate cancer. Sipuleucel-T selectively targets the prostate-specific antigen (PSA) known as prostatic acid phosphatase (PAP) that is expressed in around 95% of prostate cancers. It must be prepared specifically for each patient. In metastatic prostate cancer, it has extended survival by median 4.1 months (IMPACT Phase III trial data). Sipuleucel-T is marketed under the brand name Provenge by Dendreon Corporation. Sipuleucel-T was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic Hormone-Refractory Prostate Cancer (HRPC). The treatment initially cost $93,000 at the time of FDA approval, but rose to over $100,000 in 2014. | Moderate | 1 | [
[
[
1686,
24,
1430
]
],
[
[
1686,
63,
51
],
[
51,
24,
1430
]
],
[
[
1686,
24,
869
],
[
869,
24,
1430
]
],
[
[
1686,
25,
676
],
[
676,
63,
1430
]
],
[
[
1686,
24,
713
],
[
713,
63,
1430
]
],
[
[
1686,
25,
770
],
[
770,
24,
1430
]
],
[
[
1686,
64,
1066
],
[
1066,
24,
1430
]
],
[
[
1686,
64,
1064
],
[
1064,
25,
1430
]
],
[
[
1686,
63,
51
],
[
51,
24,
869
],
[
869,
24,
1430
]
],
[
[
1686,
24,
869
],
[
869,
63,
51
],
[
51,
24,
1430
]
]
] | [
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Temozolomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Temozolomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Temozolomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Temozolomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
],
[
[
"Temozolomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sipuleucel-T"
]
]
] | Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Temozolomide may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Temozolomide may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Temozolomide may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Temozolomide may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Sipuleucel-T
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T
Temozolomide may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Sipuleucel-T |
DB00092 | DB12498 | 58 | 76 | [
"DDInter40",
"DDInter1238"
] | Alefacept | Mogamulizumab | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Mogamulizumab is a humanized monoclonal antibody (mAb) directed against CC chemokine receptor 4 (CCR4) for the treatment of Mycosis Fungoides (MF) and Sézary Syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma. Cutaneous T-cell lymphomas occur when certain white blood cells, called T cells, become cancerous; these cancers typically affect the skin, causing various types of skin lesions. On August 8 2018, the U.S. Food and Drug Administration (FDA) approved mogamulizumab injection (also known as _Poteligeo_) for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoides (MF) or Sézary syndrome (SS) after at least one prior systemic therapy. It was approved for the same indications in Canada in June 2022. Mogamulizumab is derived from Kyowa Hakko Kirin's POTELLIGENT (®) technology, which produces antibodies with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) activity. Approval in Japan was granted on April 30 2012 by the Japanese Ministry of Health, Labour and Welfare for patients with relapsed or refractory CCR4-positive adult T-cell leukemia-lymphoma. | Moderate | 1 | [
[
[
58,
24,
76
]
],
[
[
58,
23,
1461
],
[
1461,
23,
76
]
],
[
[
58,
24,
1531
],
[
1531,
24,
76
]
],
[
[
58,
24,
987
],
[
987,
63,
76
]
],
[
[
58,
63,
1184
],
[
1184,
24,
76
]
],
[
[
58,
25,
676
],
[
676,
64,
76
]
],
[
[
58,
25,
1064
],
[
1064,
25,
76
]
],
[
[
58,
24,
908
],
[
908,
25,
76
]
],
[
[
58,
63,
1057
],
[
1057,
25,
76
]
],
[
[
58,
23,
1461
],
[
1461,
23,
1531
],
[
1531,
24,
76
]
]
] | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Alefacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vibrio cholerae CVD 103-HgR strain live antigen"
],
[
"Vibrio cholerae CVD 103-HgR strain live antigen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
],
[
"Golimumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mogamulizumab"
]
],
[
[
"Alefacept",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mogamulizumab"
]
]
] | Alefacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Mogamulizumab
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Vibrio cholerae CVD 103-HgR strain live antigen and Vibrio cholerae CVD 103-HgR strain live antigen may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab
Alefacept may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Mogamulizumab
Alefacept may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Mogamulizumab
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Golimumab and Golimumab may lead to a major life threatening interaction when taken with Mogamulizumab
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Mogamulizumab
Alefacept may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Mogamulizumab |
DB00489 | DB06663 | 17 | 1,154 | [
"DDInter1704",
"DDInter1398"
] | Sotalol | Pasireotide | Sotalol is a methanesulfonanilide developed in 1960. It was the first of the class III anti arrhythmic drugs. Sotalol was first approved as an oral tablet on 30 October 1992. A racemic mixture of sotalol is currently formulated as a tablet, oral solution, and intravenous injection indicated for life threatening ventricular arrhythmias and maintaining normal sinus rhythm in atrial fibrillation or flutter.[Label,L6373,L6376] | Pasireotide is a synthetic long-acting cyclic hexapeptide with somatostatin-like activity. It is marketed as a diaspartate salt called Signifor, which is used in the treatment of Cushing's disease. | Major | 2 | [
[
[
17,
25,
1154
]
],
[
[
17,
63,
966
],
[
966,
40,
1154
]
],
[
[
17,
21,
28900
],
[
28900,
60,
1154
]
],
[
[
17,
23,
112
],
[
112,
23,
1154
]
],
[
[
17,
1,
88
],
[
88,
24,
1154
]
],
[
[
17,
24,
959
],
[
959,
24,
1154
]
],
[
[
17,
25,
1662
],
[
1662,
63,
1154
]
],
[
[
17,
25,
480
],
[
480,
24,
1154
]
],
[
[
17,
24,
657
],
[
657,
63,
1154
]
],
[
[
17,
63,
245
],
[
245,
24,
1154
]
]
] | [
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pasireotide"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[
"Octreotide",
"{u} (Compound) resembles {v} (Compound)",
"Pasireotide"
]
],
[
[
"Sotalol",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pasireotide"
]
],
[
[
"Sotalol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pasireotide"
]
],
[
[
"Sotalol",
"{u} (Compound) resembles {v} (Compound)",
"Metoprolol"
],
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Sotalol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
],
[
"Castor oil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
],
[
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
]
]
] | Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide (Compound) resembles Pasireotide (Compound)
Sotalol (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Pasireotide (Compound)
Sotalol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pasireotide
Sotalol (Compound) resembles Metoprolol (Compound) and Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Sotalol may lead to a major life threatening interaction when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Sotalol may lead to a major life threatening interaction when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Castor oil and Castor oil may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide
Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide |
DB00598 | DB11348 | 1,523 | 1,065 | [
"DDInter1013",
"DDInter279"
] | Labetalol | Calcium Phosphate | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
1523,
24,
1065
]
],
[
[
1523,
62,
1152
],
[
1152,
24,
1065
]
],
[
[
1523,
62,
1152
],
[
1152,
23,
819
],
[
819,
24,
1065
]
],
[
[
1523,
24,
1606
],
[
1606,
24,
943
],
[
943,
63,
1065
]
],
[
[
1523,
24,
1606
],
[
1606,
63,
819
],
[
819,
24,
1065
]
],
[
[
1523,
23,
1054
],
[
1054,
24,
943
],
[
943,
63,
1065
]
],
[
[
1523,
62,
542
],
[
542,
62,
461
],
[
461,
24,
1065
]
],
[
[
1523,
63,
666
],
[
666,
24,
943
],
[
943,
63,
1065
]
],
[
[
1523,
23,
1054
],
[
1054,
62,
819
],
[
819,
24,
1065
]
],
[
[
1523,
24,
850
],
[
850,
24,
810
],
[
810,
24,
1065
]
]
] | [
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Labetalol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Labetalol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acebutolol"
],
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
],
[
"Lanthanum carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
],
[
"Sarecycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
],
[
"Lanthanum carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
],
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Labetalol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Kaolin"
],
[
"Kaolin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
],
[
"Sarecycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Labetalol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levothyroxine"
],
[
"Levothyroxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium acetate"
],
[
"Calcium acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
],
[
"Sarecycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Labetalol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Kaolin"
],
[
"Kaolin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acebutolol"
],
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Strontium chloride Sr-89"
],
[
"Strontium chloride Sr-89",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
]
] | Labetalol may cause a minor interaction that can limit clinical effects when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Labetalol may cause a minor interaction that can limit clinical effects when taken with Liothyronine and Liothyronine may cause a minor interaction that can limit clinical effects when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate and Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate and Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Labetalol may cause a minor interaction that can limit clinical effects when taken with Kaolin and Kaolin may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Labetalol may cause a minor interaction that can limit clinical effects when taken with Levothyroxine and Levothyroxine may cause a minor interaction that can limit clinical effects when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Calcium acetate and Calcium acetate may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Labetalol may cause a minor interaction that can limit clinical effects when taken with Kaolin and Kaolin may cause a minor interaction that can limit clinical effects when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Strontium chloride Sr-89 and Strontium chloride Sr-89 may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate |
DB00656 | DB06176 | 827 | 1,342 | [
"DDInter1851",
"DDInter1616"
] | Trazodone | Romidepsin | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine receptor inhibitor (SNRIs) in the treatment of depression. A unique feature of this drug is that it does not promote the anxiety symptoms, sexual symptoms, or insomnia, which are commonly associated with SSRI and SNRI therapy. Trazodone acts on various receptors, including certain histamine, serotonin, and adrenergic receptors, distinguishing it from other antidepressants that cover a narrow range of neurotransmitters. It was initially granted FDA approval in 1981. | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
827,
24,
1342
]
],
[
[
827,
23,
112
],
[
112,
23,
1342
]
],
[
[
827,
24,
485
],
[
485,
24,
1342
]
],
[
[
827,
24,
1616
],
[
1616,
63,
1342
]
],
[
[
827,
63,
1010
],
[
1010,
24,
1342
]
],
[
[
827,
40,
851
],
[
851,
24,
1342
]
],
[
[
827,
1,
623
],
[
623,
24,
1342
]
],
[
[
827,
25,
1133
],
[
1133,
24,
1342
]
],
[
[
827,
64,
1494
],
[
1494,
24,
1342
]
],
[
[
827,
23,
126
],
[
126,
24,
1342
]
]
] | [
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Trazodone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Romidepsin"
]
],
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
],
[
"Histrelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Trazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Trazodone",
"{u} (Compound) resembles {v} (Compound)",
"Nefazodone"
],
[
"Nefazodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Trazodone",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
],
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Trazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Trazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Trazodone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
]
] | Trazodone may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Pentamidine and Pentamidine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Mefloquine and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Trazodone (Compound) resembles Nefazodone (Compound) and Nefazodone may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Trazodone (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Trazodone may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Trazodone may lead to a major life threatening interaction when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Trazodone may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin |
DB00549 | DB01118 | 522 | 33 | [
"DDInter1955",
"DDInter76"
] | Zafirlukast | Amiodarone | Zafirlukast is an oral leukotriene receptor antagonist (LTRA) for the maintenance treatment of asthma, often used in conjunction with an inhaled steroid and/or long-acting bronchodilator. It is available as a tablet and is usually dosed twice daily. Another leukotriene receptor antagonist is montelukast (Singulair), which is usually taken just once daily. Zafirlukast blocks the action of the cysteinyl leukotrienes on the CysLT1 receptors, thus reducing constriction of the airways, build-up of mucus in the lungs and inflammation of the breathing passages. | Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxicity and possibly death, amiodarone use should be reserved for its approved indications, according to prescribing information.[L3561,L11265,L11286] | Moderate | 1 | [
[
[
522,
24,
33
]
],
[
[
522,
24,
540
],
[
540,
1,
33
]
],
[
[
522,
6,
7950
],
[
7950,
45,
33
]
],
[
[
522,
54,
19230
],
[
19230,
15,
33
]
],
[
[
522,
21,
28681
],
[
28681,
60,
33
]
],
[
[
522,
63,
597
],
[
597,
24,
33
]
],
[
[
522,
24,
663
],
[
663,
24,
33
]
],
[
[
522,
23,
1347
],
[
1347,
24,
33
]
],
[
[
522,
24,
1476
],
[
1476,
63,
33
]
],
[
[
522,
25,
1493
],
[
1493,
64,
33
]
]
] | [
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} (Compound) resembles {v} (Compound)",
"Amiodarone"
]
],
[
[
"Zafirlukast",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Amiodarone"
]
],
[
[
"Zafirlukast",
"{u} (Compound) is included by {v} (Pharmacologic Class)",
"Cytochrome P450 2C9 Inhibitors"
],
[
"Cytochrome P450 2C9 Inhibitors",
"{u} (Pharmacologic Class) includes {v} (Compound)",
"Amiodarone"
]
],
[
[
"Zafirlukast",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amiodarone"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Zafirlukast",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
]
],
[
[
"Zafirlukast",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
],
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
]
]
] | Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone and Dronedarone (Compound) resembles Amiodarone (Compound)
Zafirlukast (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Amiodarone (Compound)
Zafirlukast (Compound) is included by Cytochrome P450 2C9 Inhibitors (Pharmacologic Class) and Cytochrome P450 2C9 Inhibitors (Pharmacologic Class) includes Amiodarone (Compound)
Zafirlukast (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Amiodarone (Compound)
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone
Zafirlukast may cause a minor interaction that can limit clinical effects when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone
Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone
Zafirlukast may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may lead to a major life threatening interaction when taken with Amiodarone |
DB06176 | DB11113 | 1,342 | 657 | [
"DDInter1616",
"DDInter307"
] | Romidepsin | Castor oil | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic, and less than 1% linolenic fatty acids . has a hydroxyl group that provides a functional group location for various chemical reactions, making it a favourable substance in industrial applications . Castor oil does not contain ricin, which is a natural poison found in the castor oil plant; the toxic lectin remains in the bean pulp following oil isolation . Due to its renewability and high versatility in addition to being the only commercial source of a hydroxylated fatty acid , castor oil has been used as a vital raw material for the chemical industry . Castor oil was mainly used in the manufacturing of soaps, lubricants, and coatings . It is an FDA-approved food additive directly added to food products for human consumption. It can also be found in hard candies as a release agent and anti-sticking agent, or supplementary vitamins and mineral oral tablets as an ingredient for protective coatings. Castor oil is found in over-the-counter oral liquids as a stimulant laxative, and is also added in commercial cosmetic, hair, and skincare products. | Moderate | 1 | [
[
[
1342,
24,
657
]
],
[
[
1342,
24,
1079
],
[
1079,
24,
657
]
],
[
[
1342,
24,
927
],
[
927,
63,
657
]
],
[
[
1342,
64,
540
],
[
540,
24,
657
]
],
[
[
1342,
63,
534
],
[
534,
24,
657
]
],
[
[
1342,
25,
985
],
[
985,
24,
657
]
],
[
[
1342,
25,
351
],
[
351,
63,
657
]
],
[
[
1342,
24,
1079
],
[
1079,
24,
927
],
[
927,
63,
657
]
],
[
[
1342,
24,
927
],
[
927,
63,
1079
],
[
1079,
24,
657
]
],
[
[
1342,
64,
540
],
[
540,
25,
927
],
[
927,
63,
657
]
]
] | [
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
],
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
],
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Romidepsin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Telavancin"
],
[
"Telavancin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Romidepsin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
]
] | Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Romidepsin may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Romidepsin may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Romidepsin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Telavancin and Telavancin may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Romidepsin may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil |
DB00554 | DB01172 | 1,027 | 416 | [
"DDInter1478",
"DDInter1004"
] | Piroxicam | Kanamycin | A cyclooxygenase inhibiting, non-steroidal anti-inflammatory agent (NSAID) that is well established in treating rheumatoid arthritis and osteoarthritis and used for musculoskeletal disorders, dysmenorrhea, and postoperative pain. Its long half-life enables it to be administered once daily. | Kanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections. Kanamycin is isolated from the bacterium Streptomyces kanamyceticus and its most commonly used form is kanamycin sulfate. | Moderate | 1 | [
[
[
1027,
24,
416
]
],
[
[
1027,
6,
7720
],
[
7720,
46,
416
]
],
[
[
1027,
24,
712
],
[
712,
63,
416
]
],
[
[
1027,
24,
1512
],
[
1512,
24,
416
]
],
[
[
1027,
40,
1171
],
[
1171,
24,
416
]
],
[
[
1027,
25,
663
],
[
663,
24,
416
]
],
[
[
1027,
63,
91
],
[
91,
24,
416
]
],
[
[
1027,
25,
629
],
[
629,
25,
416
]
],
[
[
1027,
25,
1527
],
[
1527,
64,
416
]
],
[
[
1027,
24,
1448
],
[
1448,
35,
416
]
]
] | [
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Piroxicam",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Kanamycin"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olsalazine"
],
[
"Olsalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Piroxicam",
"{u} (Compound) resembles {v} (Compound)",
"Meloxicam"
],
[
"Meloxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Piroxicam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vancomycin"
],
[
"Vancomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
],
[
[
"Piroxicam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Kanamycin"
]
],
[
[
"Piroxicam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iothalamic acid"
],
[
"Iothalamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Kanamycin"
]
],
[
[
"Piroxicam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Streptomycin"
],
[
"Streptomycin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Kanamycin"
]
]
] | Piroxicam (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is upregulated by Kanamycin (Compound)
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Olsalazine and Olsalazine may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Piroxicam (Compound) resembles Meloxicam (Compound) and Meloxicam may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Piroxicam may lead to a major life threatening interaction when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Vancomycin and Vancomycin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin
Piroxicam may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Kanamycin
Piroxicam may lead to a major life threatening interaction when taken with Iothalamic acid and Iothalamic acid may lead to a major life threatening interaction when taken with Kanamycin
Piroxicam may cause a moderate interaction that could exacerbate diseases when taken with Streptomycin and Streptomycin (Compound) resembles Kanamycin (Compound) and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Kanamycin |
DB00959 | DB08895 | 1,486 | 976 | [
"DDInter1191",
"DDInter1825"
] | Methylprednisolone | Tofacitinib | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant to methotrexate. Besides rheumatoid arthritis, tofacitinib has also been studied in clinical trials for the prevention of organ transplant rejection, and is currently under investigation for the treatment of psoriasis. Known adverse effects include nausea and headache as well as more serious immunologic and hematological adverse effects. Tofacitinib is marketed under the brand name Xeljanz by Pfizer. | Major | 2 | [
[
[
1486,
25,
976
]
],
[
[
1486,
62,
307
],
[
307,
23,
976
]
],
[
[
1486,
23,
1193
],
[
1193,
62,
976
]
],
[
[
1486,
24,
214
],
[
214,
63,
976
]
],
[
[
1486,
63,
723
],
[
723,
24,
976
]
],
[
[
1486,
24,
1482
],
[
1482,
24,
976
]
],
[
[
1486,
64,
932
],
[
932,
24,
976
]
],
[
[
1486,
25,
652
],
[
652,
64,
976
]
],
[
[
1486,
24,
1316
],
[
1316,
64,
976
]
],
[
[
1486,
25,
1011
],
[
1011,
25,
976
]
]
] | [
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Methylprednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tofacitinib"
]
],
[
[
"Methylprednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tofacitinib"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
],
[
"Digitoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tofacitinib"
]
],
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brexucabtagene autoleucel"
],
[
"Brexucabtagene autoleucel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Durvalumab"
],
[
"Durvalumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
]
] | Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Methylprednisolone may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Methylprednisolone may lead to a major life threatening interaction when taken with Mifepristone and Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Tofacitinib
Methylprednisolone may lead to a major life threatening interaction when taken with Brexucabtagene autoleucel and Brexucabtagene autoleucel may lead to a major life threatening interaction when taken with Tofacitinib
Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Durvalumab and Durvalumab may lead to a major life threatening interaction when taken with Tofacitinib
Methylprednisolone may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Tofacitinib |
DB09128 | DB12500 | 1,241 | 283 | [
"DDInter231",
"DDInter714"
] | Brexpiprazole | Fedratinib | Brexpiprazole is an atypical antipsychotic and a novel D2 dopamine and serotonin 1A partial agonist called serotonin-dopamine activity modulator (SDAM). It has a high affinity for serotonin, dopamine and alpha (α)-adrenergic receptors. Although it is structurally similar to [aripiprazole], brexpiprazole has different binding affinities for dopamine and serotonin receptors. Compared to aripiprazole, brexpiprazole has less potential for partial agonist-mediated adverse effects such as extrapyramidal symptoms, which is attributed to lower intrinsic activity at the D2 receptor. It also displays stronger antagonism at the 5-HT1A and 5-HT2A receptors.[A182186, A38385, A259661] Brexpiprazole was first approved by the FDA on July 10, 2015. Currently approved for the treatment of depression, schizophrenia, and agitation | Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.[A183176,L8090] It is an anilinopyrimidine derivative. Fedratinib was granted FDA approval on August 16, 2019. | Major | 2 | [
[
[
1241,
25,
283
]
],
[
[
1241,
25,
351
],
[
351,
23,
283
]
],
[
[
1241,
64,
1593
],
[
1593,
23,
283
]
],
[
[
1241,
64,
1419
],
[
1419,
24,
283
]
],
[
[
1241,
63,
761
],
[
761,
24,
283
]
],
[
[
1241,
24,
159
],
[
159,
63,
283
]
],
[
[
1241,
25,
1619
],
[
1619,
24,
283
]
],
[
[
1241,
24,
1017
],
[
1017,
25,
283
]
],
[
[
1241,
64,
1670
],
[
1670,
25,
283
]
],
[
[
1241,
63,
129
],
[
129,
25,
283
]
]
] | [
[
[
"Brexpiprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Brexpiprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Brexpiprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fedratinib"
]
],
[
[
"Brexpiprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Brexpiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Brexpiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Brexpiprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
]
],
[
[
"Brexpiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Brexpiprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
],
[
[
"Brexpiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
]
]
] | Brexpiprazole may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Brexpiprazole may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a minor interaction that can limit clinical effects when taken with Fedratinib
Brexpiprazole may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Brexpiprazole may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Brexpiprazole may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Brexpiprazole may lead to a major life threatening interaction when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib
Brexpiprazole may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Fedratinib
Brexpiprazole may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may lead to a major life threatening interaction when taken with Fedratinib
Brexpiprazole may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Fedratinib |
DB08881 | DB09330 | 868 | 985 | [
"DDInter1925",
"DDInter1352"
] | Vemurafenib | Osimertinib | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered tumour resistance patterns following treatment and toxic side effects that impact patient quality of life. Treatment with first-generation EGFR-TKIs (gefitinib and erlotinib) has been associated with the development of resistance through activating mutations in the EGFR gene. Second-generation EGFR-TKIs (afatinib and dacomitinib) were then developed to be more potent inhibitors, although their use is associated with increased toxicity through nonspecific targeting of wild-type EGFR. In contrast, third-generation inhibitors are specific for the gate-keeper T790M mutations which increases ATP binding activity to EGFR and result in poor prognosis for late-stage disease. Furthermore, osimertinib has been shown to spare wild-type EGFR during therapy, thereby reducing non-specific binding and limiting toxicity.[A7926,A7927,A7931] | Major | 2 | [
[
[
868,
25,
985
]
],
[
[
868,
62,
168
],
[
168,
23,
985
]
],
[
[
868,
63,
1478
],
[
1478,
24,
985
]
],
[
[
868,
24,
1598
],
[
1598,
63,
985
]
],
[
[
868,
24,
1040
],
[
1040,
24,
985
]
],
[
[
868,
64,
1181
],
[
1181,
24,
985
]
],
[
[
868,
62,
1382
],
[
1382,
24,
985
]
],
[
[
868,
64,
843
],
[
843,
25,
985
]
],
[
[
868,
25,
484
],
[
484,
64,
985
]
],
[
[
868,
63,
171
],
[
171,
25,
985
]
]
] | [
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Vemurafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Osimertinib"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tazemetostat"
],
[
"Tazemetostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Vemurafenib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Midazolam"
],
[
"Midazolam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
]
],
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tetrabenazine"
],
[
"Tetrabenazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Vemurafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
],
[
[
"Vemurafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
],
[
"Lonafarnib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
]
]
] | Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Osimertinib
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Tazemetostat and Tazemetostat may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Vemurafenib may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Vemurafenib may cause a minor interaction that can limit clinical effects when taken with Midazolam and Midazolam may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib
Vemurafenib may lead to a major life threatening interaction when taken with Tetrabenazine and Tetrabenazine may lead to a major life threatening interaction when taken with Osimertinib
Vemurafenib may lead to a major life threatening interaction when taken with Entrectinib and Entrectinib may lead to a major life threatening interaction when taken with Osimertinib
Vemurafenib may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib and Lonafarnib may lead to a major life threatening interaction when taken with Osimertinib |
DB00819 | DB09045 | 471 | 52 | [
"DDInter15",
"DDInter607"
] | Acetazolamide | Dulaglutide | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337) | Dulaglutide, marketed by Eli Lilly as Trulicity, is a once-weekly subcutaneous glucagon-like peptide-1 (GLP-1) receptor agonist designed using recombinant DNA technology; it has been approved as an adjunct therapy to diet and exercise in the management of 2 diabetes (T2DM). Dulaglutide was initially approved by the FDA in 2014, and in February 2020 was approved for use in patients with T2DM and multiple cardiovascular risk factors for the prevention of cardiovascular events. It is the first T2DM drug approved to reduce major adverse cardiovascular events (MACE) risk in primary and secondary prevention populations. | Moderate | 1 | [
[
[
471,
24,
52
]
],
[
[
471,
24,
170
],
[
170,
23,
52
]
],
[
[
471,
63,
870
],
[
870,
24,
52
]
],
[
[
471,
24,
1411
],
[
1411,
24,
52
]
],
[
[
471,
24,
1019
],
[
1019,
63,
52
]
],
[
[
471,
1,
997
],
[
997,
24,
52
]
],
[
[
471,
24,
170
],
[
170,
62,
1103
],
[
1103,
23,
52
]
],
[
[
471,
63,
870
],
[
870,
1,
1103
],
[
1103,
23,
52
]
],
[
[
471,
63,
1573
],
[
1573,
40,
1103
],
[
1103,
23,
52
]
],
[
[
471,
63,
1179
],
[
1179,
23,
1103
],
[
1103,
23,
52
]
]
] | [
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dulaglutide"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Acetazolamide",
"{u} (Compound) resembles {v} (Compound)",
"Methazolamide"
],
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dulaglutide"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
],
[
"Sitagliptin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dulaglutide"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dulaglutide"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Prednisone"
],
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dulaglutide"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dulaglutide"
]
]
] | Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Acetazolamide (Compound) resembles Methazolamide (Compound) and Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Sitagliptin and Sitagliptin may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednisone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Dulaglutide
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a minor interaction that can limit clinical effects when taken with Amcinonide and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Dulaglutide |
DB09268 | DB11901 | 1,662 | 913 | [
"DDInter1464",
"DDInter107"
] | Picosulfuric acid | Apalutamide | Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery. The combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years. | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors . In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or . Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing human CRPC cell lines . Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer. Although most patients achieve therapeutic responses at the initial hormone therapy, many patients progress to non-metastatic castration-resistant (resistance to hormone therapy) prostate cancer which is the second-most common cause of cancer-related deaths in American males . Castration-resistant prostate cancer is often incurable, which poses significant clinical challenges for patients. Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis . Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death . In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment . In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo . Apalutamide displayed good tolerability and safety profile in clinical studies. Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant). It is available as oral tablets. Apalutamide is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer . | Moderate | 1 | [
[
[
1662,
24,
913
]
],
[
[
1662,
63,
112
],
[
112,
23,
913
]
],
[
[
1662,
63,
1322
],
[
1322,
24,
913
]
],
[
[
1662,
24,
877
],
[
877,
63,
913
]
],
[
[
1662,
24,
1267
],
[
1267,
24,
913
]
],
[
[
1662,
62,
1252
],
[
1252,
24,
913
]
],
[
[
1662,
64,
1557
],
[
1557,
24,
913
]
],
[
[
1662,
63,
593
],
[
593,
25,
913
]
],
[
[
1662,
24,
1375
],
[
1375,
64,
913
]
],
[
[
1662,
64,
1069
],
[
1069,
25,
913
]
]
] | [
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
]
],
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alfentanil"
],
[
"Alfentanil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifampridine"
],
[
"Amifampridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Picosulfuric acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Picosulfuric acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Astemizole"
],
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lefamulin"
],
[
"Lefamulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Picosulfuric acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
]
] | Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Alfentanil and Alfentanil may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Amifampridine and Amifampridine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Picosulfuric acid may cause a minor interaction that can limit clinical effects when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Picosulfuric acid may lead to a major life threatening interaction when taken with Astemizole and Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Apalutamide
Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Lefamulin and Lefamulin may lead to a major life threatening interaction when taken with Apalutamide
Picosulfuric acid may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Apalutamide |
DB00515 | DB01610 | 589 | 248 | [
"DDInter387",
"DDInter1912"
] | Cisplatin | Valganciclovir | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin. | Valganciclovir hydrochloride (Valcyte, manufactured by Roche) is an antiviral medication used to treat cytomegalovirus infections. As the L-valyl ester of ganciclovir, it is actually a prodrug for ganciclovir. After oral administration, it is rapidly converted to ganciclovir by intestinal and hepatic esterases. | Moderate | 1 | [
[
[
589,
24,
248
]
],
[
[
589,
24,
1295
],
[
1295,
1,
248
]
],
[
[
589,
21,
29209
],
[
29209,
60,
248
]
],
[
[
589,
24,
1238
],
[
1238,
24,
248
]
],
[
[
589,
24,
1480
],
[
1480,
63,
248
]
],
[
[
589,
63,
141
],
[
141,
24,
248
]
],
[
[
589,
25,
507
],
[
507,
63,
248
]
],
[
[
589,
64,
1648
],
[
1648,
24,
248
]
],
[
[
589,
25,
770
],
[
770,
24,
248
]
],
[
[
589,
25,
375
],
[
375,
64,
248
]
]
] | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valaciclovir"
],
[
"Valaciclovir",
"{u} (Compound) resembles {v} (Compound)",
"Valganciclovir"
]
],
[
[
"Cisplatin",
"{u} (Compound) causes {v} (Side Effect)",
"Anorexia"
],
[
"Anorexia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Valganciclovir"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
],
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixazomib"
],
[
"Ixazomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Floxuridine"
],
[
"Floxuridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
],
[
"Samarium (153Sm) lexidronam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Valganciclovir"
]
]
] | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Valaciclovir and Valaciclovir (Compound) resembles Valganciclovir (Compound)
Cisplatin (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Valganciclovir (Compound)
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin and Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Ixazomib and Ixazomib may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Floxuridine and Floxuridine may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Cisplatin may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam and Samarium (153Sm) lexidronam may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Cisplatin may lead to a major life threatening interaction when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Cisplatin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir
Cisplatin may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Valganciclovir |
DB08827 | DB08896 | 990 | 292 | [
"DDInter1085",
"DDInter1576"
] | Lomitapide | Regorafenib | Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor used in homozygous familial hypercholesterolemia (HoFH) patients. It is marketed under the name Juxtapid (R). | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017. | Major | 2 | [
[
[
990,
25,
292
]
],
[
[
990,
64,
79
],
[
79,
1,
292
]
],
[
[
990,
6,
8374
],
[
8374,
45,
292
]
],
[
[
990,
21,
29429
],
[
29429,
60,
292
]
],
[
[
990,
23,
1135
],
[
1135,
62,
292
]
],
[
[
990,
63,
613
],
[
613,
24,
292
]
],
[
[
990,
64,
1560
],
[
1560,
24,
292
]
],
[
[
990,
25,
1613
],
[
1613,
63,
292
]
],
[
[
990,
24,
119
],
[
119,
63,
292
]
],
[
[
990,
25,
850
],
[
850,
24,
292
]
]
] | [
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Regorafenib"
]
],
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} (Compound) resembles {v} (Compound)",
"Regorafenib"
]
],
[
[
"Lomitapide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Regorafenib"
]
],
[
[
"Lomitapide",
"{u} (Compound) causes {v} (Side Effect)",
"Infestation NOS"
],
[
"Infestation NOS",
"{u} (Side Effect) is caused by {v} (Compound)",
"Regorafenib"
]
],
[
[
"Lomitapide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Regorafenib"
]
],
[
[
"Lomitapide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Irinotecan"
],
[
"Irinotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
]
],
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
]
],
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Peginterferon beta-1a"
],
[
"Peginterferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
]
],
[
[
"Lomitapide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
],
[
"Talazoparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
]
],
[
[
"Lomitapide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Regorafenib"
]
]
] | Lomitapide may lead to a major life threatening interaction when taken with Sorafenib and Sorafenib (Compound) resembles Regorafenib (Compound)
Lomitapide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Regorafenib (Compound)
Lomitapide (Compound) causes Infestation NOS (Side Effect) and Infestation NOS (Side Effect) is caused by Regorafenib (Compound)
Lomitapide may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Regorafenib
Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Irinotecan and Irinotecan may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Lomitapide may lead to a major life threatening interaction when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Lomitapide may lead to a major life threatening interaction when taken with Peginterferon beta-1a and Peginterferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib and Talazoparib may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib
Lomitapide may lead to a major life threatening interaction when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Regorafenib |
DB00863 | DB01035 | 1,194 | 1,401 | [
"DDInter1568",
"DDInter1524"
] | Ranitidine | Procainamide | Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818] Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.[L10818,F4253] The prevalence of GERD is thought to be 10-20% in western countries. Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.[A176849,L10818] | A derivative of procaine with less CNS action. | Moderate | 1 | [
[
[
1194,
24,
1401
]
],
[
[
1194,
6,
12523
],
[
12523,
45,
1401
]
],
[
[
1194,
21,
28658
],
[
28658,
60,
1401
]
],
[
[
1194,
24,
770
],
[
770,
63,
1401
]
],
[
[
1194,
63,
1645
],
[
1645,
24,
1401
]
],
[
[
1194,
23,
286
],
[
286,
63,
1401
]
],
[
[
1194,
24,
1528
],
[
1528,
24,
1401
]
],
[
[
1194,
64,
543
],
[
543,
24,
1401
]
],
[
[
1194,
25,
1213
],
[
1213,
64,
1401
]
],
[
[
1194,
24,
478
],
[
478,
64,
1401
]
]
] | [
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
]
],
[
[
"Ranitidine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Procainamide"
]
],
[
[
"Ranitidine",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Procainamide"
]
],
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
]
],
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
]
],
[
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
]
],
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Physostigmine"
],
[
"Physostigmine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
]
],
[
[
"Ranitidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procainamide"
]
],
[
[
"Ranitidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procainamide"
]
],
[
[
"Ranitidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procainamide"
]
]
] | Ranitidine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Procainamide (Compound)
Ranitidine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Procainamide (Compound)
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Procainamide
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Procainamide
Ranitidine may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Procainamide
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Physostigmine and Physostigmine may cause a moderate interaction that could exacerbate diseases when taken with Procainamide
Ranitidine may lead to a major life threatening interaction when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Procainamide
Ranitidine may lead to a major life threatening interaction when taken with Dasatinib and Dasatinib may lead to a major life threatening interaction when taken with Procainamide
Ranitidine may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Procainamide |
DB00640 | DB11730 | 1,585 | 351 | [
"DDInter31",
"DDInter1588"
] | Adenosine | Ribociclib | The structure of adenosine was first described in 1931, though the vasodilating effects were not described in literature until the 1940s. Adenosine is indicated as an adjunct to thallium-201 in myocardial perfusion scintigraphy, though it is rarely used in this indication, having largely been replaced by [dipyridamole] and [regadenson].[A229833,A229838] Adenosine is also indicated in the treatment of supraventricular tachycardia. Adenosine was granted FDA approval on 30 October 1989. | Ribociclib is a selective cyclin-dependent kinase inhibitor, a class of drugs that help slow the progression of cancer by inhibiting two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). These proteins, when over-activated, can enable cancer cells to grow and divide too quickly. Targeting CDK4/6 with enhanced precision may play a role in ensuring that cancer cells do not continue to replicate uncontrollably. Ribociclib was approved by the U.S. FDA in March, 2017 as Kisqali. | Major | 2 | [
[
[
1585,
25,
351
]
],
[
[
1585,
40,
372
],
[
372,
24,
351
]
],
[
[
1585,
24,
1491
],
[
1491,
24,
351
]
],
[
[
1585,
63,
966
],
[
966,
24,
351
]
],
[
[
1585,
23,
578
],
[
578,
24,
351
]
],
[
[
1585,
24,
129
],
[
129,
25,
351
]
],
[
[
1585,
24,
1297
],
[
1297,
64,
351
]
],
[
[
1585,
25,
985
],
[
985,
25,
351
]
],
[
[
1585,
64,
1424
],
[
1424,
25,
351
]
],
[
[
1585,
25,
982
],
[
982,
64,
351
]
]
] | [
[
[
"Adenosine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Adenosine",
"{u} (Compound) resembles {v} (Compound)",
"Clofarabine"
],
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Adenosine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
]
],
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Adenosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osilodrostat"
],
[
"Osilodrostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Adenosine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Adenosine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
],
[
[
"Adenosine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
]
]
] | Adenosine (Compound) resembles Clofarabine (Compound) and Clofarabine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Adenosine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Ribociclib
Adenosine may cause a moderate interaction that could exacerbate diseases when taken with Osilodrostat and Osilodrostat may lead to a major life threatening interaction when taken with Ribociclib
Adenosine may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Ribociclib
Adenosine may lead to a major life threatening interaction when taken with Quinine and Quinine may lead to a major life threatening interaction when taken with Ribociclib
Adenosine may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Ribociclib |
DB00557 | DB01612 | 252 | 1,637 | [
"DDInter895",
"DDInter92"
] | Hydroxyzine | Amyl Nitrite | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect. Hydroxyzine is also used for generalized anxiety disorder, tension caused by psychoneurosis, and other conditions with manifestations of anxiety. | Amyl Nitrite is an antihypertensive medicine. Amyl nitrite is employed medically to treat heart diseases such as angina and to treat cyanide poisoning. Its use as a prescription medicine comes from its ability to lower blood pressure. As an inhalant, it also has psychoactive effect which has led to illegal drug use. | Moderate | 1 | [
[
[
252,
24,
1637
]
],
[
[
252,
64,
475
],
[
475,
24,
1637
]
],
[
[
252,
24,
401
],
[
401,
24,
1637
]
],
[
[
252,
24,
407
],
[
407,
63,
1637
]
],
[
[
252,
63,
530
],
[
530,
24,
1637
]
],
[
[
252,
40,
1630
],
[
1630,
24,
1637
]
],
[
[
252,
1,
623
],
[
623,
24,
1637
]
],
[
[
252,
64,
475
],
[
475,
25,
946
],
[
946,
24,
1637
]
],
[
[
252,
24,
401
],
[
401,
63,
946
],
[
946,
24,
1637
]
],
[
[
252,
24,
1053
],
[
1053,
64,
946
],
[
946,
24,
1637
]
]
] | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Hydroxyzine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Hydroxyzine",
"{u} (Compound) resembles {v} (Compound)",
"Perphenazine"
],
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Hydroxyzine",
"{u} (Compound) resembles {v} (Compound)",
"Quetiapine"
],
[
"Quetiapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Hydroxyzine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Buspirone"
],
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Buspirone"
],
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Buspirone"
],
[
"Buspirone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amyl Nitrite"
]
]
] | Hydroxyzine may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Hydroxyzine (Compound) resembles Perphenazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Hydroxyzine (Compound) resembles Quetiapine (Compound) and Quetiapine may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Hydroxyzine may lead to a major life threatening interaction when taken with Morphine and Morphine may lead to a major life threatening interaction when taken with Buspirone and Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Buspirone and Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Buspirone and Buspirone may cause a moderate interaction that could exacerbate diseases when taken with Amyl Nitrite |
DB08907 | DB14730 | 1,344 | 1,412 | [
"DDInter280",
"DDInter264"
] | Canagliflozin | Calaspargase pegol | Canagliflozin, also known as _Invokana_, is a sodium-glucose cotransporter 2 (SGLT2) inhibitor used in the management of type 2 diabetes mellitus along with lifestyle changes including diet and exercise [FDA label]. It was initially approved by the FDA in 2013 for the management of diabetes and later approved in 2018 for a second indication of reducing the risk of cardiovascular events in patients diagnosed with type 2 diabetes mellitus, [FDA label]. Canagliflozin is the first oral antidiabetic drug approved for the prevention of cardiovascular events in patients with type 2 diabetes. Cardiovascular disease is the most common cause of death in these patients. | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparaginase treatment in ALL , , . Calaspargase pegol, also known as _asparlas_, is an asparagine specific enzyme which is indicated as a part of a multi-agent chemotherapy regimen for the treatment of ALL . The asparagine specific enzyme is derived from Escherichia coli, as a conjugate of L-asparaginase (L-asparagine amidohydrolase) and monomethoxypolyethylene glycol (mPEG) with a succinimidyl carbonate (SC) linker to create a stable molecule which increases the half-life and decreases the dosing frequency [FDA label], . Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) . | Moderate | 1 | [
[
[
1344,
24,
1412
]
],
[
[
1344,
63,
1144
],
[
1144,
24,
1412
]
],
[
[
1344,
24,
1019
],
[
1019,
24,
1412
]
],
[
[
1344,
40,
549
],
[
549,
24,
1412
]
],
[
[
1344,
63,
1144
],
[
1144,
24,
159
],
[
159,
24,
1412
]
],
[
[
1344,
24,
1019
],
[
1019,
63,
1439
],
[
1439,
24,
1412
]
],
[
[
1344,
63,
1411
],
[
1411,
62,
1347
],
[
1347,
24,
1412
]
],
[
[
1344,
40,
549
],
[
549,
63,
1144
],
[
1144,
24,
1412
]
],
[
[
1344,
63,
245
],
[
245,
23,
1347
],
[
1347,
24,
1412
]
],
[
[
1344,
6,
4973
],
[
4973,
45,
792
],
[
792,
24,
1412
]
]
] | [
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Canagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ipilimumab"
],
[
"Ipilimumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Canagliflozin",
"{u} (Compound) resembles {v} (Compound)",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Canagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Canagliflozin",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
]
] | Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Canagliflozin (Compound) resembles Dapagliflozin (Compound) and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Ipilimumab and Ipilimumab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a minor interaction that can limit clinical effects when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Canagliflozin (Compound) resembles Dapagliflozin (Compound) and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Canagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a minor interaction that can limit clinical effects when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Canagliflozin (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Rivaroxaban (Compound) and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol |
DB00622 | DB14723 | 1,081 | 159 | [
"DDInter1287",
"DDInter1026"
] | Nicardipine | Larotrectinib | A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents. [PubChem] | Larotrectinib is an orally administered inhibitor of tropomyosin receptor kinase (Trk), a receptor tyrosine kinase activated by neurotrophins which is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Larotrectinib was granted accelerated approval by the FDA in November 2018 for the treatment of Trk-positive solid tumors. It was notable for being the second tissue-agnostic chemotherapy ever approved by the FDA. | Moderate | 1 | [
[
[
1081,
24,
159
]
],
[
[
1081,
24,
98
],
[
98,
24,
159
]
],
[
[
1081,
40,
376
],
[
376,
24,
159
]
],
[
[
1081,
63,
530
],
[
530,
24,
159
]
],
[
[
1081,
25,
1166
],
[
1166,
24,
159
]
],
[
[
1081,
23,
578
],
[
578,
24,
159
]
],
[
[
1081,
25,
129
],
[
129,
25,
159
]
],
[
[
1081,
24,
384
],
[
384,
25,
159
]
],
[
[
1081,
24,
98
],
[
98,
63,
222
],
[
222,
23,
159
]
],
[
[
1081,
24,
1446
],
[
1446,
23,
907
],
[
907,
23,
159
]
]
] | [
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Nicardipine",
"{u} (Compound) resembles {v} (Compound)",
"Amlodipine"
],
[
"Amlodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Nicardipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Nicardipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
]
],
[
[
"Nicardipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
],
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
]
],
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
]
],
[
[
"Nicardipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanreotide"
],
[
"Lanreotide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doravirine"
],
[
"Doravirine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
]
]
] | Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Nicardipine (Compound) resembles Amlodipine (Compound) and Amlodipine may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Nicardipine may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Nicardipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib
Nicardipine may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Larotrectinib
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Larotrectinib
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib
Nicardipine may cause a moderate interaction that could exacerbate diseases when taken with Lanreotide and Lanreotide may cause a minor interaction that can limit clinical effects when taken with Doravirine and Doravirine may cause a minor interaction that can limit clinical effects when taken with Larotrectinib |
DB05773 | DB08865 | 1,047 | 1,593 | [
"DDInter1848",
"DDInter448"
] | Trastuzumab emtansine | Crizotinib | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that trastuzumab emtansine and trast | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements. | Moderate | 1 | [
[
[
1047,
24,
1593
]
],
[
[
1047,
24,
1627
],
[
1627,
62,
1593
]
],
[
[
1047,
24,
1060
],
[
1060,
63,
1593
]
],
[
[
1047,
25,
1409
],
[
1409,
24,
1593
]
],
[
[
1047,
63,
1057
],
[
1057,
24,
1593
]
],
[
[
1047,
24,
788
],
[
788,
24,
1593
]
],
[
[
1047,
25,
1421
],
[
1421,
63,
1593
]
],
[
[
1047,
24,
68
],
[
68,
64,
1593
]
],
[
[
1047,
63,
1327
],
[
1327,
25,
1593
]
],
[
[
1047,
25,
503
],
[
503,
64,
1593
]
]
] | [
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Crizotinib"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enfortumab vedotin"
],
[
"Enfortumab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Trastuzumab emtansine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Trastuzumab emtansine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
],
[
"Troleandomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Trastuzumab emtansine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
],
[
"Zanubrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
]
] | Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Enfortumab vedotin and Enfortumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Trastuzumab emtansine may lead to a major life threatening interaction when taken with Apixaban and Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Trastuzumab emtansine may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin and Troleandomycin may lead to a major life threatening interaction when taken with Crizotinib
Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Saquinavir and Saquinavir may lead to a major life threatening interaction when taken with Crizotinib
Trastuzumab emtansine may lead to a major life threatening interaction when taken with Zanubrutinib and Zanubrutinib may lead to a major life threatening interaction when taken with Crizotinib |
DB05015 | DB12267 | 1,077 | 1,476 | [
"DDInter174",
"DDInter233"
] | Belinostat | Brigatinib | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL. Intravenous administration of the agent is available as Beleodaq as monotherapy and the dosing regimen involves a 21-day cycle. It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma. | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the EML4-ALK fusion gene, which is a pivotal player in the transformation of susceptible lung parenchyma. Brigatinib was developed by Ariad Pharmaceuticals, a subsidiary of Takeda Pharmaceutical Company Limited, and FDA-approved on April 28, 2017. | Moderate | 1 | [
[
[
1077,
24,
1476
]
],
[
[
1077,
63,
1184
],
[
1184,
24,
1476
]
],
[
[
1077,
24,
1531
],
[
1531,
24,
1476
]
],
[
[
1077,
25,
990
],
[
990,
24,
1476
]
],
[
[
1077,
24,
1129
],
[
1129,
63,
1476
]
],
[
[
1077,
64,
1057
],
[
1057,
25,
1476
]
],
[
[
1077,
24,
129
],
[
129,
25,
1476
]
],
[
[
1077,
25,
676
],
[
676,
64,
1476
]
],
[
[
1077,
25,
375
],
[
375,
25,
1476
]
],
[
[
1077,
63,
915
],
[
915,
25,
1476
]
]
] | [
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
],
[
"Lomitapide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Human adenovirus e serotype 4 strain cl-68578 antigen"
],
[
"Human adenovirus e serotype 4 strain cl-68578 antigen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Belinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
],
[
[
"Belinostat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
]
]
] | Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Belinostat may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Human adenovirus e serotype 4 strain cl-68578 antigen and Human adenovirus e serotype 4 strain cl-68578 antigen may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib
Belinostat may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Brigatinib
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Brigatinib
Belinostat may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Brigatinib
Belinostat may lead to a major life threatening interaction when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Brigatinib
Belinostat may cause a moderate interaction that could exacerbate diseases when taken with Atazanavir and Atazanavir may lead to a major life threatening interaction when taken with Brigatinib |
DB01072 | DB09043 | 915 | 135 | [
"DDInter129",
"DDInter36"
] | Atazanavir | Albiglutide | Atazanavir (formerly known as BMS-232632) is an antiretroviral drug of the protease inhibitor (PI) class. Like other antiretrovirals, it is used to treat infection of human immunodeficiency virus (HIV). Atazanavir is distinguished from other PIs in that it can be given once daily (rather than requiring multiple doses per day) and has lesser effects on the patient's lipid profile (the amounts of cholesterol and other fatty substances in the blood). Like other protease inhibitors, it is used only in combination with other HIV medications. The U.S. Food and Drug Administration (FDA) approved atazanavir on June 20, 2003. | Albiglutide is a glucagon-like peptide-1 agonist (GLP-1) biologic drug indicated in the treatment of type 2 diabetes. It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin. Albiglutide was approved on April 15, 2014 by the FDA. | Moderate | 1 | [
[
[
915,
24,
135
]
],
[
[
915,
63,
126
],
[
126,
23,
135
]
],
[
[
915,
64,
467
],
[
467,
23,
135
]
],
[
[
915,
63,
870
],
[
870,
24,
135
]
],
[
[
915,
24,
1142
],
[
1142,
24,
135
]
],
[
[
915,
64,
629
],
[
629,
24,
135
]
],
[
[
915,
25,
1476
],
[
1476,
63,
135
]
],
[
[
915,
40,
1327
],
[
1327,
24,
135
]
],
[
[
915,
24,
1296
],
[
1296,
63,
135
]
],
[
[
915,
25,
1491
],
[
1491,
24,
135
]
]
] | [
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Albiglutide"
]
],
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Albiglutide"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
],
[
"Orlistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Atazanavir",
"{u} (Compound) resembles {v} (Compound)",
"Saquinavir"
],
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Atazanavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
],
[
[
"Atazanavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Albiglutide"
]
]
] | Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Atazanavir may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may cause a minor interaction that can limit clinical effects when taken with Albiglutide
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Orlistat and Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Atazanavir may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Atazanavir may lead to a major life threatening interaction when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Atazanavir (Compound) resembles Saquinavir (Compound) and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Atazanavir may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide
Atazanavir may lead to a major life threatening interaction when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Albiglutide |
DB01006 | DB01175 | 300 | 318 | [
"DDInter1040",
"DDInter672"
] | Letrozole | Escitalopram | Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.[A190543,A1559,L11623,L11626] It is a third generation aromatase inhibitor like [exemestane] and [anastrozole], meaning it does not significantly affect cortisol, aldosterone, and thyroxine. Letrozole was granted FDA approval on 25 July 1997. | Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from other SSRIs via allosteric action on its target - this may be the mechanism responsible for its observed superior efficacy and faster onset compared to other SSRIs.[A185825,A185726,A185822] | Moderate | 1 | [
[
[
300,
24,
318
]
],
[
[
300,
64,
1230
],
[
1230,
1,
318
]
],
[
[
300,
6,
8374
],
[
8374,
45,
318
]
],
[
[
300,
21,
29276
],
[
29276,
60,
318
]
],
[
[
300,
24,
1478
],
[
1478,
62,
318
]
],
[
[
300,
63,
723
],
[
723,
23,
318
]
],
[
[
300,
24,
98
],
[
98,
63,
318
]
],
[
[
300,
24,
477
],
[
477,
24,
318
]
],
[
[
300,
25,
770
],
[
770,
24,
318
]
],
[
[
300,
63,
1347
],
[
1347,
24,
318
]
]
] | [
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Letrozole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Citalopram"
],
[
"Citalopram",
"{u} (Compound) resembles {v} (Compound)",
"Escitalopram"
]
],
[
[
"Letrozole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Escitalopram"
]
],
[
[
"Letrozole",
"{u} (Compound) causes {v} (Side Effect)",
"Haemoglobin"
],
[
"Haemoglobin",
"{u} (Side Effect) is caused by {v} (Compound)",
"Escitalopram"
]
],
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Escitalopram"
]
],
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Escitalopram"
]
],
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Letrozole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
],
[
[
"Letrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Escitalopram"
]
]
] | Letrozole may lead to a major life threatening interaction when taken with Citalopram and Citalopram (Compound) resembles Escitalopram (Compound)
Letrozole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Escitalopram (Compound)
Letrozole (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Escitalopram (Compound)
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a minor interaction that can limit clinical effects when taken with Escitalopram
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Escitalopram
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Letrozole may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram
Letrozole may cause a moderate interaction that could exacerbate diseases when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Escitalopram |
DB00687 | DB00999 | 870 | 504 | [
"DDInter747",
"DDInter883"
] | Fludrocortisone | Hydrochlorothiazide | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to [cortisol], differing only by a fluorine atom at the 9-position of the steroid structure - this fluorination is thought to be crucial to fludrocortisone's significant mineralocorticoid potency. | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors[L8390,L8423] or angiotensin II receptor blockers.[L7426,L7459] Hydrochlorothiazide was granted FDA approval on 12 February 1959. | Moderate | 1 | [
[
[
870,
24,
504
]
],
[
[
870,
24,
1326
],
[
1326,
40,
504
]
],
[
[
870,
24,
178
],
[
178,
1,
504
]
],
[
[
870,
63,
323
],
[
323,
40,
504
]
],
[
[
870,
21,
29561
],
[
29561,
60,
504
]
],
[
[
870,
63,
126
],
[
126,
23,
504
]
],
[
[
870,
24,
1002
],
[
1002,
63,
504
]
],
[
[
870,
63,
355
],
[
355,
24,
504
]
],
[
[
870,
23,
455
],
[
455,
24,
504
]
],
[
[
870,
1,
891
],
[
891,
24,
504
]
]
] | [
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
],
[
"Diclofenamide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Polythiazide"
],
[
"Polythiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Mood swings"
],
[
"Mood swings",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydrochlorothiazide"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alogliptin"
],
[
"Alogliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lactulose"
],
[
"Lactulose",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Fludrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Fludrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrochlorothiazide"
]
]
] | Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide and Diclofenamide (Compound) resembles Hydrochlorothiazide (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Polythiazide and Polythiazide (Compound) resembles Hydrochlorothiazide (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide and Bendroflumethiazide (Compound) resembles Hydrochlorothiazide (Compound)
Fludrocortisone (Compound) causes Mood swings (Side Effect) and Mood swings (Side Effect) is caused by Hydrochlorothiazide (Compound)
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a minor interaction that can limit clinical effects when taken with Hydrochlorothiazide
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Alogliptin and Alogliptin may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide
Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Lactulose and Lactulose may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide
Fludrocortisone may cause a minor interaction that can limit clinical effects when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide
Fludrocortisone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Hydrochlorothiazide |
DB00843 | DB05294 | 479 | 1,069 | [
"DDInter583",
"DDInter1917"
] | Donepezil | Vandetanib | In 2016, the global burden of dementia was estimated to be 43.8 million, demonstrating a significant increase from a global prevalence of 20.2 million in 1990. Donepezil, also known as Aricept, is a piperidine derivative acetylcholinesterase inhibitor used in the management of the dementia of Alzheimer's Disease, and in some cases, is used to manage other types of dementia. Donepezil was first approved by the FDA in 1996, and its extended-release form was approved in combination with [Memantine] in 2014 to manage moderate and severe forms of Alzheimer's dementia.[L7916,L7937] A donepezil transdermal delivery system, Adlarity, was approved by the FDA in March 2022 for the treatment of Alzheimer's dementia. Though it does not alter the progression of Alzheimer's disease, donepezil is effective in managing the symptoms of its associated dementia. | Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. | Moderate | 1 | [
[
[
479,
24,
1069
]
],
[
[
479,
62,
883
],
[
883,
40,
1069
]
],
[
[
479,
6,
8374
],
[
8374,
45,
1069
]
],
[
[
479,
21,
29343
],
[
29343,
60,
1069
]
],
[
[
479,
24,
1194
],
[
1194,
23,
1069
]
],
[
[
479,
24,
688
],
[
688,
24,
1069
]
],
[
[
479,
23,
159
],
[
159,
63,
1069
]
],
[
[
479,
24,
98
],
[
98,
63,
1069
]
],
[
[
479,
63,
543
],
[
543,
24,
1069
]
],
[
[
479,
24,
401
],
[
401,
25,
1069
]
]
] | [
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
]
],
[
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gefitinib"
],
[
"Gefitinib",
"{u} (Compound) resembles {v} (Compound)",
"Vandetanib"
]
],
[
[
"Donepezil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Vandetanib"
]
],
[
[
"Donepezil",
"{u} (Compound) causes {v} (Side Effect)",
"Blood creatinine increased"
],
[
"Blood creatinine increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Vandetanib"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ranitidine"
],
[
"Ranitidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vandetanib"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
]
],
[
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vandetanib"
]
],
[
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
]
]
] | Donepezil may cause a minor interaction that can limit clinical effects when taken with Gefitinib and Gefitinib (Compound) resembles Vandetanib (Compound)
Donepezil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Vandetanib (Compound)
Donepezil (Compound) causes Blood creatinine increased (Side Effect) and Blood creatinine increased (Side Effect) is caused by Vandetanib (Compound)
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Ranitidine and Ranitidine may cause a minor interaction that can limit clinical effects when taken with Vandetanib
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib
Donepezil may cause a minor interaction that can limit clinical effects when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Vandetanib
Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may lead to a major life threatening interaction when taken with Vandetanib |
DB00584 | DB01143 | 610 | 923 | [
"DDInter638",
"DDInter65"
] | Enalapril | Amifostine | Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-angiotensin-aldosterone system to lower blood pressure. It was developed from a targeted research programmed using molecular modelling. Being a prodrug, enalapril is rapidly biotransformed into its active metabolite, [enalaprilat], which is responsible for the pharmacological actions of enalapril. The active metabolite of enalapril competitively inhibits the ACE to hinder the production of angiotensin II, a key component of the renin-angiotensin-aldosterone system that promotes v | A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia. | Moderate | 1 | [
[
[
610,
24,
923
]
],
[
[
610,
21,
28642
],
[
28642,
60,
923
]
],
[
[
610,
1,
1603
],
[
1603,
63,
923
]
],
[
[
610,
24,
714
],
[
714,
24,
923
]
],
[
[
610,
40,
743
],
[
743,
24,
923
]
],
[
[
610,
1,
954
],
[
954,
24,
923
]
],
[
[
610,
24,
885
],
[
885,
63,
923
]
],
[
[
610,
63,
1061
],
[
1061,
24,
923
]
],
[
[
610,
21,
28642
],
[
28642,
60,
336
],
[
336,
24,
923
]
],
[
[
610,
1,
1603
],
[
1603,
18,
2801
],
[
2801,
57,
923
]
]
] | [
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Enalapril",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amifostine"
]
],
[
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Captopril"
],
[
"Captopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iloprost"
],
[
"Iloprost",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Lisinopril"
],
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Quinapril"
],
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Enalapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Enalapril",
"{u} (Compound) causes {v} (Side Effect)",
"Shock"
],
[
"Shock",
"{u} (Side Effect) is caused by {v} (Compound)",
"Nifedipine"
],
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amifostine"
]
],
[
[
"Enalapril",
"{u} (Compound) resembles {v} (Compound)",
"Captopril"
],
[
"Captopril",
"{u} (Compound) downregulates {v} (Gene)",
"PUF60"
],
[
"PUF60",
"{u} (Gene) is downregulated by {v} (Compound)",
"Amifostine"
]
]
] | Enalapril (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Amifostine (Compound)
Enalapril (Compound) resembles Captopril (Compound) and Captopril may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Iloprost may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Enalapril (Compound) resembles Lisinopril (Compound) and Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Enalapril (Compound) resembles Quinapril (Compound) and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Enalapril may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Enalapril (Compound) causes Shock (Side Effect) and Shock (Side Effect) is caused by Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Amifostine
Enalapril (Compound) resembles Captopril (Compound) and Captopril (Compound) downregulates PUF60 (Gene) and PUF60 (Gene) is downregulated by Amifostine (Compound) |
DB01217 | DB04575 | 630 | 35 | [
"DDInter95",
"DDInter1555"
] | Anastrozole | Quinestrol | Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer. Anastrozole is also related to [exemestane], a steroidal AI, but its non-steroidal nature provides stark advantages including a lack of steroid-associated adverse effects such as weight gain and acne. Aromatase inhibitors, including anastrozole, have become endocrine drugs of choice in the treatment of postmenopausal breast cancer due to a more favourable efficacy and adverse effect profile as compared to earlier estrogen receptor modulators such as [tamoxifen].[A186877,A186955] Anastrozole was first approved for use in the United States in 1995. | The 3-cyclopentyl ether of ethinyl estradiol. | Moderate | 1 | [
[
[
630,
24,
35
]
],
[
[
630,
24,
890
],
[
890,
1,
35
]
],
[
[
630,
63,
559
],
[
559,
1,
35
]
],
[
[
630,
24,
177
],
[
177,
40,
35
]
],
[
[
630,
24,
214
],
[
214,
63,
35
]
],
[
[
630,
64,
770
],
[
770,
25,
35
]
],
[
[
630,
24,
890
],
[
890,
1,
1417
],
[
1417,
40,
35
]
],
[
[
630,
63,
559
],
[
559,
1,
890
],
[
890,
1,
35
]
],
[
[
630,
24,
177
],
[
177,
40,
890
],
[
890,
1,
35
]
],
[
[
630,
63,
380
],
[
380,
40,
890
],
[
890,
1,
35
]
]
] | [
[
[
"Anastrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
]
],
[
[
"Anastrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
],
[
"Mestranol",
"{u} (Compound) resembles {v} (Compound)",
"Quinestrol"
]
],
[
[
"Anastrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estrone"
],
[
"Estrone",
"{u} (Compound) resembles {v} (Compound)",
"Quinestrol"
]
],
[
[
"Anastrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estrone sulfate"
],
[
"Estrone sulfate",
"{u} (Compound) resembles {v} (Compound)",
"Quinestrol"
]
],
[
[
"Anastrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinestrol"
]
],
[
[
"Anastrozole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinestrol"
]
],
[
[
"Anastrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
],
[
"Mestranol",
"{u} (Compound) resembles {v} (Compound)",
"Estramustine"
],
[
"Estramustine",
"{u} (Compound) resembles {v} (Compound)",
"Quinestrol"
]
],
[
[
"Anastrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estrone"
],
[
"Estrone",
"{u} (Compound) resembles {v} (Compound)",
"Mestranol"
],
[
"Mestranol",
"{u} (Compound) resembles {v} (Compound)",
"Quinestrol"
]
],
[
[
"Anastrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estrone sulfate"
],
[
"Estrone sulfate",
"{u} (Compound) resembles {v} (Compound)",
"Mestranol"
],
[
"Mestranol",
"{u} (Compound) resembles {v} (Compound)",
"Quinestrol"
]
],
[
[
"Anastrozole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conjugated estrogens"
],
[
"Conjugated estrogens",
"{u} (Compound) resembles {v} (Compound)",
"Mestranol"
],
[
"Mestranol",
"{u} (Compound) resembles {v} (Compound)",
"Quinestrol"
]
]
] | Anastrozole may cause a moderate interaction that could exacerbate diseases when taken with Mestranol and Mestranol (Compound) resembles Quinestrol (Compound)
Anastrozole may cause a moderate interaction that could exacerbate diseases when taken with Estrone and Estrone (Compound) resembles Quinestrol (Compound)
Anastrozole may cause a moderate interaction that could exacerbate diseases when taken with Estrone sulfate and Estrone sulfate (Compound) resembles Quinestrol (Compound)
Anastrozole may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Quinestrol
Anastrozole may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Quinestrol
Anastrozole may cause a moderate interaction that could exacerbate diseases when taken with Mestranol and Mestranol (Compound) resembles Estramustine (Compound) and Estramustine (Compound) resembles Quinestrol (Compound)
Anastrozole may cause a moderate interaction that could exacerbate diseases when taken with Estrone and Estrone (Compound) resembles Mestranol (Compound) and Mestranol (Compound) resembles Quinestrol (Compound)
Anastrozole may cause a moderate interaction that could exacerbate diseases when taken with Estrone sulfate and Estrone sulfate (Compound) resembles Mestranol (Compound) and Mestranol (Compound) resembles Quinestrol (Compound)
Anastrozole may cause a moderate interaction that could exacerbate diseases when taken with Conjugated estrogens and Conjugated estrogens (Compound) resembles Mestranol (Compound) and Mestranol (Compound) resembles Quinestrol (Compound) |
DB00539 | DB00845 | 11 | 1,490 | [
"DDInter1837",
"DDInter406"
] | Toremifene | Clofazimine | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue. | Clofazimine is a highly lipophilic antimicrobial riminophenazine dye used in combination with other agents, such as [dapsone], for the treatment of leprosy. It was originally described in 1957 and was the prototypical riminophenazine dye - a bright-red dye that, in its clinical use, results in long-lasting discoloration of the skin and bodily fluids. Although it carries _in vitro_ activity against other mycobacterium, such as _Mycobacterium tuberculosis_, it is generally considered an ineffective treatment in comparison to classic tuberculosis treatments such as [rifampicin] and [isoniazid]. | Major | 2 | [
[
[
11,
25,
1490
]
],
[
[
11,
6,
4973
],
[
4973,
45,
1490
]
],
[
[
11,
18,
16974
],
[
16974,
57,
1490
]
],
[
[
11,
21,
28787
],
[
28787,
60,
1490
]
],
[
[
11,
23,
112
],
[
112,
62,
1490
]
],
[
[
11,
25,
1250
],
[
1250,
63,
1490
]
],
[
[
11,
25,
51
],
[
51,
24,
1490
]
],
[
[
11,
36,
888
],
[
888,
24,
1490
]
],
[
[
11,
24,
455
],
[
455,
63,
1490
]
],
[
[
11,
64,
1494
],
[
1494,
24,
1490
]
]
] | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clofazimine"
]
],
[
[
"Toremifene",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Clofazimine"
]
],
[
[
"Toremifene",
"{u} (Compound) downregulates {v} (Gene)",
"TUBB6"
],
[
"TUBB6",
"{u} (Gene) is downregulated by {v} (Compound)",
"Clofazimine"
]
],
[
[
"Toremifene",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clofazimine"
]
],
[
[
"Toremifene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clofazimine"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofazimine"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Daunorubicin"
],
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofazimine"
]
],
[
[
"Toremifene",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofazimine"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofazimine"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clofazimine"
]
]
] | Toremifene (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Clofazimine (Compound)
Toremifene (Compound) downregulates TUBB6 (Gene) and TUBB6 (Gene) is downregulated by Clofazimine (Compound)
Toremifene (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Clofazimine (Compound)
Toremifene may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Clofazimine
Toremifene may lead to a major life threatening interaction when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Clofazimine
Toremifene may lead to a major life threatening interaction when taken with Daunorubicin and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Clofazimine
Toremifene (Compound) resembles Tamoxifen (Compound) and Toremifene may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Clofazimine
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Clofazimine
Toremifene may lead to a major life threatening interaction when taken with Palonosetron and Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Clofazimine |
DB09036 | DB10989 | 812 | 496 | [
"DDInter1668",
"DDInter858"
] | Siltuximab | Hepatitis A Vaccine | Siltuximab is a chimeric (human-mouse) monoclonal immunoglobulin G1-kappa antibody produced in a Chinese hamster ovary (CHO) cell line by recombinant DNA technology. Siltuximab prevents the binding of IL-6 to soluble and membrane-bound IL-6 receptors by forming high affinity complexes with human interleukin-6 (IL-6). Its use is indicated for the treatment of adult patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. MCD is a rare blood disorder caused by dysregulated IL-6 production, proliferation of lymphocytes, and subsequent enlargement of the lymph nodes. It is administered as a 1 hour intravenous infusion every 3 weeks. | Hepatitis A viral infection can lead to significant morbidity and mortality, with signs and symptoms that include anorexia, nausea, vomiting, and liver failure. Known by several trade names, such as Havrix and Twinrix, the Hepatitis A vaccine has been formulated for immunization against hepatitis A virus (HAV) infection and safely confers strong protection against the disease caused by infection with this virus.[A199185,L12756] In the US, the approved vaccine is inactivated while live Hepatitis A vaccines are currently available in other countries. | Moderate | 1 | [
[
[
812,
24,
496
]
],
[
[
812,
63,
4
],
[
4,
24,
496
]
],
[
[
812,
64,
976
],
[
976,
24,
496
]
],
[
[
812,
24,
270
],
[
270,
63,
496
]
],
[
[
812,
25,
676
],
[
676,
63,
496
]
],
[
[
812,
63,
4
],
[
4,
24,
1093
],
[
1093,
63,
496
]
],
[
[
812,
64,
976
],
[
976,
25,
1093
],
[
1093,
63,
496
]
],
[
[
812,
24,
270
],
[
270,
63,
1093
],
[
1093,
63,
496
]
],
[
[
812,
25,
676
],
[
676,
64,
1093
],
[
1093,
63,
496
]
],
[
[
812,
23,
1193
],
[
1193,
62,
1096
],
[
1096,
24,
496
]
]
] | [
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Siltuximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Siltuximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
],
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Siltuximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
],
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Siltuximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixekizumab"
],
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Siltuximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ixekizumab"
],
[
"Ixekizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
],
[
[
"Siltuximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Zinc gluconate"
],
[
"Zinc gluconate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hepatitis A Vaccine"
]
]
] | Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Siltuximab may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Siltuximab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Siltuximab may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Siltuximab may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Siltuximab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Ixekizumab and Ixekizumab may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine
Siltuximab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Hepatitis A Vaccine |
DB09330 | DB11986 | 985 | 484 | [
"DDInter1352",
"DDInter648"
] | Osimertinib | Entrectinib | Osimertinib is an oral, third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) drug developed by AstraZeneca Pharmaceuticals.[A7926,L43453] Its use is indicated for the treatment of metastatic non-small cell lung cancer (NSCLC) in cases where tumour EGFR expression is positive for the T790M mutation as detected by FDA-approved testing and which has progressed following therapy with a first-generation EGFR tyrosine kinase inhibitor. Approximately 10% of patients with NSCLC have a rapid and clinically effective response to EGFR-TKIs due to the presence of specific activating EGFR mutations within the tumour cells. More specifically, deletions around the LREA motif in exon 19 and exon 21 L858R point mutations are correlated with response to therapy. Development of third-generation EGFR-TKIs, such as osimertinib, has been in response to altered | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positive solid tumors. Entrectinib's approved use is meant as a last line of therapy due to its accelerated approval based on early trial data. This therapy offers benefit over similar ALK inhibitors such as [alectinib], [ceritinib], and [lorlatinib] due to a wider range of targets. | Major | 2 | [
[
[
985,
25,
484
]
],
[
[
985,
62,
1247
],
[
1247,
23,
484
]
],
[
[
985,
24,
466
],
[
466,
62,
484
]
],
[
[
985,
64,
1539
],
[
1539,
24,
484
]
],
[
[
985,
63,
1662
],
[
1662,
24,
484
]
],
[
[
985,
24,
1320
],
[
1320,
24,
484
]
],
[
[
985,
25,
180
],
[
180,
63,
484
]
],
[
[
985,
25,
927
],
[
927,
24,
484
]
],
[
[
985,
24,
829
],
[
829,
63,
484
]
],
[
[
985,
64,
494
],
[
494,
25,
484
]
]
] | [
[
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
],
[
[
"Osimertinib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Entrectinib"
]
],
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Entrectinib"
]
],
[
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oliceridine"
],
[
"Oliceridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ubrogepant"
],
[
"Ubrogepant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Entrectinib"
]
]
] | Osimertinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Osimertinib may lead to a major life threatening interaction when taken with Ofloxacin and Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Osimertinib may lead to a major life threatening interaction when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Osimertinib may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Ubrogepant and Ubrogepant may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib
Osimertinib may lead to a major life threatening interaction when taken with Disopyramide and Disopyramide may lead to a major life threatening interaction when taken with Entrectinib |
DB06715 | DB09293 | 239 | 116 | [
"DDInter1500",
"DDInter954"
] | Potassium Iodide | Iodide I-131 | Saturated solution of Potassium Iodide (SSKI) is used pharmaceutically for emergency use in patients experiencing acute symptoms of severe hyperthyroidism (also known as thyroid storm or thyrotoxic crisis). SSKI can also be used for radioiodine-contamination emergencies or in preparation of thyrotoxic patients for thyroidectomy. | Iodide I-131 (as Sodium iodide I-131) is a radioisotopic drug used for the treatment and palliation of thyroid malignancy. Iodine-131 is notable for causing mutation and death in cells that it penetrates, which is due to its mode of beta decay. As a result of beta decay, approximately 10% of its energy and radiation dose is via gamma radiation, while the other 90% (beta radiation) causes tissue damage without contributing to any ability to see or image the isotope. Low levels of beta radiation are also known for causing cancer as this dose is highly mutagenic. For this reason, less toxic iodine isotopes such as I-123 are more frequently used in nuclear imaging, while I-131 is reserved for its tissue destroying effects. Because the thyroid gland naturally takes up iodine from the body, therapeutic methods using radioisotopes can take advantage of this mechanism for localization of drug to the site of malignancy. Therapeutic solutions of Sodium Iodide-131 are indicated for the treatment of hyperthyroidism and thyroid carcinomas that take up iodine. Palliative effects may be observed in patients with advanced thyroid malignancy if the metastatic lesions take up iodine. It is also indicated for use in performance of the radioactive iodide (RAI) uptake test to evaluate thyroid function. | Moderate | 1 | [
[
[
239,
24,
116
]
],
[
[
239,
24,
1399
],
[
1399,
63,
116
]
],
[
[
239,
63,
914
],
[
914,
24,
116
]
],
[
[
239,
24,
1399
],
[
1399,
63,
701
],
[
701,
24,
116
]
],
[
[
239,
21,
28714
],
[
28714,
60,
1486
],
[
1486,
24,
116
]
],
[
[
239,
63,
914
],
[
914,
24,
1486
],
[
1486,
24,
116
]
],
[
[
239,
24,
1399
],
[
1399,
64,
1487
],
[
1487,
24,
116
]
],
[
[
239,
63,
914
],
[
914,
63,
167
],
[
167,
24,
116
]
],
[
[
239,
63,
914
],
[
914,
25,
365
],
[
365,
24,
116
]
],
[
[
239,
63,
914
],
[
914,
64,
834
],
[
834,
24,
116
]
]
] | [
[
[
"Potassium Iodide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Potassium Iodide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Potassium Iodide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diflunisal"
],
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Potassium Iodide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Potassium Iodide",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Potassium Iodide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diflunisal"
],
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Potassium Iodide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
],
[
"Lithium carbonate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Potassium Iodide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diflunisal"
],
[
"Diflunisal",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Potassium Iodide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diflunisal"
],
[
"Diflunisal",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dalteparin"
],
[
"Dalteparin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
],
[
[
"Potassium Iodide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diflunisal"
],
[
"Diflunisal",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Drotrecogin alfa"
],
[
"Drotrecogin alfa",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
]
]
] | Potassium Iodide may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Potassium Iodide may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Potassium Iodide may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Clemastine and Clemastine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Potassium Iodide (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Potassium Iodide may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Potassium Iodide may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate and Lithium carbonate may lead to a major life threatening interaction when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Potassium Iodide may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Potassium Iodide may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may lead to a major life threatening interaction when taken with Dalteparin and Dalteparin may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131
Potassium Iodide may cause a moderate interaction that could exacerbate diseases when taken with Diflunisal and Diflunisal may lead to a major life threatening interaction when taken with Drotrecogin alfa and Drotrecogin alfa may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 |
DB01168 | DB11601 | 1,053 | 1,270 | [
"DDInter1526",
"DDInter1889"
] | Procarbazine | Tuberculin purified protein derivative | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and appropriate therapeutic intervention. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. It is included in the World Health Organization's List of Essential Medicines. | Moderate | 1 | [
[
[
1053,
24,
1270
]
],
[
[
1053,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
1053,
63,
869
],
[
869,
24,
1270
]
],
[
[
1053,
64,
1064
],
[
1064,
24,
1270
]
],
[
[
1053,
25,
1259
],
[
1259,
63,
1270
]
],
[
[
1053,
25,
976
],
[
976,
24,
1270
]
],
[
[
1053,
24,
738
],
[
738,
63,
1270
]
],
[
[
1053,
24,
1531
],
[
1531,
24,
350
],
[
350,
24,
1270
]
],
[
[
1053,
63,
869
],
[
869,
24,
350
],
[
350,
24,
1270
]
],
[
[
1053,
64,
1064
],
[
1064,
25,
350
],
[
350,
24,
1270
]
]
] | [
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Niraparib"
],
[
"Niraparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
]
] | Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Procarbazine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Procarbazine may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Procarbazine may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Niraparib and Niraparib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Procarbazine may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative |
DB00349 | DB11901 | 902 | 913 | [
"DDInter401",
"DDInter107"
] | Clobazam | Apalutamide | Clobazam belongs to the 1,5-benzodiazepine class of drugs and is marketed under different names, Onfi, Frisium, Urbanyl, and others.. Clobazam was first synthesized in 1966 and first published in 1969, following the incidental synthesis and discovery of the first benzodiazepine chlordiazepoxide in the 1950s. Unlike older 1,4-benzodiazepines, clobazam has a better side-effects profile, particularly less sedative and amnesic effects.[A256963,A256868] This is likely because of clobazam's higher affinity to the α<sub>2</sub> subunit of the GABA<sub>A</sub> receptor, which mediates anxiolytic effects, than the α<sub>1</sub> subunit, which mediates sedative effect. Additionally, clobazam is believed | Apalutamide is a potent androgen receptor (AR) antagonist that selectively binds to the ligand-binding domain of AR and blocks AR nuclear translocation or binding to androgen response elements . It has been used in trials studying the treatment of Prostate Cancer, Hepatic Impairment, Prostatic Neoplasms, Castration-Resistant Prostate Cancer, and Prostatic Neoplasms, Castration-Resistant, among others. Exerting an antitumor action, apalutamide blocking the effect of androgens that promote tumor growth. It targets the AR ligand-binding domain and prevents AR nuclear translocation, DNA binding, and transcription of AR gene targets in prostate tumors . In mice bearing human CRPC xenograft models, apalutamide treatment produced tumor regressions in a dose-dependent manner that was more effective than that of or . Unlike bicalutamide, apalutamide antagonized AR-mediated signaling in AR overexpressing human CRPC cell lines . Androgen-deprivation therapy, or hormone therapy, can be used as part of maintenance therapy for patients with non-metastatic prostate cancer. Although most patients achieve therapeutic responses at the initial hormone therapy, many patients progress to non-metastatic castration-resistant (resistance to hormone therapy) prostate cancer which is the second-most common cause of cancer-related deaths in American males . Castration-resistant prostate cancer is often incurable, which poses significant clinical challenges for patients. Approximately 10 to 20 % of prostate cancer cases are castration-resistant, and up to 16% of these patients show no evidence of cancer metastasis at the time of castration-resistant diagnosis . Higher prostate-specific antigen (PSA) and shorter PSA doubling time (PSA DT) are associated with a higher risk for metastases and death . In a phase-2 multicenter open-label study, 89% of patients with non-metastatic, castration-resistant prostate cancer had ≥50% PSA decline at week 12 of apalutamide treatment . In a randomized trial, the median metastasis-free survival for patients taking apalutamide was 40.5 months compared to 16.2 months for patients taking a placebo . Apalutamide displayed good tolerability and safety profile in clinical studies. Apalutamide was approved in February 2018 by the FDA as Erleada for the treatment of patients with non-metastatic prostate cancer that is resistant to treatment with hormone therapy (castration-resistant). It is available as oral tablets. Apalutamide is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer . | Moderate | 1 | [
[
[
902,
24,
913
]
],
[
[
902,
63,
608
],
[
608,
23,
913
]
],
[
[
902,
63,
600
],
[
600,
24,
913
]
],
[
[
902,
40,
1237
],
[
1237,
24,
913
]
],
[
[
902,
24,
609
],
[
609,
24,
913
]
],
[
[
902,
23,
286
],
[
286,
24,
913
]
],
[
[
902,
64,
475
],
[
475,
24,
913
]
],
[
[
902,
24,
593
],
[
593,
25,
913
]
],
[
[
902,
62,
168
],
[
168,
25,
913
]
],
[
[
902,
25,
1670
],
[
1670,
25,
913
]
]
] | [
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
]
],
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Clobazam",
"{u} (Compound) resembles {v} (Compound)",
"Clomipramine"
],
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Clobazam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Clobazam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
]
],
[
[
"Clobazam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Clobazam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
],
[
[
"Clobazam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
]
]
] | Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Apalutamide
Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Clobazam (Compound) resembles Clomipramine (Compound) and Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Clobazam may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Clobazam may lead to a major life threatening interaction when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide
Clobazam may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Apalutamide
Clobazam may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may lead to a major life threatening interaction when taken with Apalutamide
Clobazam may lead to a major life threatening interaction when taken with Eliglustat and Eliglustat may lead to a major life threatening interaction when taken with Apalutamide |
DB00590 | DB01240 | 1,433 | 885 | [
"DDInter592",
"DDInter657"
] | Doxazosin | Epoprostenol | Doxazosin is an alpha-1 antagonist used for the treatment of benign prostatic hypertrophy (BPH) symptoms and hypertension. Other members of this drug class include [Prazosin], [Terazosin], [Tamsulosin], and [Alfuzosin]. Because of its long-lasting effects, doxazosin can be administered once a day. It is marketed by Pfizer and was initially approved by the FDA in 1990. | A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension. | Moderate | 1 | [
[
[
1433,
24,
885
]
],
[
[
1433,
63,
1061
],
[
1061,
1,
885
]
],
[
[
1433,
21,
28684
],
[
28684,
60,
885
]
],
[
[
1433,
24,
1450
],
[
1450,
63,
885
]
],
[
[
1433,
24,
1445
],
[
1445,
24,
885
]
],
[
[
1433,
40,
472
],
[
472,
24,
885
]
],
[
[
1433,
1,
1205
],
[
1205,
24,
885
]
],
[
[
1433,
63,
1648
],
[
1648,
24,
885
]
],
[
[
1433,
63,
1061
],
[
1061,
24,
642
],
[
642,
24,
885
]
],
[
[
1433,
21,
28684
],
[
28684,
60,
642
],
[
642,
24,
885
]
]
] | [
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} (Compound) resembles {v} (Compound)",
"Epoprostenol"
]
],
[
[
"Doxazosin",
"{u} (Compound) causes {v} (Side Effect)",
"Hypoaesthesia"
],
[
"Hypoaesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Epoprostenol"
]
],
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Doxazosin",
"{u} (Compound) resembles {v} (Compound)",
"Alfuzosin"
],
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Doxazosin",
"{u} (Compound) resembles {v} (Compound)",
"Prazosin"
],
[
"Prazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Doxazosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alprostadil"
],
[
"Alprostadil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
],
[
[
"Doxazosin",
"{u} (Compound) causes {v} (Side Effect)",
"Hypoaesthesia"
],
[
"Hypoaesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Alprostadil"
],
[
"Alprostadil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
]
]
] | Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil (Compound) resembles Epoprostenol (Compound)
Doxazosin (Compound) causes Hypoaesthesia (Side Effect) and Hypoaesthesia (Side Effect) is caused by Epoprostenol (Compound)
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Doxazosin (Compound) resembles Alfuzosin (Compound) and Alfuzosin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Doxazosin (Compound) resembles Prazosin (Compound) and Prazosin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Doxazosin may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Alprostadil and Alprostadil may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol
Doxazosin (Compound) causes Hypoaesthesia (Side Effect) and Hypoaesthesia (Side Effect) is caused by Alprostadil (Compound) and Alprostadil may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol |
DB00092 | DB05015 | 58 | 1,077 | [
"DDInter40",
"DDInter174"
] | Alefacept | Belinostat | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Belinostat is a novel agent that inhibits the enzyme histone deacetylase (HDAC) with a sulfonamide-hydroxamide structure. It was developed as an orphan drug to target hematological malignancies and solid tumors by TopoTarget. The safety and efficacy of belinostat is currently being evaluated for use in combination with traditional front-line therapies for the treatment of PTCL. Intravenous administration of the agent is available as Beleodaq as monotherapy and the dosing regimen involves a 21-day cycle. It was US-approved in July 2014 as a therapeutic agent for relapsed or refractory peripheral T-cell lymphoma. | Moderate | 1 | [
[
[
58,
24,
1077
]
],
[
[
58,
24,
482
],
[
482,
24,
1077
]
],
[
[
58,
24,
1136
],
[
1136,
63,
1077
]
],
[
[
58,
63,
305
],
[
305,
24,
1077
]
],
[
[
58,
25,
334
],
[
334,
64,
1077
]
],
[
[
58,
25,
1377
],
[
1377,
25,
1077
]
],
[
[
58,
63,
581
],
[
581,
25,
1077
]
],
[
[
58,
24,
375
],
[
375,
64,
1077
]
],
[
[
58,
24,
482
],
[
482,
63,
1253
],
[
1253,
24,
1077
]
],
[
[
58,
24,
1476
],
[
1476,
63,
1136
],
[
1136,
63,
1077
]
]
] | [
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belinostat"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belinostat"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
],
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belinostat"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belinostat"
]
],
[
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
],
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Belinostat"
]
],
[
[
"Alefacept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Belinostat"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Belinostat"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Belinostat"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palifermin"
],
[
"Palifermin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belinostat"
]
],
[
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
],
[
"Denosumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Belinostat"
]
]
] | Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Belinostat
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Belinostat
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Belinostat
Alefacept may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen and Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Belinostat
Alefacept may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Belinostat
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Belinostat
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Belinostat
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Palifermin and Palifermin may cause a moderate interaction that could exacerbate diseases when taken with Belinostat
Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a moderate interaction that could exacerbate diseases when taken with Denosumab and Denosumab may cause a moderate interaction that could exacerbate diseases when taken with Belinostat |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.